CN101331229B - Immunostimulatory oligoribonucleotides - Google Patents

Immunostimulatory oligoribonucleotides Download PDF

Info

Publication number
CN101331229B
CN101331229B CN2006800440306A CN200680044030A CN101331229B CN 101331229 B CN101331229 B CN 101331229B CN 2006800440306 A CN2006800440306 A CN 2006800440306A CN 200680044030 A CN200680044030 A CN 200680044030A CN 101331229 B CN101331229 B CN 101331229B
Authority
CN
China
Prior art keywords
orn
immunostimulating
experimenter
present
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800440306A
Other languages
Chinese (zh)
Other versions
CN101331229A (en
Inventor
亚历山大·福斯巴赫
约尔格·沃尔梅尔
格雷森·B·利浦福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Animal Health
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical GmbH filed Critical Coley Pharmaceutical GmbH
Priority claimed from PCT/US2006/045183 external-priority patent/WO2007062107A2/en
Publication of CN101331229A publication Critical patent/CN101331229A/en
Application granted granted Critical
Publication of CN101331229B publication Critical patent/CN101331229B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immnostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).

Description

Immunostimulatory oligoribonucleotides
Technical field
Generally speaking, the present invention relates to field of immunology, relate more specifically to the immunostimulating molecule.More particularly, the present invention relates to have Yeast Nucleic Acid (RNA) molecule of immunostimulatory activity, comprise oligoribonucleotide.
Background technology
Toll appearance acceptor (TLR) is pattern recognition acceptor (PRR) peptide family of high conservative, and its identification and pathogenic agent bonded molecular pattern (PAMP) play a crucial role in mammiferous congenital immunity (innate immunity).Identified at least ten family members at present, they are named as TLR1-TLR10.The endochylema structural domain of multiple TLR is characterised in that Toll-interleukin 1 receptor (TIR) structural domain.Medzhitov?R?et?al.(1998)Mol?Cell?2：253-8。The activation that TLR amplifies the identification priming signal cascade that mikrobe is invaded, this guards in fruit bat (Drosophila) and Mammals.Report: the fit albumen MyD88 that contains the TIR structural domain combines with TLR, will raise to TLR with the factor 6 (TRAF6) of interleukin 1 receptor bonded kinases (IRAK) and tumour necrosis factor (TNF) receptors bind.It is believed that the dependent signal transduction pathway of MyD88-causes NF-κ B transcription factor and c-Jun NH 2The activation of terminal kinases (Jnk) mitogen (mitogen)-activated protein kinase (MAPK), this is in the immuno-stimulating and the committed step of inflammatory cytokine generation.Summary is consulted Aderem A et al. (2000) Nature 406:782-87 and Akira S et al. (2004) Nat Rev Immunol 4:499-511.
Identified a large amount of specificity T LR parts.The part of TLR2 comprises Polysaccharides, peptide complexes and lipopeptid.Yoshimura?A?et?al.(1999)J?Immunol?163：1-5；Yoshimura?A?et?al.(1999)J?Immunol?163：1-5；Aliprantis?AO?et?al.(1999)Science?285：736-9。LPS (LPS) is the part of TLR4.Poltorak?A?et?al.(1998)Science?282：2085-8；HoshinoK?et?al.(1999)J?Immunol?162：3749-52。Bacterial flagellin is the part of TLR5.Hayashi?F?et?al.(2001)Nature?410：1099-1103。Report: Polysaccharides, peptide complexes is not only the part of TLR2, but also is the part of TLR6.Ozinsky?A?et?al.(2000)Proc?NatlAcad?Sci?USA?97：13766-71；Takeuchi?O?et?al.(2001)Int?Immunol?13：933-40。Nearest report: some lower molecular weight synthetic compound imidazole quinoline miaow quinoline not moral (imidazoquinolinesimiquimod, R-837) and resiquimod (resiquimod R-848) is the part of TLR7 and TLR8.Hemmi?H?et?al.(2002)Nat?Immunol?3：196-200；Jurk?M?et?al.(2002)Nat?Immunol?3：499。
From unmethylated DNA of bacteria of recent discovery and synthetic analogue (CpG DNA) thereof is part (Hemmi H et al. (2000) the Nature 408:740-5 of TLR9; Bauer S et al. (2001) Proc Natl Acad Sci USA 98,9237-42) beginning, report has been arranged: the part of some TLR comprises some nucleic acid molecule.The RNA that has reported at present some type is an immunostimulating with sequence-independent manner or sequence dependent form.In addition, report: these panimmunity pungencys RNA can stimulate TLR3, TLR7 or TLR8.
Summary of the invention
Generally speaking; The present invention relates to contain the oligoribonucleotide (ORN) of the immunostimulating of some immunostimulating RNA motif; And the method for use that contains related immune irritating compositions and this para-immunity pungency ORN and the compsn of this para-immunity pungency ORN.Immunostimulating ORN of the present invention is applicable to and anyly is used for stimulating or device (setting) that enhancing immunity is replied or use.Disclosed like hereinafter, immunostimulating ORN of the present invention is particularly useful for preparing the pharmaceutical composition that contains adjuvant, vaccine and other medicament, and said pharmaceutical composition is used to treat various disease conditions, comprises infection, cancer, transformation reactions and asthma.Therefore, the present invention relates to the immunostimulating compsn that contains immunostimulating ORN of the present invention in some aspects, and their method of use.Disclosed like hereinafter; Immunostimulating ORN of the present invention and immunostimulating compsn are particularly useful in the following method, and said method is used for immune cell activated, the vaccine inoculation experimenter; Treatment suffers from the experimenter of immune system defect; Treatment suffers from the experimenter of infection, and treatment suffers from the experimenter of autoimmune disease, and treatment suffers from the experimenter of cancer; Treatment suffers from the experimenter of allergic conditions, and treatment suffers from asthma, airway remodeling (airway remodeling), promotes the experimenter of epi-position expansion and ADCC (ADCC).
Disclosed in more detail like hereinafter, immunostimulating ORN of the present invention is characterised in that they comprise the immunostimulating RNA motif of at least a sequence dependent.The RNA sequence that the immunostimulating RNA motif of sequence dependent is normally short; Although this motif also can contain modification in certain embodiments, the nuclear base (nucleobase) that for example phosphoric acid connects through between the Nucleotide of modifying, warp is modified, sugar, nucleotide analog or its any combination through modifying.As described in greater detail below, in one embodiment, immunostimulating RNA motif is present in the environment of longer immunostimulating ORN of the present invention.Immunostimulating RNA motif also may reside in the environment of chimeric DNA:RNA nucleic acid molecule.
The immunostimulating RNA motif of sequence dependent has had the immunostimulating ORN of these motifs to be disclosed as the agonist of TLR8 with adding.More specifically, at least some sequence dependent immunostimulating RNA motif, immunostimulating ORN and immunostimulating DNA:RNA nucleic acid molecule to be disclosed as be the agonist of TLR8 rather than the agonist of TLR7.
The immunostimulating RNA motif of some aspects is N-U-R according to the present invention 1-R 2
N is a ribonucleotide, and N does not comprise U.In some embodiments, N is adenosine or cytosine(Cyt) (C) or derivatives thereof.
U is the uridylic or derivatives thereof.
R is a ribonucleotide, wherein R 1And R 2One of at least be adenosine (A) or cytosine(Cyt) or derivatives thereof.R is not U, only if N-U-R 1-R 2Contain at least two A.
ORN of the present invention contains at least one and contains in some embodiments more than (promptly 2,3 or 4 a) immunostimulating motif N-U-R 1-R 2ORN does not contain the TLR7/8 motif.The ORN preferred length is 4-100, and randomly contains at least one place backbone modifications.
N in some embodiments-U-R 1-R 2Can contain at least 3 As or at least 2 Cs.Randomly, N-U-R 1-R 2Contain at least one G or C.
In some embodiments, ORN is not ACCCAUCUAUUAUAUAACUC (SEQID NO:89).
In some other embodiment, the ORN motif is separated through non-nucleotide joint and 5 ' ribonucleotide.Also in some other embodiment, the ORN motif is separated through non-nucleotide joint and 3 ' ribonucleotide.Randomly, the ORN motif is separated through non-nucleotide joint and 5 ' and 3 ' ribonucleotide.
ORN also comprises pharmaceutically useful vector, and it randomly is lipid vector such as N-[1-(2,3-two oleoyl oxygen) propyl group]-N, N, N trimethyl ammonium methylsulfuric acid ester (DOTAP).In some other embodiment, ORN is not compound with DOTAP.
ORN can be strand or two strands.
In some other embodiment, ORN contains at least one AU.Also in some other embodiment, ORN contains at least one CU.
In some embodiments; ORN is one of following: A*U*A*G*G*C*A*C (SEQ IDNO:4), G*C*C*A*C*C*G*A*G*C*C*G*A*A*U*A*U*A*C*C (SEQ IDNO:11), A*U*A*U*A*U*A*U*A*U*A*U*A*U*A*U*A*U*A*U (SEQ IDNO:12), U*U*A*U*U*A*U*U*A*U*U*A*U*U*A*U*U*A*U*U (SEQ IDNO:13), A*A*U*A*A*U*A*A*U*A*A*U*A*A*U*A*A*U*A*A (SEQ IDNO:16), A*A*A*U*A*A*A*U*A*A*A*U*A*A*A*U*A*A*A*U (SEQ IDNO:17), A*A*A*A*U*A*A*A*A*U*A*A*A*A*U*A*A*A*A*U (SEQ IDNO:18), C*U*A*C*U*A*C*U*A*C*U*A*C*U*A*C*U*A*C*U (SEQ IDNO:24), U*U*A*U*U*A*U (SEQ ID NO:30), U*A*U*A*U*A*U (SEQ IDNO:33), C*C*G*A*G*C*C*G*C*A*U*U*A*C*C*C (SEQ ID NO:48), C*C*G*A*G*C*C*G*A*U*U*G*A*A*C*C (SEQ ID NO:76), C*C*G*A*G*C*C*G*A*A*U*A*C*C*C*C (SEQ ID NO:42), C*C*G*A*G*C*C*A*U*A*U*A*U*A*U*C (SEQ ID NO:39), C*C*G*A*G*C*C*G*A*U*A*U*U*A*C*C (SEQ ID NO:65), C*C*G*A*G*C*C*G*A*A*U*C*C*C*C*C (SEQ ID NO:44), C*C*G*A*G*C*C*G*C*C*U*A*C*C*C*C (SEQ ID NO:47), C*C*G*A*G*C*C*A*U*A*U*A*U*C*C*C (SEQ ID NO:38), C*C*G*A*G*C*C*G*C*U*A*U*A*C*C*C (SEQ ID NO:37), C*C*G*A*G*C*C*G*A*A*U*A*A*C*C*C (SEQ ID NO:40), C*C*G*A*G*C*C*G*C*U*A*U*C*C*C*C (SEQ ID NO:55), C*C*G*A*G*C*C*G*A*A*G*G*U*A*C*C (SEQ ID NO:82), C*C*G*A*G*C*C*G*A*A*G*A*U*A*C*C (SEQ ID NO:85), C*C*G*A*G*C*C*G*A*A*U*G*U*A*C*C (SEQ ID NO:63), C*C*G*A*G*C*C*G*C*C*U*A*A*C*C*C (SEQ ID NO:43), C*C*G*A*G*C*C*G*C*A*U*A*U*C*C*C (SEQ ID NO:36), C*C*G*A*G*C*C*G*A*A*G*C*U*A*C*C (SEQ ID NO:87), C*C*G*A*G*C*C*G*C*A*U*A*C*C*C*C (SEQ ID NO:45), C*C*G*A*G*C*C*G*C*A*U*A*A*C*C*C (SEQ ID NO:41), C*C*G*A*G*C*C*G*A*A*G*G*U*G*C*C (SEQ ID NO:83), C*C*G*A*G*C*C*G*C*A*U*C*C*C*C*C (SEQ ID NO:46), C*C*G*A*G*C*C*G*A*A*G*C*U*G*C*C (SEQ ID NO:88), C*C*G*A*G*C*C*G*C*C*G*C*C*C*C*C (SEQ ID NO:35), C*C*G*A*G*C*C*G*A*A*G*C*U*C*C*C (SEQ ID NO:84), or C*C*G*A*G*C*C*G*A*A*G*G*C*A*C*C (SEQ ID NO:56).
ORN gets rid of the TLR7/8 motif especially.The TLR7/8 motif can contain and for example is selected from following ribonucleoside acid sequence:
(i)5′-C/U-U-G/U-U-3′，
(ii)5′-R-U-R-G-Y-3′，
(iii)5′-G-U-U-G-B-3′，
(iv) 5 '-G-U-G-U-G/U-3 ' and
(v)5′-G/C-U-A/C-G-G-C-A-C-3′，
Wherein C/U is cytosine(Cyt) (C) or uridylic (U), and G/U is guanine (G) or U, and R is a purine, and Y is a pyrimidine, and B is U, G or C, and G/C is G or C, and A/C is VITAMIN B4 (A) or C.
In multiple embodiments, 5 '-C/U-U-G/U-U-3 ' is CUGU, CUUU, UUGU or UUUU.
In multiple embodiments, 5 '-R-U-R-G-Y-3 ' is GUAGU, GUAGC, GUGGU, GUGGC, AUAGU, AUAGC, AUGGU or AUGGC.In one embodiment, base sequence is GUAGUGU.
In multiple embodiments, 5 '-G-U-U-G-B-3 ' is GUUGU, GUUGG or GUUGC.
In multiple embodiments, 5 '-G-U-G-U-G/U-3 ' is GUGUG or GUGUU.In one embodiment, base sequence is GUGUUUAC.
In multiple embodiments, 5 '-G/C-U-A/C-G-G-C-A-C-3 ' is GUAGGCAC, GUCGGCAC, CUAGGCAC or CUCGGCAC.
One aspect of the present invention provides the immunostimulating compsn that comprises immunostimulating ORN of the present invention and adjuvant.In multiple embodiments, adjuvant is adjuvant, immunostimulating adjuvant that produces storage effect (depot effect) or the adjuvant that produces storage effect and stimulating immune system.In one embodiment, the immunostimulating compsn of this aspect is the conjugate of immunostimulating ORN and adjuvant according to the present invention.In the embodiment aspect this according to the present invention, immunostimulating ORN and adjuvant are covalently bound.They are not puted together in some other embodiment.In one embodiment, adjuvant is the agonist of TLR9.In one embodiment, adjuvant is the CpG nucleic acid of immunostimulating.
Compsn of the present invention can randomly contain antigen.Therefore, one aspect of the present invention provides following vaccine, and wherein said vaccine contains immunostimulating ORN of the present invention and antigen.One aspect of the present invention provides a kind of vaccine, and said vaccine contains immunostimulating ORN of the present invention and antigenic conjugate.In one embodiment, the conjugate of this aspect contains the immunostimulating ORN covalently bound with antigen according to the present invention.In some other embodiment, they are not puted together.In a plurality of embodiments, antigen can be antigen itself.Antigen can be any antigen, comprises cancer antigen, microbial antigen or allergen.
One aspect of the present invention provides the immunostimulating compsn, and said compsn contains the conjugate of immunostimulating ORN of the present invention and lipophilic portion.In one embodiment, the ORN of immunostimulating and lipophilic portion are covalently bound.In one embodiment, lipophilic portion is selected from cholesteryl, palmityl and fatty acyl group.In one embodiment, lipophilic portion is the verivate of SUV, for example cholesteryl.
In one embodiment, immunostimulating ORN contains at least one deoxyribonucleotide.Said at least one deoxyribonucleotide can appear at outside the immunostimulating RNA motif Anywhere usually.In a plurality of embodiments, said at least one deoxyribonucleotide is 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23 or 24 successive deoxyribonucleotide.The present invention has also considered to comprise the immunostimulating ORN of discrete deoxyribonucleotide.In a plurality of embodiments, at least one deoxyribonucleotide is 5 ' end, 3 ' end or 5 ' and the 3 ' two ends of immunostimulating ORN.Said at least one deoxyribonucleotide is also corresponding to the DNA part of chimeric DNA:RNA molecule.In one embodiment, the DNA component of chimeric DNA:RNA molecule comprises CpG nucleic acid, i.e. the TLR9 agonist.In one embodiment, the DNA of chimeric DNA:RNA molecule and RNA are partly covalently bound through phosphate bond between Nucleotide.In another embodiment, the DNA of chimeric DNA:RNA molecule and RNA are partly covalently bound through joint (for example non-nucleotide joint).
One aspect of the present invention provides the immunostimulating compsn, and said compsn comprises covalence closed, the nucleic acid molecule part strand, dumb-bell shape, and wherein at least one strand of this molecule partly comprises immunostimulating RNA motif of the present invention.
One aspect of the present invention provides the pharmaceutical composition of the compsn that comprises the aforementioned any aspect of the present invention and optional pharmaceutically acceptable vector, said compsn be selected from following delivery vehicle and combine: cation lipid, liposome, spiral helicine (cochleate), virion, immunostimulating mixture (ISCOM), particulate, microballoon, millimicro ball, unilamellar vesicle (LUV), multilamellar vesicle, oil-in-water emulsion, water-in-oil emulsion, newborn body (emulsome) and polycation peptide.In the embodiment aspect this according to the present invention, pharmaceutical composition comprises antigen.
Can in atomizer or sucker, prepare ORN, for example metered-dose inhaler (metered doseinhaler) or Diskus.In some embodiments, ORN also comprises additional compositions, for example chemotherapeutic, antiviral agent or pharmaceutically acceptable vector.Pharmaceutically acceptable vector can be configured to and be used for injection or mucosal administration.
In addition; According to these aspects of the present invention and others; In multiple embodiments; Immunostimulating ORN can choose wantonly comprise between at least one 5 '-5 ' Nucleotide connect, connect between at least one 3 '-3 ' Nucleotide, at least one comprises between 5 of shank '-5 ' Nucleotide and connects, at least one comprises between 3 of shank '-3 ' Nucleotide and connect, or its any combination.In one embodiment, shank is the non-nucleotide shank.
In addition; Also according to these aspects of the present invention and others; In multiple embodiments, immunostimulating ORN can choose wantonly to comprise between at least one 2 '-2 ' Nucleotide and connect or its any combination between connection, at least 2 '-5 ' Nucleotide between connection, at least one 2 '-3 ' Nucleotide.In preferred embodiments, connect between said at least one 2 '-2 ' Nucleotide, connect between at least one 2 '-3 ' Nucleotide or at least 2 '-5 ' Nucleotide between connect and be present in outside the immunostimulating RNA motif.
Also according to these and others of the present invention, in one embodiment, immunostimulating ORN comprises at least one multiplication units (multiplier unit).Therefore, in certain embodiments, immunostimulating ORN of the present invention can have branched structure.The ramose compsn can comprise 3 of arbitrary combination '-5 ', 5 '-5 ', 3 '-3 ', 2 '-2 ', 2 '-3 ' or 2 '-5 ' Nucleotide between key.In one embodiment, immunostimulating ORN comprises at least two multiplication units, produces so-called dendrimer (dendrimer).In addition; In certain embodiments; Immunostimulating ORN of the present invention can comprise two or more immunostimulating RNA motifs, and it is the linear ORN random alignment in the dissimilar arm upper edge of branched structure for example, or property ORN random alignment all along the line and being positioned on the dissimilar arm of branched structure.The optional CpG nucleic acid that comprises at least one immunostimulating of branched structure (comprising dendrimer) is for example as the independent arm of branched structure.
Also according to these and others of the present invention, in one embodiment, immunostimulating ORN does not comprise CG DNA or RNA dinucletide.
One aspect of the present invention provides and has been used to reduce the method that inhibitive ability of immunity CD4+ regulates (Treg) cell.The method of this aspect comprises the steps: the compsn of CD4+Treg cell and containing of significant quantity TLR8-specific immunity stimulation of the present invention ORN is contacted according to the present invention, to reduce the effect of CD4+Treg cell inhibiting.In one embodiment, compsn comprises TLR8-specificity ORN and immunostimulating CpG nucleic acid, and wherein TLR8-specificity ORN is not connected with immunostimulating CpG nucleic acid.In one embodiment, compsn contains TLR8-specificity ORN and immunostimulating CpG nucleic acid, and wherein specific ORN of TLR8-and immunostimulating CpG nucleic acid exist as conjugate.
The present invention provides the method that is used for regulating and control experimenter's immunne response on the other hand.The method of this aspect comprises the step of the experimenter being used the present composition of significant quantity according to the present invention.In some embodiments, ORN can be sent to the experimenter, with treatment autoimmune disease or airway remodeling in the experimenter.ORN can be used to the experimenter separately or with antigen.Randomly, send ORN with mouth for example, nose, hypogloeeis, intravenously, subcutaneous, mucous membrane, breathing, direct injection with through the approach of skin.ORN can send to the experimenter with the inducing cell factor expression with significant quantity, for example TNF α, IL-10, IL-6, IFN-γ, MCP1 and IL-12.
One aspect of the present invention provides the method to experimenter's vaccine inoculation.The method of this aspect comprises the step to experimenter's administration of antigens and immunostimulating ORN of the present invention according to the present invention.
One aspect of the present invention provides the method that is used to treat the experimenter, and said experimenter suffers from communicable disease or has the risk of suffering from communicable disease.The method of this aspect comprises the step of the experimenter being used the present composition of significant quantity according to the present invention.In one embodiment, this method comprises the step of the experimenter being used the immunostimulating ORN of the present invention of significant quantity.In one embodiment, the experimenter suffers from virus infection.Virus infection can be for example hepatitis B or hepatitis C.Also can use antiviral agent to the experimenter.Randomly, antiviral agent is connected with ORN.
One aspect of the present invention provides the method that is used to treat the experimenter, and said experimenter suffers from cancer or has cancered risk.The method of this aspect comprises the step of the experimenter being used the present composition of significant quantity according to the present invention.In one embodiment, this method comprises the step of the experimenter being used the immunostimulating ORN of the present invention of significant quantity.In one embodiment, also the experimenter is used chemotherapy or radiation.
One aspect of the present invention provides the method that is used to treat the experimenter, and said experimenter suffers from cancer or has cancered risk.The method of this aspect comprises the step of the experimenter being used the compsn of significant quantity according to the present invention, and said compsn contains TLR8-specific immunity pungency ORN of the present invention to reduce the effect of CD4+Treg cell inhibiting.In one embodiment, compsn comprises TLR8-specificity ORN and immunostimulating CpG nucleic acid, and wherein TLR8-specificity ORN is not connected with immunostimulating CpG.In one embodiment, compsn comprises TLR8-specificity ORN and immunostimulating CpG nucleic acid, and wherein TLR8-specificity ORN and immunostimulating CpG nucleic acid exist as conjugate.
One aspect of the present invention provides the method that is used to treat the experimenter, and said experimenter suffers from allergic conditions or has the risk of suffering from allergic conditions.The method of this aspect comprises the step of the experimenter being used the present composition of significant quantity according to the present invention.In one embodiment, this method comprises the step of the experimenter being used the immunostimulating ORN of the present invention of significant quantity.In one embodiment, the experimenter suffers from rhinallergosis.
One aspect of the present invention provides the method that is used to treat the experimenter, and said experimenter suffers from asthma or has the risk of suffering from asthma.The method of this aspect comprises the step of the experimenter being used the present composition of significant quantity according to the present invention.In one embodiment, this method comprises the step of the experimenter being used the immunostimulating ORN of the present invention of significant quantity.In one embodiment, the asthma that increased the weight of by virus infection of asthma.ORN can be used separately or with allergen.
Another aspect of the present invention provides the method that is used to treat the experimenter who suffers from airway remodeling.The method of this aspect comprises the step of the experimenter being used the immunostimulating ORN of the present invention of significant quantity according to the present invention.
One aspect of the present invention provides the method that is used to improve ADCC (ADCC).The experimenter of the ADCC that the method for this aspect comprises the steps: needs are increased according to the present invention uses the immunostimulating ORN of the present invention and the antibody of significant quantity, to increase ADCC.In one embodiment, antibody is the antibody to other antigen-specific of cancer antigen or cancer cells expression.In one embodiment, antibody is IgG antibody.
One aspect of the present invention provides the method that is used to strengthen the epi-position expansion.The method of this aspect comprises following sequential steps according to the present invention: immune cell is contacted with antigen, subsequently this cell is contacted with the immunostimulating ORN of the present invention of two doses at least.In one embodiment, carry out in this method body.In one embodiment; This method comprises the steps: with the amount that can effectively induce multiple epi-position specific immune response the experimenter to be used the vaccine that comprises antigen and adjuvant, subsequently the experimenter is used the immunostimulating ORN of the present invention of at least two doses.This method relates to the application of treatment scheme in one embodiment; Said scheme causes the immunity system antigen-exposed among the experimenter, with the amount that can effectively induce multiple epi-position specific immune response the experimenter is used the immunostimulating ORN of the present invention of at least two doses then.In multiple embodiments, regimen is operation, radiation, chemotherapy, other cancer medicament, vaccine or cancer vaccine.In one embodiment, the immunostimulating ORN of said at least two doses separates each other and used to a periderm at least one day.In one embodiment, the immunostimulating ORN of said at least two doses separates each other and was used at least one thoughtful one month.In one embodiment, the immunostimulating ORN of said at least two doses separates each other and was used by six months by at least one moon.
On the one hand, the present invention be through will expressing TLR8 cell and following dosage comprise N-U-R 1-R 2RNA oligoribonucleotide (ORN) contact, wherein N is that ribonucleotide and N do not comprise U, U is the uridylic or derivatives thereof, R is a ribonucleotide, wherein R 1And R 2One of at least be adenosine (A) or cytosine(Cyt) or derivatives thereof, wherein R is not U, only if N-U-R 1-R 2Contain at least two A; Wherein said ORN does not comprise the TLR7/8 motif; And wherein said ORN length is 4-100, and inflammatory cytokine production and IFN-α production of wherein responding to ORN are not significantly induced for background before the said consumption effective stimulus.In some embodiments, the IFN-α that responds to ORN produces and to be less than 300pg/ml.In one embodiment, ORN is not ACCCAUCUAUUAUAUAACUC (SEQ ID NO:89).ORN can with N-[1-(2,3-two oleoyl oxygen) propyl group]-N, N, N trimethyl ammonium methylsulfuric acid ester (DOTAP) is compound or not compound.
In some embodiments, the cell of expression TLR8 is monocyte or mDC.Also in some other embodiment, the cell of expressing TLR8 is external or intravital.
Of the present invention these will be described in the detailed Description Of The Invention part with further feature in more detail.
Summary of drawings
Fig. 1 is by ORN inductive cytokine production when being described in the PBMC stimulation.Through measuring IFN-α and TNF-α cytokine production, observe the difference between TLR8 and the TLR7/8.Using with DOTAP (25 μ g/ml, 1/3 extent of dilution) compound appointment ORN (2 μ M, 1/3 extent of dilution) or with R-848 (2 μ M, 1/3 extent of dilution) stimulation human PBMC on the titration curve fully.Collect supernatant after 16 hours, and through ELISA measure IFN-α (Fig. 1 a) with TNF-α (Fig. 1 b).Data presentation the average of three blood donors of at least three parts of independent experiments.DOTAP does not show effect separately.ORN can be compound with DOTAP, and R-848 is not compound.DOTAP is separately contrast.In Fig. 1 c, using with DOTAP (2.2 μ g/ml) or with the specified ORN of R-848 (2 μ M) compound 0.2 μ M stimulates the human PBMC.Collect supernatant after 16 hours and measure IFN-α (left figure) and TNF-α (right figure) through ELISA.Data presentation the average of 3 donors (± SEM).
Fig. 2 is one group of histogram, its described separated pDC (Fig. 2 a), when monocyte (Fig. 2 b) and mDC (Fig. 2 c) stimulate by ORN inductive cytokine production.Use and 10 μ g/mlDOTAP, 0.5 μ M CpG ODN or DOTAP compound 0.5 μ M ORN or medium alone irritation cell, and measure IFN-α (Fig. 2 a), TNF-α (Fig. 2 c) and IL-12p40 (Fig. 2 c).
Fig. 3 is one group of histogram, its set forth PBMC when stimulating by ORN inductive cytokine production.Use with 10 μ g/ml DOTAP compound and specify ORN (0.5 μ M ORN) to stimulate the human PBMC, and measure IFN-α (Fig. 3 A) and TNF-α (Fig. 3 B) and pass through Luminex commercial measurement cytokine production through elisa technique.
Fig. 4 be set forth to specify ORN (Fig. 4 a) with TNF-α (Fig. 4 b) maximum activity histogram relatively.Using with DOTAP (since 25 μ g/ml, extent of dilution 1/3) compound ORN (7 kinds of concentration are since 2 μ g/ml, 1/3 extent of dilution) stimulates the human PBMC, and the average maximum activity of the 0.6 μ M 3-6 of a place blood donor in two parts of independent experiments is measured.
Fig. 5 be set forth IFN-α maximum activity (Fig. 5 a) with IFN-α EC50 (Fig. 5 b) histogram relatively.Being used for DOTAP compound ORN stimulates the human PBMC and measures IFN-α.
Fig. 6 is a set of diagrams, its compared have TLR8 (SEQ ID NO:13) or TLR7/8 (SEQID NO:21) ORN to the PBMC of 3 blood donors, separated pDC or separated monocytic titration curve.Use irritation cell with DOTAP (since 25 μ g/ml, 1/4 extent of dilution) compound ORN (4 kinds of concentration are since 1 μ g/ml, 1/4 extent of dilution).Collect supernatant after 16 hours and pass through Luminex commercial measurement cytokine production.Figure shows SEQ ID NO:21 (0,3 μ M) cytokine production per-cent.
Fig. 7-1 has shown one group of column diagram to 7-4, and it is set forth in the average maximum activity of 3 blood donors of any concentration to PMBC, separated monocyte, separated pDC and CD14-CD123-PBMC.Use irritation cell with DOTAP (since 25 μ g/ml, 1/4 extent of dilution) compound ORN (4 kinds of concentration are since 1 μ g/ml, 1/4 extent of dilution).Collect supernatant after 16 hours and pass through Luminex commercial measurement cytokine production.The positive reaction of red square indication on the background of DOTAP and substratum.
Fig. 8 is one group of column diagram, and it has shown the difference between TLR8 (SEQ ID NO:13) and TLR7/8 (SEQID NO:21) ORN.Use irritation cell with DOTAP (since 25 μ g/ml, 1/4 extent of dilution) compound ORN (4 kinds of concentration are since 1 μ g/ml, 1/4 extent of dilution).Collect supernatant after 16 hours and pass through Luminex commercial measurement cytokine production.The average maximum cell factor under any concentration of pictorialization measurement is produced, and it is expressed as the per-cent of TLR8 ORN (SEQ ID NO:13) than TLR7/8 ORN (SEQ ID NO:21).Show to separated pDC, PBMC, separated monocyte and CD123-CD14-PBMC.
Fig. 9 is set of diagrams and curve, and it has shown in the HEK-293 of stable transfection cell through the TLR8 ORN (SEQ ID NO:13) of TLR8 effect and the reaction of TLR7/8 ORN (SEQ ID NO:21).With HEK-293 cytositimulation 16 hours, said HEK-293 cell was read report and people TLR8 stable transfection with NF κ B-luciferase with specified ORN.Remove supernatant after 16 hours, with lysis and measure luciferase activity or cytokine levels.Fig. 9 a and 9b have shown stimulates the multiple of back NF κ B-luciferase to induce.Fig. 9 c has shown stimulates the multiple of back NF κ B-luciferase to induce when having suppressor factor.Fig. 9 d has shown that the post-stimulatory IP-10 that measures through luciferase assay stimulates.
Figure 10 is the set of diagrams table, and it has shown with the surface marker that is rich in AU or be rich on the people pDC that the ORN of GU stimulates expresses.Use with 25 μ g/ml DOTAP compound 1 μ M ORN or use separately DOTAP (Figure 10 a), or specified amount with DOTAP compound ORN or use DOTAP (Figure 10 b-10c) to hatch purified pDC of CD123+ (Figure 10 a and 10b) or separated monocyte (Figure 10 c) separately.Collecting cell is also with CD123, CD11c and HLA-DR antibody (Figure 10 a and 10b) or CD14 and CD19 (Figure 10 c) dyeing after 16 hours.Expressing measurement cell surface marker thing through CD86 (Figure 10 a and 10b) or CD80 (Figure 10 c) activates.Figure 10 a shows facs analysis, and it has proved that ORN (SEQ ID NO:13) that is rich in AU and the ORN (SEQ ID NO:21) that the is rich in GU CD86 surface marker when pDC stimulates shows difference in expressing.Figure 10 b is that the CD86 surface marker expression when setting forth people pDC stimulation is a dose-dependently.Figure 10 c is the figure that shows following content: be rich in the ORN (SEQ ID NO:13) of AU and the ORN (SEQ ID NO:21) that is rich in GU shows indifference human PBMC's (data not shown) during with the stimulation of CD14-positive cell in the expression of CD80 surface marker.
Figure 11 is one group of column diagram, and it has shown the difference between TLR8 ORN (SEQ ID NO:13) and the TLR7/8ORN (SEQ ID NO:21).Use SEQ ID NO:5 ORN as contrast.Ox PBMC and 10 μ g/ml ORN (HD) or 2.5 μ g/ml ORN (LD) were hatched 48 hours.Collect supernatant and use elisa assay.Figure 11 a-c has shown the level of IL-12, IFN-γ and TNF-α respectively.
Figure 12 is one group of chart that shows following content: the interior or external ORN SEQ ID NO:13 that is rich in AU that do not respond to of mouse cell paste.The cell that uses be mouse macrophage Raw264.7 cell (Figure 12 a), J774 cell (Figure 12 b), purified mouse CD11c+ cell (sv129 mouse) (Figure 12 c-12g) and the interior mouse cell of body.Estimate cytokine concentrations through ELISA.
Figure 13 is a chart of showing following content: rat spleen cells does not respond to the ORNSEQ ID NO:13 that is rich in AU.To merge from the splenocyte of 3 Sprague-Dawley rats; And with SEQ ID NO:21, SEQ ID NO:13 (all compound, 1/5 extent of dilution), R-848 or the DOTAP of prescribed concentration with 62.5 μ g/ml DOTAP separately (62.5 μ g/ml-＞1/5 extent of dilution) stimulate.Collect supernatant after 20 hours and measure the TNF-alpha levels through ELISA.
Detailed Description Of The Invention
A part of the present invention relates to the discovery of contriver of the present invention to a large amount of sequence-specific immunostimulating RNA motifs.Have been found that at present: the molecule (making up separately or with some other composition) that contains immunostimulating RNA motif is important immunostimulating compound; It suffers from illness or has experimenter's a big metering method of ill disease risk useful being used for treating, and it can be favourable inducing, increase or change immunne response in the said illness.In one embodiment, the employed immunostimulating compsn of the present invention of this paper is immunostimulating ORN of the present invention.
Have been found that some sequence-specific RNA motif is an immunostimulating, it is opposite with other motif that acts on TLR7 and TLR8 (be rich in GU and be rich in CU) through the TLR8 effect.RNA oligonucleotide (RON) (preferably containing the sequence that is rich in AU) is replied through the TLR8 immune stimulatory.In different types of ORN (for example contain AU and contain GU multiple ORN), observed the difference between IFN-α, TNF-α, IFN-γ and the IL-12 production.What is interesting is, have been found that immunostimulating ORN of the present invention produces strong preceding inflammatory cytokine and replys, and except the IFN-α molecule relevant with IFN-α.IFN-α production is reduced or shortage when stimulating with these novel ORN.
The immunostimulating RNA motif of some aspects is N-U-R according to the present invention 1-R 2
N is a ribonucleotide, and N does not comprise U.In some embodiments, N is adenosine or cytosine(Cyt) (C) or derivatives thereof.
U is the uridylic or derivatives thereof.
R is a ribonucleotide, wherein R 1And R 2One of at least be adenosine (A) or cytosine(Cyt) or derivatives thereof.R is not U, only if N-U-R 1-R 2Contain at least two A.
ORN of the present invention contains at least one and contains more than (promptly 2,3 or 4 a) immunostimulating motif N-U-R in some embodiments 1-R 2ORN does not contain the TLR7/8 motif.
ORN is an oligonucleotide.Randomly, this oligonucleotide length is 4-100.ORN length also can be 8-40, a 15-25 or 20-30 Nucleotide for example.ORN randomly contains at least one backbone modifications.
N in some embodiments-U-R 1-R 2Can contain at least 3 As or at least 2 Cs.Randomly, N-U-R 1-R 2Contain at least one G or C.
In some embodiments, ORN is not ACCCAUCUAUUAUAUAACUC (SEQID NO:89).
ORN also can comprise pharmaceutically useful vector, and it randomly is lipid vector such as N-[1-(2,3-two oleoyl oxygen) propyl group]-N, N, N trimethyl ammonium methylsulfuric acid ester (DOTAP).In some other embodiment, ORN is not compound with DOTAP.Pharmaceutically acceptable vector can be a peptide in some other embodiment, like the polycation peptide.The polycation peptide comprise for example multiple poly-lysine, poly l-arginine and polypeptide (its more than 5, particularly the scope more than 8 amino-acid residues contains basic aminoacids, particularly l-arginine or lysine residue more than 50%) or its mixture, and can for example contain naturally occurring insect antimicrobial protein.
In some other embodiment, ORN contains at least one AU.
Except be sequence-specific, as single stranded RNA, partially double stranded RNA or fully the immunostimulating RNA motif of double-stranded RNA be effective.
As far as ORN of the present invention with have the TLR7/8 motif ORN of (promptly containing the repetition of GU), observe the clear difference between the production of IFN-α and IFN-α associated molecule and other preceding inflammatory cytokine such as TNF-α, IFN-γ, IL-10, IL-6 and IL-12.Has N-U-R 1-R 2The ORN of the present invention of motif, for example those ORN that contain AU or AUU repetition (SEQ ID NO:12, SEQ IDNO:13) show no IFN-α cytokine production when PBMC and pDC stimulation.On the contrary, the ORN with three or more U (SEQ ID NO:14, SEQ ID NO:15) in the row induces IFN-α production, although there is As.What is interesting is that when using identical, single chamber with the ORN group of A exchange G, the strong IFN-α when observing PBMC and stimulating produces.The existence that the data that this paper exists are pointed out two different ORN kinds consumingly: a kind of cell of expressing TLR8 that acts on; Like monocyte and mDC (SEQ ID NO:12; SEQ ID NO:13, SEQ ID NO:16-SEQ IDNO:18), contain N-U-R of the present invention 1-R 2The ORN of motif, another kind act on and express the two cell of TLR7/8, for example contain monocyte, mDC and the pDC (SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:19-SEQ ID NO:23) of CU, GU and GUU sequence.
Therefore, ORN of the present invention have induce immune response and non-induction phase for the ability of the significant quantity IFN-α or the IFN-α associated molecule of background.Preferably change with respect to the IFN-α of the significant quantity of background or IFN-α associated molecule and to be less than 20% with respect to the IFN-α of background or IFN-α associated molecule level.In some embodiments, it is less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%.In some other embodiment, derivative IFN-α or associated molecule equal background or are less than background level.Also in some other embodiment, be less than or equal by 20% of TLR7/8 ORN inductive IFN-α by ORN inductive IFN-α of the present invention.By ORN inductive IFN-α of the present invention optional 300pg/ml that is less than in vitro test, maybe can have EC50 greater than 1.5 μ M.
The IFN-α associated molecule that this paper uses is cytokine or the factor relevant with the IFN-alpha expression.These molecules include but not limited to MIP1-β, IP-10 and MIP1-α.
Report CD4+Treg cell expressing TLR8 at present, and the TLR8 signal transduction in these cells reduces or has reversed their immunostimulation sexual function.Peng?G?et?al.(2005)Science309：1380-4。In the patient who suffers from the broad variety cancer, observe the CD4+Treg cell population of increase, wherein immunosuppression can help the growth of immunity " escape " and these cancers of downward modulation.Therefore, estimate the Treg-mediation inhibition to be reversed in the treatment cancer be favourable.
PRN gets rid of the TLR7/8 motif especially.Have been found that the TLR7/8 motif can produce the dominance result, it has shielded the immunostimulatory properties of the uniqueness of ORN of the present invention.The TLR7/8 motif comprises for example ribonucleoside acid sequence, as 5 '-C/U-U-G/U-U-3 ', 5 '-R-U-R-G-Y-3 ', 5 '-G-U-U-G-B-3 ', '-G-U-G-U-G/U-3 ' or 5 '-G/C-U-A/C-G-G-C-A-C-3 '.C/U is cytosine(Cyt) (C) or uridylic (U), and G/U is guanine (G) or U, and R is a purine, and Y is a pyrimidine, and B is U, G or C, and G/C is G or C, and A/C is VITAMIN B4 (A) or C.5 '-C/U-U-G/U-U-3 ' can be CUGU, CUUU, UUGU or UUUU.In a plurality of embodiments, 5 '-R-U-R-G-Y-3 ' is GUAGU, GUAGC, GUGGU, GUGGC, AUAGU, AUAGC, AUGGU or AUGGC.In one embodiment, base sequence is GUAGUGU.In a plurality of embodiments, 5 '-G-U-U-G-B-3 ' is GUUGU, GUUGG or GUUGC.In a plurality of embodiments, 5 '-G-U-G-U-G/U-3 ' is GUGUG or GUGUU.In one embodiment, base sequence is GUGUUUAC.In a plurality of embodiments, 5 '-G/C-U-A/C-G-G-C-A-C-3 ' is GUAGGCAC, GUCGGCAC, CUAGGCAC or CUCGGCAC.
Generally speaking; The present invention relates to immunostimulatory oligoribonucleotides; It comprises one or more immunostimulating RNA motifs, contains the method for use of immunostimulating compsn and immunostimulating ORN of the present invention and the immunostimulating compsn of one or more immunostimulating ORN of the present invention.
" the natural RNA " of term " RNA " that this paper uses and equivalence is intended to represent through the covalently bound two or more ribonucleotides (being that each molecule comprises a ribose that is connected with purine or pyrimidine nuclear base (for example guanine, VITAMIN B4, cytosine(Cyt) or uridylic) with phosphate) together of 3 '-5 ' phosphodiester bond.
The RNA motif of immunostimulating may reside in the end (when immunostimulating ORN has free-end) of immunostimulating ORN.For example, the immunostimulating ORN that has the free-end immunostimulating RNA motif terminal with being positioned at immunostimulating ORN can be used as X aM or as MX bExist, wherein M representes immunostimulating RNA motif, X aAnd X bRepresent the one or more identical or different Nucleotide of immunostimulating ORN except that immunostimulating RNA motif independently of one another.
Perhaps, immunostimulating RNA motif can be connected with at least one extra Nucleotide of immunostimulating ORN in its both-side ends, and no matter whether this immunostimulating ORN has free-end.For example, the immunostimulating ORN that has the Nucleotide of free-end and immunostimulating RNA motif flank can be used as X aMX bExist, wherein M representes immunostimulating RNA motif, X aAnd X bRepresent the one or more identical or different Nucleotide of immunostimulating ORN except that immunostimulating RNA motif independently of one another.
In different embodiments, the immunostimulating ORN that comprises immunostimulating RNA motif can contain single motif or more than one immunostimulating RNA motif.It possibly be favourable having among the single immunostimulating ORN that two or more immunostimulating RNA motifs are considered to, if for example motif is spaced and makes when immunostimulating ORN can combine two or more TLR.For example, immunostimulating ORN can combine two or more TLR8 acceptors, thus the immunostimulation that amplification or modification obtain.
When immunostimulating ORN comprised more than an immunostimulating RNA motif, immunostimulating ORN can be used as M in one embodiment 1XM 2Exist, wherein M 1And M 2Represent immunostimulating RNA motif independently of one another, X representes the one or more identical or different Nucleotide of immunostimulating ORN except that immunostimulating RNA motif.In one embodiment, X comprises non-nucleotide joint as herein described.In one embodiment, X comprises cladon as herein described.
When existing more than an immunostimulating RNA motif among the immunostimulating ORN, this motif generally can take place in any position along immunostimulating ORN.For example, when having two motifs, they can be present in the end of immunostimulating ORN separately.Perhaps, a motif may reside in an end, and a motif can be enclosed in its both-side ends through at least one outer Nucleotide of immunostimulating ORN.Also in another embodiment, each motif can be enclosed in its both-side ends through at least one extra Nucleotide of immunostimulating ORN.
Immunostimulating ORN includes but not limited to following, shows from left to right to read 5 ' to 3 ':
In some embodiments; One of ORN active ORN that to be following table 1 show with table 2, for example below: U*U*A*G*G*C*A*C (SEQ ID NO:2), A*U*A*G*G*C*A*C (SEQID NO:4), G*C*C*A*C*C*G*A*G*C*C*G*A*A*U*A*U*A*C*C (SEQ IDNO:11), A*U*A*U*A*U*A*U*A*U*A*U*A*U*A*U*A*U*A*U (SEQ IDNO:12), U*U*A*U*U*A*U*U*A*U*U*A*U*U*A*U*U*A*U*U (SEQ IDNO:13), A*A*U*A*A*U*A*A*U*A*A*U*A*A*U*A*A*U*A*A (SEQ IDNO:16), A*A*A*U*A*A*A*U*A*A*A*U*A*A*A*U*A*A*A*U (SEQ IDNO:17), A*A*A*A*U*A*A*A*A*U*A*A*A*A*U*A*A*A*A*U (SEQ IDNO:18), C*U*A*C*U*A*C*U*A*C*U*A*C*U*A*C*U*A*C*U (SEQ IDNO:24), U*U*A*U*U*A*U (SEQ ID NO:30), U*A*U*A*U*A*U (SEQ IDNO:33), C*C*G*A*G*C*C*G*C*A*U*U*A*C*C*C (SEQ ID NO:48), C*C*G*A*G*C*C*G*A*U*U*G*A*A*C*C (SEQ ID NO:76), C*C*G*A*G*C*C*G*A*A*U*A*C*C*C*C (SEQ ID NO:42), C*C*G*A*G*C*C*A*U*A*U*A*U*A*U*C (SEQ ID NO:39), C*C*G*A*G*C*C*G*A*U*A*U*U*A*C*C (SEQ ID NO:65), C*C*G*A*G*C*C*G*A*A*U*C*C*C*C*C (SEQ ID NO:44), C*C*G*A*G*C*C*G*C*C*U*A*C*C*C*C (SEQ ID NO:47), C*C*G*A*G*C*C*A*U*A*U*A*U*C*C*C (SEQ ID NO:38), C*C*G*A*G*C*C*G*C*U*A*U*A*C*C*C (SEQ ID NO:37), C*C*G*A*G*C*C*G*A*A*U*A*A*C*C*C (SEQ ID NO:40), C*C*G*A*G*C*C*G*C*U*A*U*C*C*C*C (SEQ ID NO:55), C*C*G*A*G*C*C*G*A*A*G*G*U*A*C*C (SEQ ID NO:82), C*C*G*A*G*C*C*G*A*A*G*A*U*A*C*C (SEQ ID NO:85), C*C*G*A*G*C*C*G*A*A*U*G*U*A*C*C (SEQ ID NO:63), C*C*G*A*G*C*C*G*C*C*U*A*A*C*C*C (SEQ ID NO:43), C*C*G*A*G*C*C*G*C*A*U*A*U*C*C*C (SEQ ID NO:36), C*C*G*A*G*C*C*G*A*A*G*C*U*A*C*C (SEQ ID NO:87), C*C*G*A*G*C*C*G*C*A*U*A*C*C*C*C (SEQ ID NO:45), C*C*G*A*G*C*C*G*C*A*U*A*A*C*C*C (SEQ ID NO:41), C*C*G*A*G*C*C*G*A*A*G*G*U*G*C*C (SEQ ID NO:83), C*C*G*A*G*C*C*G*C*A*U*C*C*C*C*C (SEQ ID NO:46), C*C*G*A*G*C*C*G*A*A*G*C*U*G*C*C (SEQ ID NO:88), C*C*G*A*G*C*C*G*C*C*G*C*C*C*C*C (SEQ ID NO:35), C*C*G*A*G*C*C*G*A*A*G*C*U*C*C*C (SEQ ID NO:84) or C*C*G*A*G*C*C*G*A*A*G*G*C*A*C*C (SEQ ID NO:56).
As stated, RNA is the polymer through the ribonucleotide of 3 '-5 ' phosphodiester bond connection.In certain embodiments, immunostimulating ORN of the present invention is RNA.Yet immunostimulating ORN of the present invention is not limited to RNA, will describe like hereinafter.
In one embodiment, immunostimulating ORN of the present invention can comprise two or more the nuclear base through modifying, i.e. verivates of A, C, G and U.These particular through the nuclear base of modifying include but not limited to the substituted cytosine(Cyt) of 5-(for example 5-methyl-cytosine(Cyt), 5-fluoro-cytosine(Cyt), 5-chloro-cytosine(Cyt), 5-bromo-cytosine(Cyt), 5-iodo-cytosine(Cyt), 5-hydroxyl-cytosine(Cyt), 5-methylol-cytosine(Cyt), 5-difluoromethyl-cytosine(Cyt); With unsubstituted or substituted 5-alkynyl-cytosine(Cyt)), the substituted cytosine(Cyt) of 6-; The substituted cytosine(Cyt) of N4-(for example N4-ethyl-cytosine(Cyt)), 5-aza-cytosine, 2-sulfydryl-cytosine(Cyt), iso-cytosine, false iso-cytosine, have the cytosine(Cyt) analogue (N for example of condensed ring system; N '-propylene cytosine(Cyt) Huo phenoxazine); With uridylic and verivate (for example 5-fluoro-uracil, 5-bromo-uridylic, 5-bromo vinyl-uridylic, 4-sulfo--uridylic, 5-hydroxyl-uridylic, 5-proyl-uridylic) thereof; Thymine derivative (for example 2-thio-thymine, 4-thio-thymine, the substituted thymus pyrimidine of 6-); Guanosine verivate (7-deazaguanine, the substituted guanine of 7-denitrogenation-7-(for example 7-denitrogenation-7-(C2-C6) alkynyl guanine), the substituted guanine of 7-denitrogenation-8-, xanthoglobulin, the substituted guanine of N2-(for example N2-methyl-guanine), the substituted guanine of 8-(for example 8-hydroxyl guanine and 8-bromo guanine) and 6-thioguanine) or adenosine derivative (5-amino-3-methyl-3H; 6H-thiazolyl [4; 5-d] pyrimidine-2; 7-diketone, 2,6-diaminopurine, 2-aminopurine, purine, indoles, VITAMIN B4, substituted VITAMIN B4 (for example N6-methyl-VITAMIN B4,8-oxygen-VITAMIN B4)).Base also can be by universal base (for example 4-methyl-indoles, 5-nitro-indoles, 3-nitro-pyrrole, P-base and K-base), aromatic ring (for example benzoglyoxaline or two chloro-benzoglyoxalines, 1-methyl isophthalic acid H-[1; 2,4] triazole-3-carboxylic acid amine), aromatic ring system (for example fluorobenzene or difluoro diphenyl) or Wasserstoffatoms (dSpacer) replace.Preferred base modification is uridylic and 7-denitrogenation-guanine.These can get from commercial supplier with their corresponding Yeast Nucleic Acid through the U nuclear base of modifying.
The particular of examining base through the G that modifies comprises N 2-dimethylguanine, 7-deazaguanine, guanozola, the substituted guanine of 7-denitrogenation-7-, 7-denitrogenation-7-(C2-C6) alkynyl guanine, the substituted guanine of 7-denitrogenation-8-, 8-hydroxyl guanine, 6-thioguanine and 8-oxo guanine.In one embodiment, be 8-hydroxyl guanine through the G nuclear base of modifying.These can derive from commercial supplier through the G nuclear base of modifying with their corresponding ribonucleoside.
In certain embodiments; At least one β-ribose unit can be by β-D-ribodesose or the sugar unit displacement through modifying; Wherein for example be selected from β-D-ribose, α-D-ribose, β-L-ribose (in ' Spiegelmers '), α-L-ribose, 2 '-amino-2 '-ribodesose, 2 '-fluoro-2 '-ribodesose, 2 '-O-(C1-C6) alkyl ribose through the sugar unit of modifying, preferred 2 '-O-(C1-C6) alkyl ribose is 2 '-O-methylribose, 2 '-O-(C2-C6) alkenyl ribose, 2 '-[O-(C1-C6) alkyl-O-(C1-C6) alkyl] ribose, LNA and α-LNA (Nielsen P et al. (2002) Chemistry-A European Journal8:712-22), β-D-wood-furanose, α-arbinofuranose, 2 '-fluoro arbinofuranose and carbocyclic ring and/or ring-opened saccharides seemingly thing (for example be described in Vandendriessche et al. (1993) Tetrahedron49:7223 in) and/or dicyclo sugar analogue (for example be described in Tarkov M et al. (1993) HelvChim Acta 76:481 in).
Perhaps; Each ribonucleotide of immunostimulating ORN of the present invention can be connected through the joint of non-nucleic acid with ribonucleoside, especially dealkalize base joint (abasic linkers (dSpacers)), triethylene glycol unit or six vinyl terepthaloyl moietie (hexaethylene glycol) unit.Other joint is alkylamino (alkylamino) joint, for example C3, C6 and C12 amino joint, and alkyl sulfhydryl (alkylthiol) joint, for example C3 or C6 mercaptan joint.Perhaps, the individual Nucleotide of immunostimulating ORN of the present invention can be connected through aromatic residue with ribonucleoside, and said aromatic residue also can be replaced by alkyl or substituted alkyl.
RNA is the polymer that connects the ribonucleotide that links up through 3 '-5 ' phosphodiester.The Nucleotide of immunostimulating ORN of the present invention also can link up through the connection of 3 '-5 ' phosphodiester.Yet the present invention also comprises having the ORN that connects between unusual Nucleotide, comprise 5 '-5 specifically ', 3 '-3 ', 2 '-2 ', 2 '-3 ' and 2 '-5 ' Nucleotide between key.In one embodiment, the unusual connection of this type is excluded outside immunostimulating RNA motif, although one or more this connection can be present in the other places of immunostimulating ORN.For immunostimulating ORN, comprise between one 3 '-3 ' Nucleotide to connect and to cause immunostimulating ORN to have two free, 5 ' end with free-end.On the contrary, for immunostimulating ORN, comprise between one 5 '-5 ' Nucleotide to connect and to cause the ORN of immunostimulating to have two free 3 ' ends with free-end.
Immunostimulating compsn of the present invention can contain two or more immunostimulating RNA motifs, and it can connect through the ramose unit.Connect between Nucleotide can be 3 '-5 ', 5 '-5 ', 3 '-3 ', 2 '-2 ', 2 '-3 ' or 2 '-5 ' connect.Wherein, title 2 '-5 ' is selected according to the carbon atom of ribose.Connecting between unusual Nucleotide can be that phosphodiester connects, but it also can be modified to thiophosphatephosphorothioate or any other connection through modifying as herein described.Following formula shows the general structure of ramose immunostimulating ORN of the present invention through the Nucleotide cladon.Nu wherein 1, Nu 2And Nu 3Can be through 3 '-5 ', 5 '-5 ', 3 '-3 ', 2 '-2 ', 2 '-3 ' or 2 '-5 '-connect and connect.The branch of immunostimulating ORN also can relate to non-nucleotide joint and the use at interval of dealkalize base.In one embodiment, Nu 1, Nu 2And Nu 3Represent identical or different immunostimulating RNA motif.In another embodiment, Nu 1, Nu 2And Nu 3Comprise at least one immunostimulating RNA motif and at least one immunostimulating CpG DNA motif.
Immunostimulating ORN can contain double or (Glen Research, Sterling VA), especially have the immunostimulating ORN of 3 '-3 ' key in the triple unit.In one embodiment, double unit can be with 1, and 3-is two-and [5-(4,4 '-dimethoxy three tyloxypals) amyl group carboxamido-group] propyl group-2-[(2-cyanoethyl)-(N, N-di-isopropyl)]-phosphoramidite be basic.In one embodiment, three times of unit can be with Tris-2,2,2-[3-(4,4 '-dimethoxy three tyloxypals) propyl group oxygen methyl] ethyl-[(2-cyanoethyl)-(N, N-di-isopropyl)]-phosphoramidite be integrated into the basis.Multiple double, three times or other many times of unit cause dendrimer to the branch of immunostimulating ORN, and it is another embodiment of the present invention.Ramose immunostimulating ORN can cause acceptor (like TLR3, TLR7 and TLR8) crosslinked of immunostimulating RNA, has with the immunostimulating ORN of branch form not to compare different immunizations.In addition, branch or other many bodies (multimeric) immunostimulating ORN synthetic can be stablized RNA and be not degraded, maybe can make weak or part effectively the RNA sequence demonstrate the useful immunocompetence level of treatment.Immunostimulating ORN also can contain connector unit, and it derives from peptide and modifies reagent or oligonucleotides-modified reagent (Glen Research).In addition, immunostimulating ORN can contain through peptide (acid amides) and connect the one or more natural or non-natural amino-acid residue that is connected with polymer.
3 '-5 ', 5 '-5 ', 3 '-3 ', 2 '-2 ', 2 '-3 ' and 2 '-5 ' Nucleotide between connect can be direct or non-directly.In this context, directly connect the phosphoric acid that is meant disclosed phosphoric acid connection of this paper or warp modification and connect, do not contain the insertion shank.Inserting shank is to connect with the disclosed phosphoric acid of this paper or the different organic moiety of phosphoric acid connection through modifying, and it can comprise for example polyoxyethylene glycol, triethylene glycol, six terepthaloyl moietie, dSpacer (being dealkalize base deoxynucleotide), two times of unit or three times of unit.
In certain embodiments, immunostimulating ORN and another entity are puted together the generation conjugate.The conjugate that this paper uses is meant the combination of any two or a plurality of entities that are bonded to each other through any physical chemistry approach (comprising hydrophobic interaction and covalent coupling).
In another embodiment, immunostimulating ORN can put together with the small molecular weight part of being discerned by the immunostimulating acceptor.This receptor is the member of TLR family preferably, for example TLR2, TLR3, TLR4, TLR7, TLR8 or TLR9.The small molecular weight part is the mimicry to the native ligand of these acceptors.Example includes but not limited to: stimulate the two R-848 (Resiquimod), R-837 (Imiquimod of TLR7 and TLR8; ALDARA TM, 3M Pharmaceuticals), 7-denitrogenation-guanosine, 7-sulfo--8-oxygen-guanosine and 7-allyl group-8-oxygen-guanosine (Loxoribine).D-glucopyranose derivatives such as 3D-MPL (TLR4 part) also can put together with immunostimulating ORN.Pam3-Cys is an example of the TLR2 part that can put together with immunostimulating ORN.The oligodeoxynucleotide that contains the CpG motif is the TLR9 part, and these also can be puted together with immunostimulating ORN of the present invention.In one embodiment, at least one oligodeoxynucleotide and immunostimulating ORN of the present invention that comprises stimulating the effective CpG motif of TLR9 signal transduction puts together.Get into the multimerization that can cause acceptor of puting together of a molecule to the part of different TLR, this causes comparing enhanced immunostimulation or different immunostimulation spectrums with any single this type part causes.
One aspect of the present invention provides the conjugate of immunostimulating ORN of the present invention and lipophilic portion.In certain embodiments, immunostimulating ORN and lipotropy part are covalently bound.The lipotropy part can be present on one or more ends of the immunostimulating ORN with free-end usually; Although in certain embodiments; The lipotropy part can exist in the other places of immunostimulating ORN, thereby and does not require that immunostimulating ORN has free-end.In one embodiment, immunostimulating ORN has 3 ' end, and the lipotropy part is terminal covalently bound with said 3 '.Lipophilic group generally can be a cholesteryl; Through the cholesteryl of modifying; Cholesterol derivative; The SUV that is reduced; Substituted SUV; Cholestane; The C16 alkyl chain; Bile acide; Cholic acid; Tca; Septochol; Oleoyl lithocholic acid (oleyl litocholic acid); The oleoyl cholenic acid; Glycolipid; Phosphatide; Sphingolipid; Isoprenoid such as steroid; VITAMINs such as vitamin E; Sfas; Unsaturated fatty acids; Fatty ester such as triglyceride level; Pyrene; Tetrazaporphin; Texaphyrine; Amantadine; Acridine; Vitamin H; Tonka bean camphor; Resorcinolphthalein; Rhodamine; Texas-Red; Digoxin (digoxygenin); Two pairs of methoxy trityls; T-butyl dimethylsilane; T-butyl diphenyl silicomethane; Cyanine dyes (for example Cy3 or Cy5); The Hoechst33258 dyestuff; Psoralene or Ibuprofen BP/EP.In certain embodiments, lipotropy partly is selected from cholesteryl, palmityl and fatty acyl group.In one embodiment, lipotropy partly is a cholesteryl.Think and comprise that one or more this type lipotropys parts give their extra stability to nuclease degradation again among the immunostimulating ORN of the present invention.When having two or more lipotropy part among the single immunostimulating ORN of the present invention, this type lipotropy part can be selected independently of one another.
In one embodiment, on the 2 ' position of lipotropy part attached to the Nucleotide of immunostimulating ORN.Lipophilic group or or be connected with the heteronucleus base of the Nucleotide of immunostimulating ORN extraly.The lipotropy part can be covalently bound through any suitable direct or indirect connection and immunostimulating ORN.In one embodiment, this connection is directly and is ester or acid amides.In one embodiment, this connection is indirect and comprises compartment, the nucleotide residue of for example one or more dealkalize bases, oligomeric ethylene glycol such as triethylene glycol (interval 9) or six terepthaloyl moietie (interval 18) or alkanediol such as butyleneglycol.
In one embodiment, immunostimulating ORN of the present invention advantageously makes up with cation lipid or cationic peptide.Cation lipid and cationic peptide are considered to help immunostimulating ORN is transported in the endosome compartment, and TLR8 is present in wherein.In one embodiment, cation lipid is DOTAP (N-[1-(2,3-two oleoyl oxygen) propyl group]-N, N, a N-trimethyl ammonium methylsulfuric acid ester).DOTAP is considered to that the transhipment of RNA oligomer is got into cell and also is transported to specifically in the endosome compartment, and it can discharge the RNA oligomer with the dependent pattern of pH there.In the time of in the endosome compartment, RNA can interact with TLR in some cell, causes the TLR Mediated Signal Transduction approach that the design immunne response produces.Other reagent with similar characteristics (comprise and be transported to the endosome compartment) can replace DOTAP or except that DOTAP, use.Other liquid formulations comprises for example EFFECTENE TM(non-liposome lipid) and SUPERFECT with specific DNA compression enhanser TM(novel effect dendrimeric technology).Liposome can commerce derive from Gibco BRL, for example LIPOFECTIN TMAnd LIPOFECTACE TM, they are by cation lipid such as N-[1-(2,3 two oleoyl oxygen)-propyl group]-N, N, and N-trimethyl ammonium chloride (DOTMA) and dimethyl-bromination octacosane ammonium (DDAB) form.The method that is used for making liposome is known in the art and is described in many publications.Liposome is also summarized by Gregoriadis G (1985) TrendsBiotechnol 3:235-241.
In one embodiment, immunostimulating ORN of the present invention is the form with covalence closed, dumb-bell shape molecule of primary structure and secondary structure.As disclosed herein, this type ring-type oligoribonucleotide comprises two single-stranded loops that connect through the double-stranded section that inserts in one embodiment.In one embodiment, at least one single-stranded loop comprises immunostimulating RNA motif of the present invention.Other molecule covalence closed, dumb-bell shape of the present invention comprises chimeric DNA:RNA molecule, and wherein for example double-stranded section part at least is that the DNA (for example homodimer dsDNA or the dimer DNA:RNA of hospital) and the ring of at least one strand comprise immunostimulating RNA motif of the present invention.Perhaps, the double-stranded section of chimeric molecule is RNA.
In certain embodiments, the ORN of immunostimulating is separated.Separated molecule is substantially pure and molecule that do not contain other material; Said other material in the system, exists degree to reach can put into practice and the suitable degree of said molecule purpose purposes in said molecule is present in occurring in nature or body usually.Immunostimulating ORN is especially enough pure and enough not celliferous other biological components, thereby is applicable to and for example produces pharmaceutical prepn.Because separated pungency ORN of the present invention can mix in pharmaceutical prepn with pharmaceutically acceptable vector, so immunostimulating ORN can only comprise by weight the preparation of per-cent in a small amount.But immunostimulating ORN is a substantially pure, because said ORN bonded separating substances with it basically and in the living system.
For the purposes among the present invention, immunostimulating ORN of the present invention can use or adapt to any of a large amount of steps well known in the art and synthesize from new.β cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) Tetrahedron Lett 22:1859) for example; Nucleosides H-SULPHOSUCCINIC ACID ESTER method (Garegg P et al. (1986) Tetrahedron Lett 27:4051-4; Froehler BC et al. (1986) Nucl Acid Res 14:5399-407; Garegg P et al. (1986) Tetrahedron Lett 27:4055-8; Gaffney BL et al. (1988) Tetrahedron Lett 29:2619-22).These chemistry can carry out through commercially available a large amount of automatic nucleic acid synthesizers.Other compound method that is suitable for according to the present invention is disclosed among Uhlmann E et al. (1990) Chem Rev 90:544-84 and Goodchild J (1990) the Bioconjugate Chem 1:165.
Can in solution or on solid support, carry out the synthetic of oligoribonucleotide.In solution, preferably block linked reaction (dimer, tripolymer, the tetramer etc.), and solid phase synthesis uses preferably the monomer members piece in the process of substep, to carry out.Describe (Eckstein F (1991) Oligonucleotides and Analogues, A Practical Approach, IRL Press, Oxford) different chemistry, for example phosphotriester method, H-SULPHOSUCCINIC ACID ESTER method and phosphoramidite method.Although in the phosphotriester method, reactive phosphorus group according to phosphoramidite and H-SULPHOSUCCINIC ACID ESTER approach, uses in the linked reaction to have more reactive Phosphor+III verivate in rate of oxidation+V.In back two kinds of approach, P (V) verivate that phosphorus oxidized generation behind coupling step is stable.If oxygenant is iodine/water/base, then behind deprotection, obtain phosphodiester.On the contrary, if oxygenant is vulcanizing agent such as Beaucage ' s reagent, then behind deprotection, obtain thiophosphatephosphorothioate.
Being used for effective ways of oligoribonucleotide synthetic is to use the solid of (described to oligodeoxynucleotide at first like Matteucci andCaruthers) phosphoramidite chemistry to support the combination of synthesis method.Matteucci?MD?et?al.(1981)J?Am?Chem?Soc?103：3185。
To the synthetic of oligoribonucleotide and to the synthetic of oligodeoxynucleotide is similarly, and difference is that the 2 ' hydroxyl that exists in the oligoribonucleotide must be by suitable hydroxy-protective group protection.Monomer can be for example by 2 '-O-t-butyl dimetylsilyl (TBDMS) radical protection in the RNA monomer members piece.Yet, use to contain 2 '-O-triisopropyl silicomethane yloxymethyl (TOM) group (TOM-Protecting-Group TM) the synthetic RNA of monomer produced higher coupling and render a service by report because the TOM blocking group shows the steric hindrance lower than TBDMS group.Although use fluorochemical to remove the TBDMS blocking group, be to use methylamine in the ethanol/water at room temperature to reach the quick deprotection of TOM group.In oligomerization (ribose) Nucleotide was synthetic, preferably from 3 '-5 ' terminal chain extension, this ribonucleoside acid unit or 5 ' oh group coupling that dissociates of its verivate that is activated and another nucleotide units through will having 3 '-phosphorus (III) group was reached.
Synthesizing to use robotization DNA/RNA synthesizer to carry out expediently.The synthesis cycle that wherein can use synthesizer supplier to recommend.For the ribonucleoside phosphoramidite monomer, coupling time is compared longer (for example 400 seconds) with the deoxynucleoside monomer.As solid support; Can use 500 to controlled pore glass (CPG) upholder or organic Support Polymer of , for example primer upholder PS200 (Amersham).Solid support contains through its first nucleosides of 3 '-terminal bonded usually, for example two pairs of methoxy trityls of 5 '-O--N-6-benzoyl adenosine.After two pairs of methoxy trityl group of trichoroacetic acid(TCA) cutting 5 '-O-, chain extension is reached in use for example-2 '-O-t-butyldimethylsilyl-nucleosides-3 ' of two pairs of methoxy trityl-N-protecteds of 5 '-O--O-phosphoramidite.After the successive recirculation, through with strong aqua/ethanol (3: 1, v: v) 30 ℃ handle 24 hours with the oligoribonucleotide of accomplishing from upholder cutting and deprotection.Use triethylamine/HF that the TBDMS blocking groups is excised at last.Can analyze through the thick oligoribonucleotide of ion exchange column HPLC (HPLC), pair ion reversed-phase HPLC or polyacrylamide gel electrophoresis (PAGE) purifying and through mass spectroscopy.
The synthetic back of 5 ' conjugate directly in solid phase synthesis with the phosphoramidite of molecule to be connected and 5 ' hydroxyl coupling of terminal nucleotide.Can the commercial multiple phosphoramidite verivate that obtains this type part, for example SUV, acridine, vitamin H, general element draw human relations (psoralene), terepthaloyl moietie or aminoalkyl group residue.Perhaps, can during solid phase synthesis, introduce the aminoalkyl group function, it allows to synthesize the back derivatize through activatory conjugate molecule (for example active ester, isothiourea or iodo-ethanamide).
The synthetic of 3 ' end conjugate accomplished through the corresponding adorned solid support of use usually, and said upholder for example can the commercial cholesteryl deutero-solid support that obtains.Yet, put together also and can carry out on key, nuclear base or the ribose residue (for example 2 ' of ribose-position) between Nucleotide.
For the ring-type oligoribonucleotide, the extension of oligonucleotide chain can use standard phosphoramidite chemistry on Nucleotide PS solid support (Glen Research), to carry out.Use phosphotriester coupling step (Alazzouzi et al. (1997) Nucleosides Nucleotides 16:1513-14) on solid support, to carry out cyclization then.With the final deprotection of volatile caustic the time, the unique product that in fact gets in the solution is the ring-type oligonucleotide of expectation.
Ring-type oligoribonucleotide of the present invention comprises the RNA of closed loop, and can comprise the single stranded RNA that has or do not have double-stranded RNA.For example, in one embodiment, said ring-type oligoribonucleotide comprises double-stranded RNA and presents the dumbbell conformation with two single standard rings that said two rings connect through the double-stranded section that inserts.CpG oligodeoxynucleotide covalence closed, dumb-bell shape has been described in U.S.Pat.No.6, in 849,725.In another embodiment, the ring-type oligoribonucleotide comprises double-stranded RNA and presents following configuration that said configuration has three or the more single-stranded loop that connects through the double-stranded section that inserts.In one embodiment, immunostimulating RNA is arranged in one or more strand sections.
Immunostimulating ORN of the present invention is applicable to separately or uses with other reagent such as adjuvant combination.The adjuvant that this paper uses is represented: except that antigen, strengthen the material of replying antigenic activated immune cell (for example body fluid and/or cellullar immunologic response).Adjuvant promotes the gathering and/or the activation of accessory cell, with the special immunne response of enhancement antigen.Adjuvant is used to strengthen the efficient of vaccine, and said vaccine promptly is used to induce the antigen compsn that contains to antigenic protective immunity.
Adjuvant generally includes adjuvant, immunostimulation adjuvant of calling in storage effect and the adjuvant of creating storage effect and stimulating immune system.The adjuvant of the establishment storage effect that this paper uses is meant and causes that antibody slowly discharges in vivo, thereby prolongs the adjuvant of immunocyte to antigen-exposed.This adjuvant includes but not limited to alum (for example white lake, phosphagel phosphaljel); The prescription of emulsion-based comprises MO, non-mineral oil, water-in-oil or water-in-oil bag oil-emulsion, oil-in-water emulsion for example the Seppic ISA series of Montanide adjuvant (for example Montanide ISA 720; AirLiquide, Paris, France); MF-59 (with the stable water bag squalene emulsion of Span 85 and Tween 80, Chiron Corporation, Emeryville, Calif.); (contain and stablize washing composition and the oil-in-water emulsion that becomes the micelle agent with PROVAX; IDEC Pharmaceuticals Corporation, San Diego, Calif.).
The immunostimulation adjuvant is to cause immune system cell activatory adjuvant.It can for example cause the production of immunocyte and the secretion of cytokine.This type adjuvant includes but not limited to the saponin(e of purifying from Q.saponaria tree bark, like the QS21 (glycolipid of wash-out in the 21st peak that the HPLC level is divided; Aquila Biopharmaceuticals, Inc., Worcester, Mass.); Poly [two (carboxylic acid phenoxy (carboxylatophenoxy)) phosphonitrile] (PCPP polymer; Virus Research Institute, the U.S.); Lipopolysaccharide derivant such as monophosphoryl lipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, Mont.), Muramyl-dipeptide (MDP; Ribi), andthreonyl-Muramyl-dipeptide (t-MDP; Ribi); OM-174 (the glycosamine disaccharides relevant with lipid A; OM Pharma SA, Meyrin is Switzerland) with Leishmania elongation factor (purified Leishmania albumen; Corixa Corporation, Seattle, Wash.).The adjuvant of this kind also comprises CpGDNA.
The adjuvant of creating storage effect and stimulating immune system is the compound with above-mentioned two kinds of functions.This type adjuvant include but not limited to ISCOMS (immunostimulating complex, its contain blended saponin(e, lipid and with can keep the particle that antigenic hole forms the virus size; CSL, Melbourne, Australia); SB-AS2 (SmithKline Beecham adjuvant system #2, it is the oil-in-water emulsion that contains MPL and QS21: SmithKline Beecham Biologicals [SBB], Rixensart, Belgium); SB-AS4 (SmithKline Beecham adjuvant system #4, it contains alum and MPL; SBB, Belgium); Non-ionic block copolymer, (these contain the hydrophobicity polyoxypropylene linear chain that flank is a polyoxyethylene chain for its formation micelle such as CRL 1005; Vaxcel, Inc., Norcross, Ga.); (SAF contains the oil-in-water emulsion of Tween 80 and the segmented copolymer of non-example with the Syntex adjuvant prescription; Syntex Chemicals, Inc., Boulder, Colo.).
One aspect of the present invention provides the adjuvant that self comprises immunostimulating ORN of the present invention.In another embodiment, the invention provides the adjuvant (combination adjuvant) that comprises immunostimulating ORN of the present invention and at least a other adjuvant.Said other adjuvant can comprise the adjuvant of creating the storage effect, immunostimulating adjuvant, create adjuvant and any combination thereof of storage effect and stimulating immune system.In one embodiment, immunostimulating ORN of the present invention and at least a other adjuvant are covalently bound each other.Combination adjuvant according to the present invention is compared with the independent effect sum of at least a other adjuvant separately with immunostimulation ORN, can show collaborative immunostimulation.In addition or perhaps, can show that according to combination adjuvant of the present invention independent with immunostimulating ORN or at least a other adjuvant compares the immunostimulation spectrum of change separately.For example, combination adjuvant can provide the more Th1/Th2 immunostimulation of branch's form in one embodiment, or it can provide the Th1/Th2 immunostimulation of (skewed) form that more tilts in another embodiment.Those skilled in the art are understood that how to select individual components to promote the immunostimulation of desired type, for example about Th1 and branch or the more inclination more of Th2 characteristic.Th1 and Th2 further describe hereinafter.
A kind of compsn also is provided, and said compsn comprises immunostimulating ORN of the present invention and adds another adjuvant, and wherein said other adjuvant is a cytokine.In one embodiment, said composition is the conjugate of immunostimulating ORN of the present invention and cytokine.
Cytokine is by the inducing inflammatory reaction of many kinds of cells produce and immunoreactive soluble protein and gp.Interchange between the cytokine mediated immune system cell, local and general ground is done in order to raise cell and the function and the propagation of regulating them.The category of cytokine comprises medium and the setter of congenital immunity, the medium and the setter of adaptive immunity, and the stimulator of hemopoietic.Be included in the cytokine is interleukin (for example IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18 and interleukin-11 9-32 (IL-19-IL-32); Except other), chemokine (for example IP-10, RANTES, MIP-1 α, MIP-1 β, MIP-3 α, MCP-1, MCP-2, MCP-3, MCP-4, eotaxin, I-TAC and BCA-1; Except other) and other cytokine; Comprise 1 type Interferon, rabbit (for example IFN-α and IFN-β), 2 type Interferon, rabbit (for example IFN-γ), tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β) and multiple G CFS (CSF), comprise GM-CSF, G-CSF and M-CSF.
Also provide and comprised the compsn that immunostimulating ORN of the present invention adds immunostimulating CpG nucleic acid.In one embodiment, this is combined as the conjugate of immunostimulating ORN of the present invention and CpG nucleic acid, for example RNA:DNA conjugate.In one embodiment, said composition is the mixture of immunostimulating ORN of the present invention and CpG nucleic acid, promptly is not the RNA:DNA conjugate.
This paper uses immunostimulating CpG nucleic acid to be meant natural or the synthetic dna sequence dna, and it contains the activation or the propagation of CpG motif and stimulating immune system cell.Immunostimulating CpG nucleic acid is described in a large amount of patent, disclosed patented claim and other publications of publishing, and comprises U.S.Pat.Nos.6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116 and 6,339,068.In one embodiment, immunostimulating CpG nucleic acid is the long CpG oligodeoxynucleotide (CpG ODN) of 6-100 Nucleotide.In one embodiment, immunostimulating CpG nucleic acid is the long CpG oligodeoxynucleotide (CpG ODN) of 8-40 Nucleotide.
Immunostimulating CpG nucleic acid comprises different types of CpG nucleic acid.A kind of can activate the B cell but when inducing IFN-α and NK cell activation relatively a little less than; This kind has been named as category-B.Typically, category-B CpG nucleic acid is by complete stability, and it has unmethylated CpG dinucletide in some preferred base environment.Consult for example U.S.Pat.Nos.6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116 and 6,339,068.Another kind can be induced IFN-α and NK cell activation, but when stimulating the B cell relatively a little less than, this kind has been known as category-A.Category-A CpG nucleic acid typically has sequence and the stable poly G sequence of phosphoric acid diester CpG dinucletide of at least 6 Nucleotide of the palindrome at 5 ' and 3 ' two ends.Consult for example disclosed International Patent Application WO 01/22990.Another Class Activation B cell of CpG nucleic acid and NK cell are also induced IFN-α; This kind has been known as the C class.As at first analyze, C class CpG nucleic acid comprises category-B type sequence and the palindromic sequence or the approximate palindromic sequence that are rich in GC typically by complete stability.This kind has been described in the disclosed U.S. patented claim 2003/0148976, and its full content is incorporated this paper by reference into.
Immunostimulating CpG nucleic acid comprises that also the full content of said application is incorporated this paper by reference into like disclosed so-called soft and medium-soft property CpG nucleic acid in the disclosed U.S. patented claim 2003/0148976.Soft and the medium-soft property immunostimulating CpG nucleic acid of this type is integrated the combination of key between nucleicacidase resistance and nuclease sensitivity Nucleotide, and wherein dissimilar keys is according to some principle location.
Also provide to comprise the compsn that immunostimulating ORN of the present invention fastens another adjuvant, wherein said another adjuvant is lipopeptid such as Pam3Cys, cationic polysaccharide such as chitosan, or cationic peptide such as protamine.In one embodiment, compsn is the conjugate of immunostimulating ORN of the present invention and another adjuvant.
One aspect of the present invention provides and has comprised immunostimulating ORN of the present invention and antigenic vaccine." antigen " expression that this paper uses: can be by any molecule of T cell antigen receptor or B cell antigen receptor identification.This term comprises the molecule that is identified as any kind of external source by host immune system widely.Antigen generally comprises but is not limited to peptide and non-peptide mimicry, small molecules, lipid, glycolipid, polysaccharide, glucide, virus and viral extract and multicellular organism such as the parasite and the allergen of cell, cell extract, protein, polypeptide, peptide, polysaccharide, polysaccharide conjugates, polysaccharide and other molecule.For for the antigen of protein, polypeptide or peptide, this type antigen can comprise the antigenic nucleic acid molecule of this type of coding.Antigen includes but not limited to more specifically: cancer antigen, and it comprises cancer cells and in cancer cells or the molecule of expressing on the cancer cells; Microbial antigen, it comprises mikrobe and in mikrobe or the molecule of expressing on the mikrobe; And allergen.Therefore, the present invention provides in certain embodiments and has been used for cancer, infectious agent and allergenic vaccine.
One aspect of the present invention provides immunostimulating ORN of the present invention to be used to prepare the purposes of medicament, and said medicament is used for the vaccine inoculation experimenter.
One aspect of the present invention provides the method that is used to prepare vaccine.This method comprises the steps: immunostimulating ORN of the present invention placed with antigen and optional the direct of pharmaceutically acceptable vector and combines.
In multiple embodiments, antigen is microbial antigen, cancer antigen or allergen." microbial antigen " that this paper uses is meant the antigen of mikrobe, and it includes but not limited to virus, bacterium, parasite and fungi.This type antigen comprises complete mikrobe and natural conivium or fragment or verivate thereof, also comprises same or similar and induce the synthetic compound to the special immunne response of this mikrobe with natural microbial antigen.If compound is induced the antigenic immunne response of natural microbial (body fluid and/or cell), then itself and natural microbial Antigens are seemingly.This type antigen is that this area routine is used and is that this area routine techniques personnel are known.
Virus is little infectious agent, contains nucleic acid core and protein enclosure as the one of which, but the biology that can not live on one's own life.Virus also can take to lack the form of proteinic INA.Do not exist virus can duplicate therein life cell the time, virus can not exist.Virus gets into special life cell and breeding through endocytosis or direct injection DNA (phage), causes disease.The virus of breeding can be released or infect other cell then.Some viruses are the virus that contains DNA, and other is the virus that contains RNA.Aspect some; The present invention also is intended to treat disease, and infectious month first protein (prion) is replicated in PD in the said disease, and said disease for example mad cow disease (is a mad cow disease; BSE) or the scrapie in the animal infect or the Creutzfeldt-Jakob disease of philtrum.
Virus includes but not limited to: enterovirus (including but not limited to picornaviridae section, for example poliovirus, Coxsackie virus (coxsackie virus), ECHO virus (echo virus)), rotavirus, adenovirus, hepatitis virus.The special example of the virus of having found at philtrum includes but not limited to: (for example human immunodeficiency virus such as HIV-1 (are also referred to as HTLV-III, LAV or HTLV-III/LAV or HIV-III to Retroviridae; With other conivium, for example HIV-LP)); Picornaviridae (for example poliovirus, hepatitis A virus; Enterovirus, human coxsackievirus, rhinovirus, ECHO virus); Calciviridae (for example causing the bacterial strain of gastro-enteritis); Togaviridae (for example equine encephalitis virus, rubella virus); Flaviviridae (for example dengue fever virus, encephalitis, yellow fever virus); Coronaviridae (for example coronavirus); Rhabdoviridae (for example stomatitis herpesvirus, rabies virus); Filoviridae (for example Ebola virus); Paramyxoviridae (for example parainfluenza virus, mumps virus, Measles virus, respiratory syncytial virus); Orthomyxoviridae (for example influenza virus); Bunyaviridae (for example Hantaan virus (Hantaan viruses), bunya virus, Phlebovirus (phleboviruses) and Nairo virus); Arenaviridae (hemorrhagic fever virus); Reoviridae (for example reovirus, orbiviurses and rotavirus); Birnaviridae; Hepadnaviridae (hepatitis B virus); Parvoviridae (parvovirus group); Papovaviridae (Papillomavirus, polyomavirus); Adenoviridae (most of adenovirus); Herpesviridae (hsv (HSV) 1 and 2, varicella one varicella zoster virus, cytomegalovirus (CMV)); Poxviridae (alastrim virus, vaccinia virus, poxvirus); Iridoviridae (for example African swine fever virus); With non-classified virus (cause of disease of SE (etiological agent) for example, the cause of disease of hepatitis D (the defective satellite that is considered to hepatitis B virus), cause of disease (the kind 1=internal transmission of non-first type, non-hepatitis B; The transmission of kind 2=parenteral) (being hepatitis C); Norwalk and correlated virus and Astrovirus).
Bacterium is through the binary vegetative unicellular organism of fissioning.They are classified and name according to its morphology, staining reaction, nutrition and metabolism needs, antigenic structure, chemical constitution and genetic homogeny.Bacterium can be divided into three types according to its morphological form: spherical (coccus), directly bar-shaped (bacillus) and bending or spiral bar-shaped (vibrios, Campylobacter, spirillum and spirochete).Bacterium also more generally is divided into two types of biologies, Gram-positive and Gram-negatives according to their staining reaction.Gram is meant the dyeing process that in microbiology laboratory, carries out usually.The Gram-positive biology keeps dyeing and shows grape behind staining procedure.But gram-negative biological does not keep dyeing absorbs redying, thus and demonstration pink colour.
Communicable bacterium includes but not limited to Gram-negative and gram positive bacterium.Gram positive bacterium includes but not limited to: the kind of the kind of Pasteurella, the kind of Staphylococci and Streptococcus.Gram negative bacterium includes but not limited to: the kind of Escherichia coli, Pseudomonas and the kind of Salmonella.The special example of infective bacterial includes but not limited to: Helicobacter pyloris; Borrelia burgdorferi; Legionella pneumophilia; Mycobacteria sps (M.tuberculosis for example; M.avium; M.intracellulare; M.kansasii; M.gordonae); Staphylococcus aureus; Neisseria gonorrhoeae; Neisseria meningitidis; Listeria monocytogenes; Streptococcus pyogenes (A organizes Streptococcus); Streptococcus agalactiae (B organizes Streptococcus); Streptococcus (viridans group); Streptococcus faecalis; Streptococcus bovis; Streptococcus (anaerobism kind); Streptococcus pneumoniae; PathogenicCampylobacter sp.; Enterococcus sp.; Haemophilus influenzae; Bacillusanthracis; Corynebacterium diphtheriae; Corynebacterium sp.; Erysipelothrix rhusiopathiae; Clostridium perfringens; Clostridium tetani; Enterobacter aerogenes; Klebsiella pneumoniae; Pasturella multocida; Bacteroides sp.; Fusobacterium nucleatum; Streptobacillus moniliformis; Treponema pallidum; Treponema pertenue; Leptospira; Rickettsia and Actinomyces israelli.
Parasite is to depend on other biology and the biology of survival, so it must get into or infect other biology to continue their life cycle.Infected biology (being the host) provides nutrition and habitat to parasite.Although this term parasite with its most widely implication can comprise all infectious agents (being bacterium, virus, fungi, protozoon and worm); But generally speaking, this term is used for representing separately protozoon, worm and ectoparasite arthropods (for example tick, mite etc.).Protozoon is single celled biology, but its cell is interior or duplicate in the extracellular, especially in blood, enteron aisle or cells of tissues epimatrix.Worm is almost always at extracellular multicellular organism (except that Trichinella spp.).Worm need withdraw from and shift from elementary host usually and get among the secondary host, thereby duplicates.Opposite with these above-mentioned kinds, ectoparasite arthropods forms the parasitism with host's health outside surface.
Parasite comprises the cytozoon of cytozoon and obligate.Parasitic example includes but not limited to Plasmodium falciparum; Plasmodium ovale; Plasmodiummalariae; Plasmdodium vivax; Plasmodium knowlesi; Babesia microti; Babesia divergens; Trypanosoma cruzi; Toxoplasma gondii; Trichinellaspiralis; Leishmania major; Leishmania donovani; Leishmaniabraziliensis; Leishmania tropica; Trypanosoma gambiense; Trypanosomarhodesiense and Schistosoma mansoni.
Fungi is an eukaryote, and only some causes infection in the vertebrates Mammals.Because fungi is an eukaryote, so they are significantly different on size, structure establishment, life cycle and reproduction mechanisms with the bacterium of protokaryon.Fungi is classified with its morphological feature, reproduction pattern and cultural characteristic usually.Although fungi can cause dissimilar diseases in the experimenter; The mycetism that for example suck respiratory allergies behind the fungal antigen, (the Amanitaphalloides toxin of for example being produced by poisonous mushroom and phallotoxin and the Toxins, afla of being produced by the aspergillar kind) causes because the picked-up toxicant, still not every fungi produces communicable diseases.
The infectivity fungi can cause infection general or shallow table property.Elementary systemic infection can take place in the normal healthy experimenter, and opportunistic infection the most often are present among the immunocompromised experimenter.The most common fungi material that causes elementary systemic infection comprises Blastomyces, Coccidioides and Histoplasma.The common fungi that in immunocompromised or immunosuppressant experimenter, causes opportunistic infection includes but not limited to the kind of Candida albicans, Cryptococcusneoformans and multiple Aspergillus.Systemic fungal infection is internal's a invasive infection.Biological usually through lung, gi tract or intravenous catheter entering health.The infection of these types can be caused by elementary pathogenic fungi or opportunistic fungi.
The fungi infestation of shallow table property relates to the externally surperficial growth of fungi and does not invade interior tissue.Typical shallow table property fungi infestation comprises the epidermis fungi infestation that relates to skin, hair or nail.
The disease relevant with fungi infestation comprises aspergillosis, blastomycosis, moniliosis, chromoblastomycosis, coccidioidomycosis; Torulosis, fungi eye infections, fungi hair, nail and skin infections, histoplasmosis; Keloidal blastomycosis, mycetoma, otomycosis, paracoccidioidomycosis; The Penicillium marneffei that scatters, phaeohyphomycosis, rhinosporidiosis, sporotrichosis and zygomycosis.
The mikrobe that other medical science is relevant is extensively described in document, for example consults C.G.AThomas, Medical Microbiology, and Bailliere Tindall, Great Britain 1983, its entirety is incorporated this paper by reference into.Each content of previous list all is illustrative but not is intended to restriction.
The term " cancer antigen " that this paper uses and " tumour antigen " make convertibly and are used for representing compound; Like peptide, protein or gp; It is relevant with tumour or cancer cells, and can excite immunne response during expression on the antigen presenting cell surface in main histocompatibility complex (MHC) branchs subenvironment.Cancer antigen by the cancer cells differential expression can be utilized with target cancer cell.Cancer antigen is the antigen that possibly stimulate the tomour specific immunne response significantly.In these antigens some are encoded by normal cell, although must do not expressed by normal cell.These antigens can be characterized as being some stage antigen (for example EA and fetal antigen) expression and transient expression usually reticent (promptly not expressing), that only breaking up in normal cell.Other cancer antigen is by the cytogene coding of sudden change, for example oncogene (for example activated ras oncogene), suppressor gene (the for example p53 of sudden change), derive from the fusion rotein of inner disappearance or chromosome translocation.Also have other cancer antigen can encode the virogene that for example is loaded with on RNA and the DNA tumour virus by virogene.
Cancer antigen can be through preparation cancer cells crude extract (for example described in Cohen PA et al. (1994) the Cancer Res 54:1055-8), through partial purification antigen, through recombinant hormone or from cancer cells, preparing from newly synthetic through known antigens.Cancer antigen includes but not limited to by recombinant expressed antigen, its immunogenicity part or its complete tumour or cancer or cell.This type antigen can separate or preparation by reorganization ground or through any other means known in the art.
The example of tumour antigen comprises MAGE; MART-1/Melan-A; Gp100; DPP IV (DPPIV); ABP (ADAbp); Cyclophilin b; Colorectum related antigen (CRC)--C017-1A/GA733; CEACAMS (CEA) and immunogenicity epi-position CAP-1 and CAP-2; Etv6; Aml1; PSA (PSA) and immunogenicity epi-position PSA-1 thereof; PSA-2 and PSA-3; Prostatic specific membrane antigen (PSMA); T-cell receptors/CD3-ζ chain; The tumour antigen of MAGE-family (MAGE-A1 for example; MAGE-A2; MAGE-A3; MAGE-A4; MAGE-A5; MAGE-A6; MAGE-A7; MAGE-A8; MAGE-A9; MAGE-A10; MAGE-A11; MAGE-A12; MAGE-Xp2 (MAGE-B2); MAGE-Xp3 (MAGE-B3); MAGE-Xp4 (MAGE-B4); MAGE-C1; MAGE-C2; MAGE-C3; MAGE-C4; MAGE-C5); The tumour antigen of GAGE-family (GAGE-1 for example; GAGE-2; GAGE-3; GAGE-4; GAGE-5; GAGE-6; GAGE-7; GAGE-8; GAGE-9); BAGE; RAGE; LAGE-1; NAG; GnT-V; MUM-1; CDK4; Tyrosine oxidase; P53; MUC family; HER2/neu; P21ras; RCAS1; α-peptide protein; The E-cadherin; α-catenin; White and the γ catenin of beta-catenin; P120ctn; Gp100 Pmel117, tumour antigen, lmp-1, the P1A of PRAME, NY-ESO-1, cdc27, adenomatous polyposis coli albumen (APC), fodrin, connection protein 37, Ig-idiotype, p15, gp75, GM2 and GD2 ganglioside, viral product such as human papillomavirus albumen, Smad family, NA (EBNA)-1, brain glycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 and the CT-7 of EBV-coding, and c-erbB-2.Restriction is not represented in this tabulation.
" allergen " that this paper uses is the molecule that can excite immunne response, and said immunne response is characterised in that produces IgE.Allergen also is the material that can in the experimenter of susceptible, induce allergic response or asthma to reply.Therefore, in context of the present invention, the term allergen is represented the antigen of special type, and it causes by the antibody-mediated allergic response of IgE.
Allergenic tabulation is huge and can comprises pollen, insect venom, animal scurf dust, fungal spore and medicine (for example penicillium mould).The allergenic example of natural animal and plant comprises with the special protein of subordinate: Canis (Canis familiaris); Dermatophagoides (for example Dermatophagoides farinae); Felis (Felis domesticus); Ambrosia (Ambrosiaartemisiifolia); Lolium (for example Lolium perenne and Lolium multiflorum); Cryptomeria (Cryptomeria japonica); Alternaria (Alternaria alternata); Alder; Alnus (Alnus gultinosa); Betula (Betula verrucosa); Quercus (Quercus alba); Olea (Olea europa); Artemisia (Artemisia vulgaris); Plantago (for example Plantagolanceolata); Parietaria (for example Parietaria officinalis and Parietaria judaica); Blattella (for example Blattella germanica); Apis (for example Apis multiflorum); Cupressus (for example Cupressus sempervirens, Cupressus arizonica and Cupressusmacrocarpa); Juniperus (for example Juniperus sabinoides, Juniperus virginiana, Juniperus communis and Juniperus ashei); Thuya (for example Thuya orientalis); Chamaecyparis (for example Chamaecyparis obtusa); Periplaneta (for example Periplaneta americana); Agropyron (for example Agropyron repens); Secale (for example Secale cereale); Triticum (for example Triticum aestivum); Dactylis (for example Dactylis glomerata); Festuca (for example Festuca elatior); Poa (for example Poapratensis and Poa compressa); Avena (for example Avena sativa); Holcus (for example Holcus lanatus); Anthoxanthum (for example Anthoxanthum odoratum); Arrhenatherum (for example Arrhenatherum elatius); Agrostis (for example Agrostisalba); Phleum (for example Phleum pratense); Phalaris (for example Phalarisarundinacea); Paspalum (for example Paspalum notatum); Sorghum (for example Sorghum halepensis) and Bromus (for example Bromus inermis).
One aspect of the present invention provides immunostimulating ORN of the present invention and antigenic conjugate.In one embodiment, immunostimulating ORN of the present invention and antigen are covalently bound.It can be the covalency connection of any suitable species that covalency between immunostimulating ORN and the antigen connects, as long as immunostimulating ORN and antigen keep measurable functionally active of setting up separately when so combining.In one embodiment, the covalency connection is direct.In another embodiment, it is indirect that covalency connects, and for example passes through shank.Covalently bound immunostimulating ORN and antigen can be processed to discharge each other in cell.With this kind mode, it was sent and compares and can be enhanced when arbitrary component was delivered to cell and uses as independent preparation or independent component.In one embodiment, antigen is antigen itself, and promptly it is preformed antigen.
One aspect of the present invention provides a kind of pharmaceutical composition, and it comprises and delivery medium bonded compsn of the present invention.In multiple embodiments; Delivery medium can be selected from cation lipid, liposome, spirochete, virion, immunostimulating complex (ISCOM), particulate, microballoon, millimicro ball, unilamellar vesicle (LUV), multilamellar vesicle, oil-in-water emulsion, water-in-oil emulsion, newborn body and polycation peptide and optional pharmaceutically useful vector.Pharmaceutically useful vector is discussed hereinafter.Pharmaceutical composition of the present invention randomly can further comprise antigen.Compsn of the present invention is with the antigen of existence, uses suitable method to be admitted in the physical bond with delivery medium.The immunostimulating compsn can be included in the delivery medium, or on the surface that exposes of its solvent that may reside in delivery medium or combine with it.In one embodiment, immunostimulating ORN is present on the surface that the solvent of delivery medium exposes or combines with it, and if have antigenic words, it is included in the delivery medium.In another embodiment, immunostimulating ORN and antigen the two all be present on the solvent exposed surface of delivery medium or with it and combine.Also in another embodiment, antigen is present on the solvent exposed surface of delivery medium or with it and combines, and immunostimulating ORN is included in the delivery medium.Also in another embodiment, immunostimulating ORN and antigen the two (if comprising antigenic words) all are included in the delivery medium.
The present invention also provides the method for use of immunostimulating compsn of the present invention.One aspect of the present invention provides the method for immune cell activated.The method of this aspect comprises the steps: immunocyte is contacted in or the body external with the present composition of significant quantity according to the present invention, with immune cell activated.Compsn of the present invention can randomly contain antigen." immunocyte " that this paper uses is meant the cell of any bone marrow derived, and it participates in immunne response inborn or that adapt to.Immune cell includes, but are not limited to dendritic cells (DC), NK (NK) cell, monocyte, scavenger cell, granulocyte, bone-marrow-derived lymphocyte, plasmocyte, T lymphocyte and precursor cell thereof.
The term " significant quantity " that this paper uses is meant the necessary of the biological effect that causes expecting or amount fully.Significant quantity can still must not be subject to the amount of using in the single administration.
The term " immune cell activated " that this paper uses is meant that inducing immune cells gets into the active state relevant with immunne response.Term " immune cell activated " be meant induce and increase immunne response the two.This paper use a technical term " immunne response " be meant that any aspect of inborn or the immunne response that adapts to, said immunne response have reflected immune cell propagation, carried out the activation that effector immunologic function or production relate to the gene product of immunne response.The gene product that relates to immunne response can comprise the interior and cell surface molecule (for example some cluster of differentiation (CD), transcription factor and genetic transcription thing) of distinctive cell of excretory product (for example antibody, cytokine and chemokine) and immunologic function.Term " immunne response " can be applied to individual cells or cell population.
Can assess the production of cytokine through any method in the Several Methods well known in the art, said method comprises that fluorescence activated cell sorting (FACS) is analyzed and ThermoScript II/polymerase chain reaction (RT-PCR) in biological respinse mensuration, enzyme-linked immunosorbent assay (ELISA), the cell.
In one embodiment, the generation of inflammatory cytokine immunne response before immunne response relates to.Preceding inflammatory cytokine immunne response can comprise expression any in some cytokine and the chemokine, comprises IFN-γ, TNF-α, IL-12, IL-10, IL-6 and any combination thereof.It gets rid of IFN-α with regard to the object of the invention specifically.
In one embodiment, immunne response relates to the rise of immunocyte activated cell surface marker, for example CD25, CD80, CD86 and CD154.The method that is used to measure the cell surface expression of this type mark is well known in the art and comprises facs analysis.
In order to measure the immunne response in cell or the cell population, in one embodiment, cell or cell population are expressed TLR8.Cell can be expressed TLR natively, maybe can it be operating as through the suitable expression vector of in cell, introducing TLR and express TLR.In one embodiment, the cell of acquisition or cell population are PMBC (PBMC).In one embodiment, the cell of acquisition or cell population are for expressing the clone of TLR.In one embodiment, the cell of acquisition or cell population are for expressing the transient transfection body of TLR.In one embodiment, the cell of acquisition or cell population are the stable transfection bodies of expressing TLR.
Also in order to be used for measuring the immunne response of cell or cell population, in cell or cell population, introducing the sub-construct of report can be easily, and said construct responds to the intracellular signal transduction that TLR causes.In one embodiment, report is the gene that is positioned under the NF-κ B promoter regulation here.In one embodiment, the gene that is positioned under the said promoter regulation is a luciferase.Under suitable activation condition, luciferase reports that sub-construct expressed and send detectable optical signal, and said signal can use luminometer to measure quantitatively.The sub-construct of this type report can commercially obtain with the sub-construct of other suitable report.
The present invention has also considered the purposes of the acellular method of monitoring TLR activated.
The present invention relates to compsn and the method that is used for therepic use in some aspects.Immunostimulating compsn of the present invention can use separately or use with other therapeutical agent combination.The immunostimulating compsn can while or continuous administration with other therapeutical agent.When immunostimulating compsn of the present invention and other therapeutical agent were used simultaneously, they can be identical or independently use in the prescription, but use simultaneously.In addition, when immunostimulating compsn of the present invention and other therapeutical agent are used simultaneously, they can through identical or independently route of administration used, but use simultaneously.When using of immunostimulating compsn of the present invention temporarily separated with using of another therapeutical agent, immunostimulating compsn of the present invention and another therapeutical agent were by continuous administration.Temporal separation can be a big approximate number minute or can be more of a specified duration between these compound administration.In one embodiment, immunostimulating compsn of the present invention was used before using another therapeutical agent.In one embodiment, immunostimulating compsn of the present invention is used after using another therapeutical agent.In addition, when immunostimulating compsn of the present invention and another therapeutical agent during by continuous administration, they can through identical or independently route of administration used.Other therapeutical agent includes but not limited to be applicable to adjuvant, antigen, vaccine and the medicine of treatment infection, cancer, transformation reactions and asthma.
One side of the present invention provides the method to experimenter's vaccine inoculation.The method of this aspect comprises the step to the experimenter's administration of antigens and the present composition according to the present invention.In one embodiment, administration of antigens comprises the nucleic acid of using coding for antigens.
" experimenter " that this paper uses is meant vertebrates.In a plurality of embodiments, the experimenter is people, non-human primates or other Mammals.In certain embodiments, the experimenter is mouse, rat, guinea pig, rabbit, cat, dog, pig, sheep, goat, ox or horse.
In order in vaccine inoculation experimenter's method, to use, compsn of the present invention comprises antigen in one embodiment.Antigen can separate from ORN of the present invention or is covalently bound with it.In one embodiment, compsn of the present invention self does not comprise antigen.In this embodiment, this antigen can be used to the experimenter with compsn of the present invention discretely or with compsn of the present invention.Independently use independent, the site that comprises the time or the independence of route of administration, or time and site or route of administration are all independent.When compsn of the present invention and antigen during in time by individual application, antigen can be used before or after compsn of the present invention.In one embodiment, antigen was used to 4 periderms after compsn of the present invention is used in 48 hours.This method also considered after initial application antigen and compsn, and the antigen of one or more booster immunization dosage is used separately, compsn is used separately or the using of antigen and compsn.
The present invention also comprises: can prepare the experimenter who meets with unknown antigen in the future through the experimenter being used compsn of the present invention, wherein said compsn does not contain antigen.According to this embodiment, experimenter's immunity system is prepared as has stronger the replying of antigen that the experimenter is met with after a while, and said experience is for example through environment or occupational exposure.These class methods can be used for for example possibly being exposed to tourist, medical worker and the soldier of microbiological materials.
One side of the present invention provides treatment to suffer from the experimenter's of immune system defect method.The method of this aspect comprises that the compsn of the present invention that the experimenter is used significant quantity is to treat experimenter's step according to the present invention." immune system defect " that this paper uses is meant that the immunity system of being prevented unusually is directed against the ability of antigen generation immunne response.In one embodiment, immune system defect is a kind of disease or illness, and wherein experimenter's immunity system is with normal ability effect, or the immunne response of wherein strengthening the experimenter can be applicable to tumour or cancer or the infection of for example eliminating among the experimenter." experimenter who suffers from immunodeficient " that this paper uses is meant following experimenter, and wherein experimenter's immunity system is prevented to the ability of antigen generation immunne response.The experimenter who suffers from immunodeficient comprises experimenter with acquired immunodeficiency and the experimenter with innate immune system defective.The experimenter who suffers from acquired immunodeficiency includes but not limited to: suffer from the chronic inflammatory illness the experimenter, suffer from chronic renal insufficiency or renal failure the experimenter, suffer from infection the experimenter, suffer from cancer the experimenter, accept immunosuppressive drug the experimenter, accept the experimenter of other immunosuppressant therapy and suffer from underfed experimenter.In one embodiment, the experimenter has repressed CD4+T cell population.In one embodiment, the experimenter has infected human immunodeficiency virus (HIV) or has suffered from AIDS (AIDS).Thereby the method for this aspect provides the method that is used for replying or strengthening taking place at experimenter's booster immunization of the stronger immunne response of needs the ability of immunne response according to the present invention.
The compositions and methods of the invention can use separately or be used in combination with being applicable to other reagent and method that treatment is infected.One aspect of the present invention provides treatment to suffer from the experimenter's of infection method.The method of this aspect comprises that the present composition from significant quantity to the experimenter who suffers from infection that use is to treat experimenter's step according to the present invention.
One side of the present invention provides treatment to suffer from the experimenter's of infection method.The method of this aspect comprises to the experimenter who suffers from infection and uses the present composition and the infection medicine of the significant quantity step with the treatment experimenter according to the present invention.
One side of the present invention provides immunostimulating ORN of the present invention to be used to prepare the purposes of medicine, and said medicine is used for treating experimenter's infection.
One side of the present invention provides the compsn that is applicable to that treatment is infected.Compsn according to this aspect comprises immunostimulating ORN of the present invention and infection medicine.
The term " treatment " that this paper uses about the experimenter's that suffers from disease or illness aspect should be illustrated among the experimenter and prevent, improves or eliminate a disease or at least one sign or the symptom of illness.
" experimenter who suffers from infection " is following experimenter, and said experimenter suffers from the illness that the invasion of the shallow table of experimenter, partial or general is caused by infectious microorganism.Infectious microorganism can be aforesaid virus, bacterium, fungi or parasite.
Infection medicine includes but not limited to: antiseptic-germicide, antiviral agent, anti-mycotic agent and antiparasitic.For example " anti-infection agent ", " microbiotic ", " antiseptic-germicide ", " antiviral agent ", " anti-mycotic agent ", " antiparasitic ", " parasiticide " have definite implication to this area routine techniques personnel and in the medical article of standard, define.In brief, antiseptic-germicide kills or suppresses bacterium, and comprises that microbiotic and other have the synthetic or natural compound of similar functions.Antiviral agent can separate from natural origin or be synthetic, and is applicable to and kills or suppress virus.Anti-mycotic agent is used to treat the fungi infestation and the opportunistic and elementary systemic fungal infection of shallow table.Antiparasitic kills or suppresses parasite.A lot of microbiotic are low-molecular-weight molecules, and its stimulation meta-bolites as cell such as mikrobe is produced.Microbiotic nonspecific infection mikrobe special, be not present in one or more functions or structure in the host cell.
One of problem of anti-infective therapy is the spinoff that takes place among the host when treating with anti-infection agent.For example, many anti-infection agents can kill or suppress the mikrobe of wide spectrum, and not special to the species of particular type.Anti-infection agent treatment with these types causes killing the normal microflora and the infective micro-organisms of living among the host.The forfeiture of said flora can cause the disease complication and the host is easy to by other pathogenic infection, because the effect to the barrier of infectious agent is competed and played to said flora and infectious agent.Other spinoff can be caused host's the non-microorganism cell or the specificity or the nonspecific action of tissue by these chemical entities.
Another problem of widely-used anti-infection agent is the development of the microorganism strains of antibiotics resistance.Develop the S.aureus of the enterococci of vancomyein resistance, the pneumococci of penicillin resistance, multiple resistance and the tuberculosis bacterial strain of multiple resistance, and become the main clinical problem.Being widely used of anti-infection agent may produce the bacterial isolates of many antibiotics resistances.Therefore, need new anti-infective strategy to resist these mikrobes.
Effectively killing or suppress on a large scale, the antibiotic microbiotic of bacterium is meant Broad spectrum antibiotics.The antibiotic microbiotic of other type is mainly effective to the bacterium of Gram-positive or Gram-negative kind.The microbiotic of these types is known as narrow-spectrum antibiotic.Single biology or disease effectively and not are known as limit spectrum microbiotic (limited-spectrum antibiotics) to other microbiotic of the bacterium of other type.
Antiseptic-germicide is classified according to their main binding mode sometimes.Antiseptic-germicide generally is cell walls synthetic inhibitor, cytolemma suppressor factor, protein synthesis inhibitor, nucleic acid is synthetic or depressant of functions and competitive inhibitor.The cell walls synthetic inhibitor suppresses a step in the cell walls building-up process, usually in bacterial peptide glycan synthetic.The cell walls synthetic inhibitor comprises beta-lactam antibiotics, natural penicillin, semisynthetic penicillin, Ampicillin Trihydrate, clavulanic acid, cephalosporins and bacitracin.
Beta-lactam is the microbiotic that contains the quaternary beta-lactam nucleus, its inhibiting peptide glycan synthetic final step.Beta-lactam antibiotics can be a synthetic or natural.The beta-lactam antibiotics of being produced by penicillium is natural penicillium mould, for example penicillin G or V-cillin.These fermentations through Penicillium chrysogenum produce.Natural penicillin has the activity of narrow spectrum, and effective to Streptococcus, Gonococcus and Staphylococcus usually.The gram positive bacterium also natural penicillin of effective other type is comprised penicillin-f, X, K and O.
The modification of the 6-amino-penicillanic acid molecule that semisynthetic penicillium mould is normally produced by mould.6-amino-penicillanic acid can be modified through adding side chain, and this has produced to compare with natural penicillin has the more penicillium mould of active or multiple other favorable characteristics of wide spectrum.The semisynthetic penicillin of some types has the wide spectrum to Gram-positive and gram negative bacterium, but by the penicillinase deactivation.These semisynthetic penicillium mould comprise Ampicillin Trihydrate, Gepcillin, Oxazacillin, azlocillin, mezlocillin and piperacillin.The semisynthetic penicillin of other type has the narrower activity to gram positive bacterium, thereby but has flourishing characteristic not by the penicillinase deactivation.These comprise for example X-1497, dicloxacillin and nafcillin.Some wide spectrum semisynthetic penicillins can with beta-lactamase inhibitor for example the combination of clavulanic acid and sulbactam (sulbactam) use.Beta-lactamase inhibitor does not have anti-microbial effect, but they act on the inhibition penicillinase, thereby protects semisynthetic penicillium mould not to be degraded.
The beta-lactam antibiotics of another kind of type is a cephalosporins.They are responsive to the degraded of bacterium β-Nei Xiananmei, thereby and usually not separately not effectively.Yet cephalosporins is the penicillinase resistance.They are effective to multiple Gram-positive and gram negative bacterium.Cephalosporins includes, but are not limited to cefoxitin, Cephapirin, Cephalexin Monohydrate Micro/Compacted, Mol, cefaclor, Cephazolin, cephalofruxin, cefoxitin, cefotaxime, cefsulodin, cefetamet, Cefixime Micronized, ceftriaxone, cefoperazone, ceftazime and latamoxef.
Bacitracin is the microbiotic of another kind, and to suppress cell walls from the release of following molecule synthetic through suppressing muramyl peptide subunit or Polysaccharides, peptide complexes for it, and said molecule is delivered to subunit in the outside of film.Although bacitracin is effectively to gram positive bacterium, because its high toxicity, its purposes is limited in the topical application usually.
Carbapenems is another kind of wide spectrum beta-lactam antibiotics, and it is synthetic that it can suppress cell walls.The example of carbapenem includes, but are not limited to imipenum (imipenem).Monocycle beta-lactam also is the wide spectrum beta-lactam antibiotics, and it comprises excellent Tener (euztreonam).By a kind of antibiotic vancomycin that Streptomyces produces, also be synthetic effective to gram-positive microorganism through suppressing cytolemma.
Another kind of antiseptic-germicide is the antiseptic-germicide that belongs to the cytolemma suppressor factor.These compounds destroy the structure of bacterial film or suppress its function.A problem that belongs to the antiseptic-germicide of cytolemma suppressor factor is: because the similarity of phosphatide in bacterium and the eukaryote film, they can generation effect in eukaryotic cell and in the bacterium.Therefore, these compounds are seldom enough special allowing these compounds to be used by general ground, and the topical application of prevention high dosage.
A kind of clinical useful cytolemma suppressor factor is polymyxin (Polymyxin).Polymyxin is through combining the inteferometer coating function with membrane phospholipid.It is effective that polymyxin is primarily aimed at gram negative bacterium, and be normally used for less toxicity antibiosis is have in the serious Pseudomonas infection or Pseudomonas infection of resistance.Use the relevant serious side effects of this compound with general and comprise damage kidney and other organ.
Other cytolemma suppressor factor comprises amphotericin B (Amphotericin B) and nystatin (Nystatin), and it is the anti-mycotic agent that is mainly used in treatment systemic fungal infection and the Candida yeast infection.Imidazoles is the another kind of microbiotic that belongs to the cytolemma suppressor factor.Imidazoles is used as antiseptic-germicide and anti-mycotic agent, for example is used to treat yeast infection, dermatozoon infection and systemic fungal infection.Imidazoles includes but not limited to clotrimazole (clotrimazole), miconazole (miconazole), KETOKONAZOL (ketoconazole), itraconazole (itraconazole) and fluconazole (fluconazole).
Many antiseptic-germicides are protein synthesis inhibitors.These compounds stop bacterium composite structure protein and enzyme, thereby cause the inhibition or the necrocytosis of bacterial cell growth or function.Usually, these compounds disturb the process of transcribing or translating.The antiseptic-germicide that obstruction is transcribed includes but not limited to Rifampin (Rifampins) and Tibutol (Ethambutol).The Rifampin that suppresses RNA polymerase has broad spectrum of activity, and effective to Gram-positive and gram negative bacterium and Mycobacterium tuberculosis.Tibutol is effective to Mycobacterium tuberculosis.
The antiseptic-germicide interfere with bacterial rrna that sealing is transcribed is translated into protein to stop mRNA.Usually, the compound of this kind includes but not limited to tetracyclines, paraxin, Macrolide (for example Oxacyclotetradecane,erythromycin deriv) and aminoglycoside (for example Streptomycin sulphate).
Aminoglycoside is a kind of microbiotic of being produced by bacterium Streptomyces, for example Streptomycin sulphate, kantlex, tobramycin, amikacin (amikacin) and qingfengmeisu qiong.Aminoglycoside has been used for infecting to the various bacteria that is caused by Gram-positive and gram negative bacterium.Streptomycin sulphate has been widely used as the main medicine of treatment white plaque (tuberculosis).Qingfengmeisu qiong is used to (particularly with the tobramycin combination) comprises Pseudomonas to multiple Gram-positive and gram negative bacterium infection.Kantlex is used to comprise the Staphylococci of penicillin resistance to many gram positive bacteriums.A spinoff of restriction aminoglycoside clinical application is: under the essential dosage of effect, life-time service shows the damage renal function and causes the injury of acoustic nerve that causes deafness.
The TI antiseptic-germicide of another kind of type is a tetracyclines.Tetracyclines is a kind of microbiotic, and it is wide spectrum and effective to multiple Gram-positive and gram negative bacterium.The example of tetracyclines comprises tsiklomitsin, Minocycline HCl, Vibravenos and duomycin.They are important for the bacterium of the many types of treatment, but in the treatment of Lyme disease (Lyme disease), are even more important.Because their hypotoxicity and minimum direct spinoff, tetracyclines is used by the medical circle excess and abuses, and causes a plurality of problems.For example, their excess is used the extensive generation that has caused resistance.
Antiseptic-germicide such as Macrolide combine with the 50S ribosomal subunit is reversible, and the extension through peptidyl transferase arrestin matter or stop uncharged tRNA to discharge from bacterial ribosome, or the two has concurrently.These compounds comprise Oxacyclotetradecane,erythromycin deriv, Roxithromycin, clarithromycin, romicil and Azythromycin.Oxacyclotetradecane,erythromycin deriv is active to most gram positive bacteriums, Neisseria, Legionella and Haemophilus, is not active to Enterobacteriaceae still.Closed protein matter lincomycin that peptide bond forms between synthesis phase and clindamycin are used for to gram positive bacterium.
The TI of another kind of type is a paraxin.Paraxin combines the 70S rrna, suppresses the bacterial enzyme peptidyl transferase, thus the growth of peptide chain during the prevention protein synthesis.A severe side effect relevant with paraxin is aplastic anemia.In small portion (1/50,000) patient, aplastic anemia takes place under the paraxin dosage of effectively treating bacterium.Because the death that anaemia causes, the microbiotic paraxin of once being prescribed are in a large number seldom used now.It still is used for life-threatening situation (for example typhoid) because of validity.
Some antiseptic-germicides destroy the synthetic or function of nucleic acid, thus for example combines with DNA or RNA they signal can not they include but not limited to by reading: quinolones and trimethoprim-sulfamethoxazole (co-trimoxazole) (the two is the synthetic chemical) and rifomycin (natural or semisynthetic chemical).Quinolone is through suppressing the dna replication dna of DNA gyrase (gyrase) sealing bacterium, and bacterium needs said gyrase to produce their cyclic DNA.They are wide spectrums, and example comprises norfloxicin, CIPROFLOXACIN USP 24, enoxacin, Nalidixic Acid and temafloxacin.Nalidixic Acid is the sterilant that combines DNA gyrase (topoisomerase), and it is crucial for duplicating of DNA, and allows superhelix to be released and formation again, and it is active to suppress the DNA gyrase.The main application of Nalidixic Acid is treatment lower urinary tract infection (UTI), because it is to the common cause of UTI---and the kind of some kinds of Gram-negative bacterias such as E.coli, Enterobacter aerogenes, K.pneumoniae and Proteus is effective.Trimethoprim-sulfamethoxazole is the combination of SULPHAMETHOXAZOLE USP (sulfamethoxazole) and trimethoprim (trimethoprim), and its sealing is made the bacterium of the required folic acid of DNA Nucleotide and synthesized.Rifampin is the verivate to gram positive bacterium (comprising Mycobacterium tuberculosis and the meningitis that is caused by Neisseria meningitidis) and the activated rifomycin of some gram negative bacteriums.Rifampin combines and seals the interpolation of first Nucleotide (it is that the activation polysaccharase is necessary) with the β subunit of polysaccharase, thereby sealing mRNA is synthetic.
Another kind of antiseptic-germicide is the compound that plays the competitive inhibitor effect of bacterial enzyme.Almost all similar with the bacterial growth factor structure and the competition of competitive inhibitor combines, still in cell, does not carry out metabolic function.These compounds comprise the sulfanilamide (SN) of sulfamido and chemically modified form, and it has higher or anti-microbial activity widely.Sulfamido (for example Sulfafurazole and the pyridine of methylamine benzyl) is applicable to treatment Streptococcus pneumoniae, beta hemolytic streptococcus and E.coli, and has been used for treating uncomplicated UTI that is caused by E.coli and the treatment that is used for meningococcal meningitis.
Antiviral agent is to prevent that cell is by virus infection or prevent the compound of virus replication in the cell.Existence is than antimicrobial drug antiviral drug still less, because the dna replication dna in the process of virus replication and the host cell is closely related, makes nonspecific antiviral agent poisonous to host cell usually.In the process of virus infection, have some stages, it can or suppress by the antiviral agent sealing.These stages comprise that virus combines the synthetic of (Tegeline or binding peptide), uncoating (for example amantadine), virus mRNA or translates the duplicating of (for example Interferon, rabbit), viral RNA or DNA (for example nucleoside analog), new virus protein with host cell maturation (for example proteinase inhibitor) and viral sprouts and discharge.
Another category of antiviral agent is a nucleoside analog.Nucleoside analog is and the synthetic compound of nucleoside analogues, still has incomplete or unusual ribodesose or ribose groups.In a single day nucleoside analog is in the cell just by phosphorylation, produces the triphosphate form, and it is integrated among viral DNA or the RNA with normal Nucleotide competition.In case the triphosphate form of nucleoside analog is integrated in the nucleic acid chains of growth, it causes the irreversible chain termination that combines and cause thus with varial polymerases.Nucleoside analog includes, but are not limited to acyclovir (being used to treat hsv and varicella one varicella zoster virus), ganciclovir (gancyclovir) (being used to treat cytomegalovirus), iodoxuridine, ribavirin (being used to treat respiratory syncytial virus (respiratory syncitial virus)), dideoxyinosine, zalcitabine and zidovudine (Zidovodine).
Another kind of antiviral agent comprises cytokine, for example Interferon, rabbit.Interferon, rabbit is by the cell of virus infection and immunocyte excretory cytokine.Interferon, rabbit acts on as follows: with by the special receptors bind on the cells infected adjacent cells, cause the change in the cell, said change protection cell is avoided virus infection.α and IFN-are also induced the expression of I class and II class MHC molecule on the infected cells surface, and the host immune cell recognition appears being used in the antigen that causes increasing.α and IFN-can be used as recombinant form and obtain, and have been used to treat chronic hepatitis B and hepatitis C infection.Under antagonism viral therapy effective dosage, Interferon, rabbit has severe side effect and for example has a fever, do not accommodate and lose weight.
Immunoglobulin therapy is used to prophylaxis of viral infections.The immunoglobulin therapy that is used for virus infection be used for the different of infectation of bacteria because immunoglobulin therapy is through combining the extracellular virus body and stop their to attack and get into the cell to the virus infection susceptible, rather than antigen-specific.This therapy is applicable to prophylaxis of viral infections in antibody is present in one period among the host.Two types immunoglobulin therapy is arranged usually, normal immunoglobulin therapy and hyperimmune globulin therapy.Normal immunoglobulin therapy utilizes a kind of antibody product, and said antibody product prepares from the serum of normal blood donor and merges.The product of this merging has the low antibody titer to large-scale Human virus, and said virus is hepatitis A, parvovirus, enterovirus (particularly in the newborn infant) for example.The antibody that the utilization of hyperimmune globulin therapy prepares from the serum of following individuality, said individuality have the high antibody titer to concrete virus.Use these antibody to special virus then.The example of hyperimmune globulin comprises Z/G (be applicable in immunocompromised children and newborn infant and prevent varicella), Human Rabies Immunoglobulin's (being applicable to by in the experimenter's of mad animal bite the post-exposure prophylaxis), HBIG (being applicable to the prevention hepatitis B virus, particularly in being exposed to this viral experimenter) and RSV Tegeline (being applicable to the treatment respiratory syncytial virus infection).
Anti-mycotic agent is applicable to treatment and preventing infection property fungi.Anti-mycotic agent is classified through their mechanism of action sometimes.Some anti-mycotic agents are through suppressing glucosylceramide synthase as the effect of cell walls suppressor factor.These include but not limited to basiungin/ECB.The film integrality unstability is fixed to be acted on other anti-mycotic agent through making.These comprise; But be not limited to imidazoles; For example clotrimazole, sertaconzole, fluconazole, itraconazole, KETOKONAZOL, miconazole and Vorionazole, and FK 463, amphotericin B, BAY 38-9502/MK 991, pradimicin, UK 292, butenafine and TF.Other anti-mycotic agent is through degraded chitin (for example chitinase) or immunosuppression (501 breast frost) effect.
Parasiticide is directly to kill the parasite material.This compounds is known in the art and can commercially obtains usually.The example that is applicable to the parasiticide that the people uses includes but not limited to albendazole; Amphotericin B; Rochagan; Bithionol; Chloroquine HCl; Chloroquini phosphas; Clindamycin; Dehydroemetine; Diethylcarbamazine; Diloxanide (diloxanide furoate); Eflornithine; Nifurazolidone; Glucocorticosteroid; Halfan (halofantrine); Iodoquinol (iodoquinol); Ivermectin (ivermectin); Mebendazole (mebendazole); Mefloquine hydrochloride (mefloquine); Meglumine antimonate (meglumine antimoniate); Melarsoprol (melarsoprol); Metrifonate (metrifonate); Metronidazole (metronidazole); Niclosamide (niclosamide); Nifurtimox (nifurtimox); Oxamniquine (oxamniquine); Paromycin (paromomycin); Pentamidine Isethionate (pentamidine isethionate); Piperazine (piperazine); PRAZIQUANTEL BP 98 (praziquantel); Primaquine (primaquine phosphate); Chloroguanide (proguanil); Pyrantel (pyrantel pamoate); Pyrimethamine hcl-sulfamido (pyrimethanmine-sulfonamides); Pyrimethamine-Sulfadoxine (pyrimethanmine-sulfadoxine); Hydrochloric acid quinacrine (quinacrineHCl); Quinine Sulphate Di HC; Quinaglute (quinidine gluconate); Spiramycin Base; Sodium stibogluconate (sodium stibogluconate sodium antimony gluconate); Suramine; Tsiklomitsin; Vibravenos; Thiabendazole; Tinidazole; Trimethroprim-sulfamethoxazole and Trypothane.
ORN also is applicable to treatment and prevention autoimmune disease.Autoimmune disease is one type of disease, wherein experimenter's self antibody and host tissue reaction, or wherein effector T lymphocyte and endogenous self peptide react automatically and cause disorganization.Therefore, caused the immunne response that is directed against experimenter's self antigen (being called self antigen).Autoimmune disease includes but not limited to rheumatoid arthritis; Crohn ' s is sick; Multiple sclerosis; Systemic lupus erythematous (SLE); The autoimmunization encephalomyelitis; Myasthenia gravis (MG); Hashimoto ' s thyroiditis; Goodpasture ' s syndrome; Pemphigus (for example pemphigus vulgaris); Grave ' s is sick; Autoimmune hemolytic anemia; Idiopathic thrombocytopenic purpura; The scleroderma that has the anticol original antibody; Mixed connective tissue disease; Polymyositis; Pernicious anemia; Primary Addison ' s is sick; The autoimmunization dependency is sterile; Glomerulonephritis (crescentic glomerulonephritis for example; Proliferative glomerulonephritis); Bullous pemphigoid; syndrome; Insulin resistant and autoimmune diabetes.
This paper uses " self antigen " to be meant the antigen of normal host tissue.Normal host tissue does not comprise cancer cells.Therefore; In the context of autoimmune disease, the immunne response that causes to self antigen is the immunne response of not expecting, and helps to destroy and the damage healthy tissues; And the immunne response that is directed against the cancer antigen initiation is the immunne response of expectation, and helps the destruction of tumour or cancer.Therefore, the present invention is directed to the treatment autoimmune disorder some aspect, do not recommend ORN is used with self antigen, especially belong to those self antigen of the target of autoimmune disorder.
In other cases, ORN can be sent with the self antigen of low dosage.A large amount of zooscopies have proved that the antigenic mucosal administration of low dosage can cause the state of immune low reactivity or " tolerance ".Actual mechanism shows it is cytokine mediated immune deviation, said deviation from Th1 to the deviation of replying that is mainly Th2 and Th3 (being that TGF-b arranges).Effective inhibition of low dosage antigen delivery also can suppress incoherent immunne response (onlooker's inhibition), and it receives significant concern in autoimmune disease (for example rheumatoid arthritis and SLE) treatment.The onlooker suppress to relate to Th1-anti--regulate, the secretion of suppressor factor cytokine in local environment, the cytokine and the Th1 cytokine of short inflammation are released with mode antigen-specific or antigen non-specific in the said local environment.This paper uses " tolerance " to be meant this phenomenon.In fact; Be that effectively said disease comprises in the treatment of oral tolerance a large amount of autoimmune diseases in animal: EAE (EAE), experimental autoimmunization myasthenia gravis, collagen-induced sacroiliitis (CIA) and insulin-dependent diabetes.In these models, the prevention of autoimmune disease is relevant with the migration that inhibition and the body fluid and the cell response of antigen-specific are replied from Th1 to Th2/Th3.
The compositions and methods of the invention can use separately or be used in combination with other reagent and the method that are applicable to the treatment cancer.One aspect of the present invention provides treatment to suffer from the experimenter's of cancer method.The method of this aspect comprises that the present composition that the experimenter who suffers from cancer is used significant quantity is to treat experimenter's step according to the present invention.
One aspect of the present invention provides treatment to suffer from the experimenter's of cancer method.The method of this aspect comprises the experimenter who suffers from cancer is used compsn of the present invention and the anti-cancer therapies of the significant quantity step with the treatment experimenter according to the present invention.
One aspect of the present invention provides immunostimulating ORN of the present invention to be used to prepare the purposes of medicine, and said medicine is used for treating experimenter's cancer.
One aspect of the present invention provides the compsn that is applicable to the treatment cancer.Compsn according to this aspect comprises immunostimulating ORN of the present invention and cancer drug.
The experimenter who suffers from cancer be have can detected cancer cells the experimenter.Cancer can be pernicious or nonmalignant cancer.This paper uses " cancer " to be meant uncontrolled cell growth, and it disturbs the normal function of body member and system.Can finally cause the experimenter dead through the deterioration of affected organ from the cancer of migration of their original position and entering vitals.Hematopoiesis cancer for example white blood disease can be defeated normal hematopoiesis compartment in the experimenter, thereby causes hematopoiesis failure (with the form of anaemia, thrombopenia and neutrophil leucocyte minimizing), finally causes death.
MET is the cancer cells in a zone, and its position with primary tumor is different, derives from cancer cells is disseminated to health from initial tumour other part.During the diagnosing primary tumor mass, can monitor the existence of experimenter's MET.Except that the special symptom of monitoring, MET is surveyed through being used alone or in combination nuclear magnetic resonance (MRI) scanning, computer tomography (CT) scanning, blood and platelet count, Liver Function, chest X-ray examination and bone scanning usually.
Cancer includes but not limited to: rodent cancer, cholangiocarcinoma; Bladder cancer; Osteocarcinoma; Brain and cns (CNS) cancer; Mammary cancer; Cervical cancer; Choriocarcinoma; The colon and the rectum cancer; The reticular tissue cancer; Digestive system cancer; Carcinoma of endometrium; The esophageal carcinoma; Cancer eye; The H&N cancer; Last intracutaneous true tumor; Kidney; Laryngocarcinoma; White blood disease; Liver cancer; Lung cancer (for example minicell and nonsmall-cell lung cancer); Lymphoma comprises Hodgkin ' s and Non-Hodgkin ' s lymphoma; Melanoma; Myelomatosis; Neuroblastoma; Oral cancer (for example lip, tongue, mouth and pharynx cancer); Ovarian cancer; Carcinoma of the pancreas; Prostate cancer; Retinoblastoma; Rhabdosarcoma; The rectum cancer; The respiratory system cancer; Sarcoma; Skin carcinoma; Cancer of the stomach; Carcinoma of testis; Thyroid carcinoma; Uterus carcinoma; Urinary system cancer and other cancer (carcinomas), gland cancer and sarcoma (sarcomas).
Immunostimulating compsn of the present invention can also be used with anti-cancer therapies.Anti-cancer therapies comprises cancer medicament, radiation and operation technique." cancer medicament " that this paper uses is meant and is used the reagent that is to treat cancer to experimenter, purpose." the treatment cancer " that this paper uses comprise preventing cancer generation, reduce the symptom of cancer, and/or the growth of the cancer that suppresses to confirm.In others, the cancer medicament is used the experimenter of taking place under the risk of cancer to being in, and purpose is to reduce the risk that cancer takes place.Herein disclosed is the polytype medicament that is used to treat cancer.With regard to the purpose of this specification sheets, the cancer medicament is classified as chemotherapeutic, immunotherapeutic agent, cancer vaccine, hormonotherapy and biological response modifier.
Chemotherapeutic can be selected from: Rheumatrex; Vincristine(VCR); Zorubicin; Cis-platinum; Not sacchariferous chloroethylnitrosoureas; 5 FU 5 fluorouracil; Ametycin; Bleomycin; Dx; Dicarbazine; Safe plain; Fragyline; Meglamine GLA; Valrubicin; Carmustine and poliferposan; MMI270; BAY 12-9566; The RAS farnesyl transferase inhibitor; Farnesyl transferase inhibitor; MMP; MTA/LY231514; LY264618/Lometexol; Glamolec; CI-994; TNP-470; With U.S. new/hycamtin (Hycamtin/Topotecan); PKC412; Valspodar (Valspodar)/PSC833; Novantrone (Novantrone)/Mitroxantrone; Metaret/ Suramine (Suramin); BB-94 (Batimastat); E7070; BCH-4556; CS-682; 9-AC; AG3340; AG3433; Incel/VX-710; VX-853; ZD0101; ISI641; ODN 698; TA2516/Marmistat; BB2516/Marmistat; CDP 845; D2163; PD183805; DX8951f; Lemonal DP 2202; FK 317; Dissolve chain bacterium (Picibanil)/OK-432; AD 32/ valrubicin (Valrubicin); Strontium chloride (Metastron)/strontium verivate; Temodal/ TM (Temozolomide); Evacet (Evacet)/Mycocet; Yewtaxan/ taxol (Paclitaxel); Safe plain (Taxol)/taxol (Paclitaxel); Xi Luoda (Xeload)/capecitabine (Capecitabine); Furtulon (Furtulon)/doxifluridine (Doxifluridine); The oral taxol of Cyclopax/; Oral Taxan; The SPU-077/ cis-platinum; HMR 1275/Flavopiridol; CP-358 (774)/EGFR; CP-609 (754)/RAS oncogene suppressor factor; The oral platinum of BMS-182751/; UFT (Tegafur/uridylic); Ergamisol/ LEVAMISOLE HCL (Levamisole); Eniluracil (Eniluracil)/776C85/5FU enhanser; Campto/ LEVAMISOLE HCL (Levamisole); Camptosar/ irinotecan (Irinotecan); Tumodex/Ralitrexed; Leustatin/ CldAdo (Cladribine); The Paxex/ taxol; The Doxil/ Mycocet; The Caelyx/ Mycocet; Fuda China (Fludara)/fludarabine (Fludarabine); Pharmarubicin/ epirubicin (Epirubicin); DepoCyt; ZD1839; LU 79553/Bis-Naphtalimide; LU 103793/ dolastatin (Dolastain); The Caetyx/ Mycocet; Strong (the Gemzar)/gemcitabine (Gemcitabine) of selecting; ZD 0473/Anormed; YM 116; Iodine particle (Iodine seeds); CDK4 and CDK2 suppressor factor; The PARP suppressor factor; D4809/Dexifosamide; Ifes/Mesnex/ ifosfamide (Ifosamide); Brave and fierce (Vumon)/teniposide (Teniposide); Paraplatin (Paraplatin)/carboplatin (Carboplatin); Cis-platinum (Plantinol)/cis-platinum; Etoposide (Vepeside)/VP (Etoposide); ZD 9331; TX (Taxotere)/Docetaxel (Docetaxel); The prodrug of guanine cytosine arabinoside; 10-deacetyltaxol; Nitrosourea; Alkylating agent such as melphelan and endoxan; Aminoglutethimide (Aminoglutethimide); Asparaginase; Busulfan (Busulfan); Carboplatin; TV (Chlorombucil); Spongocytidine-hydrochloride (Cytarabine HCl); Gengshengmeisu (Dactinomycin); Daunorubicin hydrochloride (DaunorubicinHCl); Estramustine phosphate sodium (Estramustine phosphate sodium); VP (VP16-213); NSC-27640 (Floxuridine); Fluracil (5-FU); Flutamide; Hydroxyurea (hydroxycarbamide); Ifosfamide (Ifosfamide); Intederon Alpha-2a; α-2b; TAP-144 (Leuprolide acetate) (LHRH-releasing factor analogs); Lomustine (Lomustine) (CCNU); Hydrochloric acid chlormethine (Mechlorethamine HCl) (mustargen); Mercaptopurine (Mercaptopurine); Mesna (Mesna); Mitotane (Mitotane) (o.p '-DDD); NSC-301739 (Mitoxantrone HCl); Sostatin (Octreotide); Plicamycin (Plicamycin); Procarbazine hydrochloride (Procarbazine HCl); Streptozocin (Streptozocin); Tamoxifen Citrate (Tamoxifen citrate); Thioguanine; Plug is for sending (Thiotepa); Vinealeucoblastine(VLB) (Vinblastinesulfate); Amsacrine (Amsacrine) (m-AMSA); Azacitidine (Azacitidine); Erthropoietin; Altretamine (Hexamethylmelamine) (HMM); Interleukin-(Interleukin) 2; Mitoguazone (Mitoguazone) (methyl-GAG; Methyl-prop keto-aldehyde two-methyl GAG; MGBG), pentostatin (Pentostatin) (2 ' deoxycoformycin), semustine (Semustine) (Semustine), teniposide (Teniposide) (VM-26) and LY-099094, but be not limited only to this.
Immunotherapeutic agent can be selected from 3622W94,4B5, ANA Ab, anti--FLK-2, anti-VEGF, ATRAGEN, AVASTIN (rhuMAb-VEGF (bevacizumab); Genentech), BABS, BEC2, BEXXAR (tositumomab (tositumomab); GlaxoSmithKline), C225, CAMPATH (alemtuzumab (alemtuzumab); Genzyme Corp.), CEACIDE, CMA 676, EMD-72000, ERBITUX (Cetuximab (cetuximab); ImClone Systems, Inc.), Gliomab-H, GNI-250, HERCEPTIN (trastuzumab (trastuzumab); Genentech), IDEC-Y2B8, ImmuRAIT-CEA, ior c5, ior egf.r3, ior t6, LDP-03, LymphoCide, MDX-11, MDX-22, MDX-210, MDX-220, MDX-260, MDX-447, MELIMMUNE-1, MELIMMUNE-2, Monopharm-C, NovoMAb-G2, Oncolym, OV103, Ovarex, Panorex, Pretarget, Quadramet, Ributaxin, RITUXAN (Mabthera (rituximab); Genentech), SMART 1D10 Ab, SMART ABL 364Ab,, SMART M195, TNT and ZENAPAX (daclizumab; But be not limited only to this Roche).
Cancer vaccine can be selected from cancer vaccine, Gp75 antigen, GMK melanoma vaccine, MGV Sphingolipids,sialo conjugate vaccine, HeR2/neu, Ovarex, M-Vax, O-Vax, L-Vax, STn-KHL theratope, BLP25 (MUC-1), liposome idiotype vaccine, Melacine (Melacine), peptide antigen vaccine, toxin/antigen vaccine, the vaccine based on MVA, PACIS, BCG vacine, TA-HPV, TA-CIN, the DISC-virus andImmuCyst/TheraCys of EGF, anti-idiotype, but is not limited only to this.
The compositions and methods of the invention can use separately, or use with being applicable to the combination of allergic other reagent of treatment and method.One aspect of the present invention provides treatment to suffer from the experimenter's of allergic conditions method.The method of this aspect comprises that the compsn of the present invention that the experimenter who suffers from allergic conditions is used significant quantity is with the treatment experimenter according to the present invention.
One aspect of the present invention provides treatment to suffer from the experimenter's of allergic conditions method.The method of this aspect comprises that compsn of the present invention and anti-allergic therapy that the experimenter who suffers from allergic conditions is used significant quantity are with the treatment experimenter according to the present invention.
One aspect of the present invention provides immunostimulating ORN of the present invention to be used to prepare the purposes of medicine, and said medicine is used for treating experimenter's allergic conditions.
One aspect of the present invention provides the compsn that is applicable to the treatment allergic conditions.Compsn according to this aspect comprises immunostimulating ORN of the present invention and transformation reactions medicament.
" experimenter who suffers from allergic conditions " representes experiencing at present or before once living through the experimenter who responds to allergenic atopic reaction.
" allergic conditions " or " transformation reactions " is meant the acquired supersensitivity to material (allergen).Allergic conditions includes but not limited to eczema, rhinallergosis or rhinitis (coryza), spring fever (hay fever), allergic conjunctivitis, bronchial asthma, urticaria (hives) and food allergy; Other atopy illness comprises atopic dermatitis; Anaphylaxy (anaphylaxis); Drug allergy and angioedema.
Typically, transformation reactions is and is directed against the relevant of short duration illness of allergenic antibody producing that said antibody is from concrete Tegeline kind IgE.By the generation that general source of the gas property allergen is replied of IgE mediation also is the factor that indication trends towards taking place the inducement of asthma.If allergen meets with on basophilic leucocyte (in blood, circulating) or mastocyte (the being scattered in solid tissue everywhere) surface and the special IgE of IgE Fc acceptor (FceR) bonded; Then cell is activated; Cause the production and the release of medium, said medium is histamine, serotonin and lipid medium for example.
When tissue sensitivity's Tegeline of IgE type and the reaction of external source allergen, atopic reaction takes place.IgE antibody combines with mastocyte and/or basophilic leucocyte, and when receiving allergen with the terminal bridge joint of antibody molecule and stimulate, these specialized cells discharge the chemical mediator (vasoactive amines) of atopic reactions then.Histamine, platelet activation factor, arachidonic acid metabolite and serotonin are the known best media of philtrum atopic reaction.Histamine is stored in mastocyte and the basophil with other vasoactive amines usually.Mastocyte is dispersed in animal tissues everywhere, and basophilic leucocyte circulates in vascular system.These cells are made histamine and it are stored in the cell, take place only if relate to the incident of IgE bonded specialization sequence, cause its release.
The symptom of atopic reaction is according to the position in the health and difference, and said position is IgE and antigen reactive position.Take place if be reflected on the respiratory epithelium, then symptom normally sneeze, cough and asthma reaction.Occur in (for example under the situation of food allergy) in the digestive tube, then common stomachache and diarrhoea if interact.The atopic reaction of general (after for example after honeybee bites or to the experimenter, using penicillium mould) can be serious, and usually is life-threatening.
Transformation reactions is relevant with Th2 type immunne response, its at least part convert the IgE sign into by Th2 cytokine IL-4 and IL-5 and antibody isotype.Th1 and Th2 immunne response are mutual re, thereby the immunne response of Th2 type can prevented or improve to immunne response towards the skew of Th1 type immunne response, comprises transformation reactions.Therefore, immunostimulating ORN of the present invention self is applicable to and treats the experimenter who suffers from allergic conditions, because immunostimulating ORN can make the immunne response of immunne response deflection Th1 type.Perhaps or in addition, immunostimulating ORN of the present invention can use the experimenter that suffer from allergic conditions with treatment with the allergen combination.
Immunostimulating compsn of the present invention also can with anti-allergic therapy combined administration.Be used to treat or prevent allergic ordinary method to relate to the use of transformation reactions medicament or hyposensitization therapy.Be used for treating or prevent more allergic development therapies comprise in the use of anti-IgE antibodies.The seriousness of allergic symptoms is regulated in the antihistamine of the chemical mediator of sealing atopic reaction and other medicines help, but can not react by prevention of allergic, and allergic response is not subsequently acted on.Preferred hyposensitization therapy, said hyposensitization therapy was induced originally to allergenic IgG type and was replied through giving (usually through subcutaneous injection) low dose of allergic effect.Think that the existence of IgG helps the production of neutralization medium, the production of said medium derives from inducing of IgE antibody.The initial usefulness very allergen of low dosage is treated the experimenter to avoid inducing serious reaction, and dosage is slowly increased.The therapy of the type is dangerous, because in fact the experimenter has been used the compound that causes allergic response and can cause serious atopic reaction.
The transformation reactions medicament includes but not limited to, antihistamine, cortin and prostaglandin(PG) inductor.Antihistamine is the compound of offsetting the histamine of mastocyte or basophil release.These compounds are well known in the art, and are generally used for treating transformation reactions.Antihistamine includes, but are not limited to acrivastine (acrivastine), astemizole (astemizole), azatadine (azatadine), azelastine (azelastine), betatastine, Parabromdylamine (brompheniramine), buclizine (buclizine), cetirizine (cetirizine), cetirizine analogue, chlorphenamine (chlorpheniramine), clemastine (clemastine), CS 560, Cyproheptadine (cyproheptadine), Desloratadine (desloratadine), dexchlorpheniramine (dexchlorpheniramine), ebastine (ebastine), epinastine (epinastine), fexofenadine (fexofenadine), HSR 609, hydroxyzine (hydroxyzine), levocabastine (levocabastine), loratidine, epoxytropine tropate (methscopolamine), mizolastine (mizolastine), promise astemizole (norastemizole), phenindamine (phenindamine), promethazine (promethazine), Pyrilamine (pyrilamine), terfenadine (terfenadine) and tranilast (tranilast).
Cortin includes but not limited to: methylprednisolone (methylprednisolone), prednisolone (prednisolone), prednisone (prednisone), beclometasone (beclomethasone), budesonide (budesonide), DEXAMETHASONE BP98 (dexamethasone), RS 3999 (flunisolide), fluticasone propionate (fluticasone propionate) and triamcinolone (triamcinolone).Although DEXAMETHASONE BP98 is the reflunomide with anti-inflammatory action, it is not used to treat transformation reactions or asthma with the form that sucks usually, because it has secular inhibition spinoff by high absorption and under effective dose.Yet DEXAMETHASONE BP98 can be used to treat transformation reactions or asthma according to the present invention, because when using with combination of compositions of the present invention, thereby it can use with low dosage and reduces spinoff.Use some relevant spinoffs to comprise cough, mogiarthria, white mouth (moniliosis) and the systemic effect when the high dosage more with reflunomide, for example suprarenal gland inhibition, glucose intolerance, osteoporosis, aseptic necrosis of bone, cataract generation, growth-inhibiting, hypertension, myasthenia, thinning of skin (skin thinning) abrade with easy.Barnes & Peterson (1993) Am Rev Respir Dis148:S1-S26 and Kamada AK et al. (1996) Am J Respir Crit Care Med 153:1739-48.
The compositions and methods of the invention can use separately or be used in combination with other reagent and the method that are applicable to treatment asthma.One aspect of the present invention provides treatment to suffer from the experimenter's of asthma method.The method of this aspect comprises that the present composition that the experimenter who suffers from asthma is used significant quantity is to treat experimenter's step according to the present invention.
One aspect of the present invention provides treatment to suffer from the experimenter's of asthma method.The method of this aspect comprises the experimenter who suffers from asthma is used compsn of the present invention and the asthma therapy of the significant quantity step with the treatment experimenter according to the present invention.
One aspect of the present invention provides immunostimulating ORN of the present invention to be used to prepare the purposes of medicine, and said medicine is used for treating experimenter's asthma.
One aspect of the present invention provides the compsn that is applicable to treatment asthma.Compsn according to this aspect comprises immunostimulating ORN of the present invention and asthma medicament.
" asthma " that this paper uses is meant the illness of respiratory system, it is characterized in that the inflammation of air flue and narrow, and air flue is to the reactivity of the raising of inhalation.Asthma (but not exclusively) usually combines with atopy or allergic conditions.The symptom of asthma comprise by air-flow hinder stridulating of causing, asthma, chest is urgent and the periodical attack of cough.The airway inflammation relevant with asthma can through observe a large amount of physiology change monitored, for example the degrading of airway epithelia, basilar membrane collagen deposition, oedema, mastocyte activation, inflammatory cell (comprising neutrophil leucocyte, EC and lymphocyte) infiltration down.As the result of airway inflammation, it is chronic that asthmatic patient often experiences airway hyperreactivity, airway limitation, respiratory symptom and disease.Airway limitation comprises that polarity bronchoconstriction, air flue oedema, cervical plug form and airway remodeling, and these characteristics often cause bronchial obstruction.Half basilar membrane fibrosis (sub-basement membrane fibrosis) can take place under the certain situation of asthma, causes the pulmonary function permanent anomaly.
Research in the past few years shows that asthma possibly be to be interacted by the complicacy between other cell of inherent in inflammatory cell, medium and the air flue and tissue to cause.Mastocyte, EC, epithelial cell, scavenger cell and activated T cells all play important effect in the inflammatory process relevant with asthma.Djukanovic?R?et?al.(1990)Am?Rev?Respir?Dis?142：434-457。Think these cells can be through secretion preformed and synthetic medium influence air flue function recently, said medium can act on local organization directly or indirectly.Thought that T lymphocyte (Th2) subgroup is through discharging cytokine optionally and set up that disease is chronic to play an important role in the alterative inflammation of regulating air flue.Robinson?DS?et?al.(1992)N?Engl?J?Med?326：298-304。
Asthma is a kind of illness of complicacy, and it takes place in the different steps of growing, and can be classified as acute, subacute or chronic according to the degree of symptom.Acute inflammatory response is relevant with raising in early days of cell entering air flue.Subacute inflammatory response relates to the activation of raising of cell and intrinsic cell, and this causes more persistent inflammation pattern.Chronic inflammatory diseases is replied cell injury and the ongoing repair process that is characterised in that lasting level, and it can cause the permanent anomaly in the air flue.
" experimenter who suffers from asthma " is meant that the experimenter who suffers from respiratory disorder, said illness are characterised in that the inflammation of air flue and narrow, and air flue is to the reactivity of the raising of inhalation.The factor relevant with asthma attack includes, but are not limited to allergen, cold temperature, motion, virus infection and SO 2
As stated, asthma maybe be relevant with Th2 type immunne response, its at least part convert the IgE sign into by Th2 cytokine IL-4 and IL-5 and antibody isotype.Th1 and Th2 immunne response are mutual re, thereby the immunne response of Th2 type can prevented or improve to immunne response towards the skew of Th1 type immunne response, comprises transformation reactions.Therefore, of the present invention self being applicable to through the oligoribonucleotide analogue of modifying treated the experimenter who suffers from asthma, because said analogue can make the immunne response of immunne response deflection Th1 type.Perhaps or in addition, of the present inventionly can use the experimenter that suffer from asthma with treatment with the allergen combination through the oligoribonucleotide analogue of modifying.
Immunostimulating compsn of the present invention also can with the asthma therapies combined administration.Be used to treat or the ordinary method of prevention of asthma relates to the use of anti-allergic therapy (as stated) and a large amount of other reagent (comprising inhalation).
The medicine that is used to treat asthma is divided into two types, rapid delivery of pharmaceuticals and long-term control medicine usually.Asthmatic patient adopts the long-term control medicine to reach and to keep the control of long-term asthma on the basis of every day.The long-term control medicine comprises anti-inflammatory agent, for example cortin, Gerhard Cromme (chromolyn) sodium and nedocromil (nedocromil); Long-acting bronchodilator, for example long-acting beta 2-agonist and methyl xanthine; With the leukotrienes modifier.Rapid delivery of pharmaceuticals comprises fugitive β 2-agonist, anticholinergic agents and general cortin.Exist with these medicines in every kind of relevant many spinoffs, do not have a kind of medicine or its combination can prevent or treat fully asthma.
Asthmatic medicament includes, but are not limited to the suppressor factor and the proteinase inhibitor of PDE-4 suppressor factor, bronchodilator/β-2 agonist, K+ channel opener, VLA-4 antagonist, neurokinin (neurokin) antagonist, thromboxane (thromboxane) A2 (TXA2) synthetic inhibitor, xanthine, arachidonic acid antagonist, 5 fats oxidn enzyme inhibitorss, TXA2 receptor antagonist, TXA2 antagonist, 5-lipox activation of protein.
Bronchodilator/β 2-agonist is a compounds that causes bronchiectasis or smooth muscle loosening.Bronchodilator/β 2-agonist includes, but are not limited to Salmeterol (salmeterol), salbutamol (salbutamol), salbutamol (albuterol), terbutaline (terbutaline), D2522/ formoterol (formoterol), Partusisten (fenoterol), bitolterol (bitolterol), pirbuterol methyl xanthine (pirbuerol methylxanthines) and Orciprenaline (orciprenaline).Long-acting beta 2Agonist and bronchodilator are the compounds that except that anti-inflammatory therapy, is used for preventing for a long time symptom.Long-acting beta 2Agonist includes, but are not limited to Salmeterol and salbutamol.Common and the cortin combination use of these compounds, and when having no the inflammation therapy, do not use.The spinoff that with in the overdose for example tachycardia, Skelettmuskel tremble for they, hypokalemia and QTc prolong at interval is relevant.
Methyl xanthine (comprising for example theophylline) has been used to long-term control and prevention symptom.These compounds cause the bronchiectasis by phosphodiesterase suppresses and possible adenosine antagonism causes.The acute toxicity that dosage is relevant is the particular problem of these type compounds.Therefore, thus must monitor conventional serum-concentration and calculate toxicity and limit the therapeutic scope (therapeutic range) that the MCR difference between individuals causes.Spinoff comprises tachycardia, the rhythm of the heart market of overrunning, nausea and vomiting, cns excitement, headache, epileptic seizures, spitting blood, hyperglycemia and hypokalemia.Fugitive β 2Agonist includes, but are not limited to salbutamol (albuterol), bitolterol (bitolterol), pirbuterol (pirbuterol) and terbutaline (terbutaline).With fugitive β 2Agonist uses that some relevant undesirable actions comprise that tachycardia, Skelettmuskel tremble, hypokalemia, lactic acid increase, headache and hyperglycemia.
Gerhard Cromme (chromolyn) sodium and nedocromil are used as the long-term control medicine, and said medicine is used to prevent by kinetic primary SOA or the allergic symptoms that caused by allergen.These compounds are considered to through disturbing muriate approach function to seal allergenic early stage and late phase response.They are also stablized mast cell membrane and suppress the activation and the release from inosineophils and epithelial cell thereof of medium.Usually need using of four to six weeks to reach maximum benefit.
Anticholinergics is normally used for alleviating the acute bronchus spasm.These compounds are considered to play a role through the competitive inhibition mAChR.Anticholinergics includes, but are not limited to ipratropium bromide.These compounds only can reverse the bronchospasm of cholinomimetic mode (cholinerigically) mediation, do not change antigenic any reaction.Spinoff comprise dry with breathe secretion (respiratory secretions) if, in some individualities, increase stridulate and the visual field when spraying into eyes fuzzy.
Immunostimulating ORN of the present invention is also applicable to the treatment airway remodeling.Airway remodeling is thickened by smooth muscle cell proliferation in the air flue and/or submucosa and causes, and finally causes airway constriction, causes flow limitation.Immunostimulating ORN of the present invention can prevent further reconstruction, and even possibly reduce the tissue construction that process of reconstruction causes.
Immunostimulating ORN of the present invention also is applicable to survival, differentiation, activation and the maturation that promotes dendritic cells.The oligoribonucleotide of immunostimulating has cell survival, differentiation, activation and the sophisticated unique ability that promotes dendritic cells.
Immunostimulating ORN of the present invention also improves the cytotoxicity (ADCC) of natural killer cell lytic activity and antibody dependent.ADCC can be through using immunostimulating ORN to carry out with the antibody combination, and said antibody pair cell target such as cancer cells are special.When immunostimulating ORN and antibody combined administration were given the experimenter, experimenter's immunity system was induced the kill tumor cell.Be applicable to that the antibody in the ADCC process comprises and the interactional in vivo antibody of cell.Special many these antibody-likes of pair cell target are described in this area, and many can commercially the acquisition.In one embodiment, said antibody is IgG antibody.
In some aspects, the invention provides the method that is used to strengthen the epi-position expansion.This paper uses " epi-position expansion " to be meant that epitope specificity is from the various accessory and/or hiding epi-position that turns on said protein (intramolecularly expansion) or other protein (intermolecular expansion) of initially concentrated, main epitope specificity immunne response (point to self or exogenous protein).The epi-position expansion causes the immunne response that multi-epitope is special.
Immunne response was made up of initial amplification phase (magnification phase) and downward modulation phase afterwards; The said amplification phase can be deleterious (as in autoimmune disease) or useful (as in vaccine inoculation), and the said downward modulation phase reverts to immunity system stable state and produces memory.The epi-position expansion can be the integral part in these two stages.The enhancing of epi-position expansion allows experimenter's immunity system to confirm extra target epi-position (it is not responded to the immune system identification of original therapy scheme at first) in tumour takes place; Reduce the possibility of escape variant in the tumour population simultaneously, thereby influence advancing of disease.
Oligoribonucleotide of the present invention is applicable to promoting treatment to go up the epi-position expansion in the useful indication (for example cancer, virus and infectation of bacteria, and transformation reactions).Said method comprises the steps: the experimenter is used the vaccine that comprises antigen and adjuvant in one embodiment; Subsequently the experimenter is used the immunostimulating ORN of the present invention of at least two doses of certain consumption, said consumption is effectively induced the special immunne response of multi-epitope.This method comprises the steps: the experimenter is used the vaccine that comprises tumour antigen and adjuvant in one embodiment; Subsequently the experimenter is used the immunostimulating ORN of the present invention of at least two doses of certain consumption, said consumption is effectively induced the special immunne response of multi-epitope.This method relates in one embodiment uses a kind of regimen; Said regimen causes the immunity system antigen-exposed among the experimenter; Use at least twice immunostimulatory oligoribonucleotides of the present invention subsequently,, promptly promote the epi-position expansion to induce the special immunne response of multi-epitope.In a plurality of embodiments, this regimen is surgical operation, radiation, chemotherapy, other cancer drug, vaccine or cancer vaccine.
Except immunostimulation therapy subsequently, regimen can carry out with the immunopotentiating agent combination.For example, when regimen was vaccine, it can combine to use with adjuvant.The combination of vaccine and adjuvant can be mixture or independently use, i.e. injection (being identical drainage district (drainage field)).Use must not be simultaneously.If use the injection of non-while, then arrangement of time can comprise first injection adjuvant, is vaccine formulation then.
After accomplishing regimen, beginning immunostimulation monotherapy.Target and other factors should be depended in best frequency of administration, time length and site, but can for example be every month or using per bimester the in six months to 2 years time period.Perhaps, using can be based on every day, weekly or carry out in per two weeks, or use can be in one day, a week or January repeatedly.In some cases, the time length of using can be depending on the length of therapy, and for example it can or stop after the several years after a week, after one month, after 1 year.In other cases, monotherapy can be a successive, as using intravenous drip.Immunostimulant can be used to the common drainage district of target.
With regard to the purposes in the therapy, different dosages possibly be essential for the treatment experimenter, and this depends on the activity, route of administration of compound, purpose (being preventative or therapeutic), the character of illness and seriousness experimenter's the age and the body weight of immunity.Using of given dose can be accomplished through single administration with the form of individual dose unit or the form of several small dosage units.With the special interval of separately several weeks or several months repeatedly application dosage be applicable to the immunne response of strengthening antigen-specific.
The instruction that provides in conjunction with this paper; Through in various active compound and the weighing factor (for example potential, relative bioavailability, weight in patients, the seriousness of adverse side effect and the preference pattern of using), selecting; Can plan effectively preventative or therapeutic treatment system, said treatment system does not cause remarkable toxicity and for the concrete experimenter of treatment, is in full force and effect.The significant quantity that is used for any concrete application can be according to factors and difference, and said factor is like the disease of treatment or illness, the concrete therapeutical agent of using, experimenter's build, or the seriousness of disease or illness.One of this area routine techniques personnel can rule of thumb confirm the significant quantity of concrete nucleic acid and/or other therapeutical agent and must not carry out unsuitable experiment.
Experimenter's dosage of compound as herein described is typically from about 0.1mg to 10,000mg, more typically from about 1mg/ to 8000mg, the most typically in the scope from about 10mg to 100mg.With experimenter's body weight, typical dosage from about 0.1mg to 20mg/kg/ days, more typically from about 1 to 10mg/kg/ day, the most typically in about 1 to 5mg/kg/ day scope.
The pharmaceutical composition that contains nucleic acid and/or other compound can be used through any suitable pathways that is used for drug administration.Can obtain multiple route of administration.Certainly, the concrete pattern of selection will depend on one or more concrete reagent of selection, the concrete illness and the required dosage of result of treatment of treatment.Generally speaking, method of the present invention can be used the acceptable any mode of administration of medical science and carries out, and promptly produces the efficient immune level and does not cause any pattern of unacceptable undesirable action clinically.Preferred mode of administration is in this paper discussion.As far as the purposes in the treatment, the nucleic acid of significant quantity and/or other therapeutical agent can be used to the experimenter through any pattern, said pattern is delivered to the surface of expectation with said reagent, for example mucous membrane, general.
Using pharmaceutical composition of the present invention can accomplish through the known any approach of technician.The approach of using includes but not limited in the mouth, parenteral, intravenously, intramuscular, intraperitoneal, nose, in the hypogloeeis, tracheae, suction, subcutaneous, eye, vagina and rectum.With regard to asthma or allergic treatment or prevention, this compounds preferably is inhaled into, takes in or used through the general approach.The general approach comprises oral and parenteral.The preferred in some embodiments medicine that sucks, because directly be delivered to lung, the inflammation site that asthmatic patient Central Plains is sent out.Usually use the equipment of some types to be used for using through suction.The equipment of these types comprises metered dose inhaler (MDI), breathe the MDI start, Diskus (DPI), with the interval/repository and the atomizer of MDI combination.
Therapeutical agent of the present invention can be delivered to concrete tissue, cell type by means of carrier, or is delivered to immunity system, or the two has concurrently." carrier " is meant any media that can be convenient to compsn is transferred to target cell in the implication the most widely at it.Carrier usually with immunostimulatory nucleic acid, antibody, antigen and/or disease specific transport of drug to target cell, have the degraded of minimizing for the degraded scope that obtains when not having carrier.
Usually, be applicable to that carrier of the present invention is divided into two types: biological vehicle and chemical/physical carrier.Biological vehicle and chemical/physical carrier are applicable to sending and/or taking in of therapeutical agent of the present invention.
The various biological carrier is used to nucleic acid delivery, this belong to immunostimulatory nucleic acid or comprise in the therapeutic agent delivery of immunostimulatory nucleic acid the most suitable.
Except the biological vehicle that this paper discusses, the chemical/physical carrier can be used to send the therapeutical agent that comprises immunostimulatory nucleic acid, antibody, antigen and illness specificity medicament.This paper uses " chemical/physical carrier " to be meant that except from the natural or synthetic molecules bacterium or the viral source, they can nucleic acid delivery and/or other medicines.
The preferred chemical/physical carrier of the present invention is a colloidal dispersion system.Colloidal dispersion system comprises with the lipid being the system on basis, comprises oil-in-water emulsion, micelle, blended micelle and liposome.The preferred colloid system of the present invention is a liposome.Liposome is to be applicable in the body or the artificial rust vascular (vessel) of external delivery vector.Show: size range can be with big macromole encapsulate from the big unilamellar vesicle (LUV) of 0.2-4.0mm.RNA, DNA and complete virion can be delivered to cell by encapsulate in aqueous interior and with biologically active form.Fraley?et?al.(1981)Trends?Biochem?Sci6：77。
Can pass through liposome and special part (for example monoclonal antibody, sugar, glycolipid or protein) the coupling tissue that the liposome target is concrete.Can be used for the part of liposome target immunocyte is included but not limited to: with the special acceptor of immunocyte and interactional complete molecule of molecule (like antibody) or fragment, the cell surface marker thing of said acceptor and molecule and immunocyte interacts.This type part can easily known by one of skill in the art combination be measured evaluation.Also in some other embodiment, can be through making liposome by target on cancer the coupling of one of the immunotherapeutical antibody of liposome and preamble discussion.In addition, carrier can with the coupling of nuclear target peptide, said nuclear target peptide can point to host cell nuclear with carrier.
The lipid prescription that is used for transfection can obtain with commercial sources from QIAGEN, for example EFFECTENE TM(non-liposome lipid) and SUPERFECT with special DNA compression enhanser TM(novel effect dendrimer technology).
Liposome can obtain with commercial sources from Gibco BRL, for example LIPOFECTIN TMAnd LIPOFECTACE TM, its by cation lipid such as N-[1-(and 2,3dioleyloxy)-propyl group]-N, N, N-trimethyl ammonium chloride (DOTMA) and dimethyl-octacosyl brometo de amonio (DDAB) form.The method that is used to make liposome is well known in the art, and in many publications, is described.Liposome is also summarized by Gregoriadis G (1985) Trends Biotechnol 3:235-241.
Particularly advantageous when some cation lipid (especially comprising N-[1-(2,3 two oleoyl oxygen)-propyl group]-N, N, N-trimethyl ammonium methylsulfuric acid ester (DOTAP)) shows the oligoribonucleotide analogue combination of modifying with warp of the present invention.
In one embodiment, media is to be applicable to biocompatible particulate or the implant of implanting or being applied to mammalian receptors.The exemplary biological erosion that is applicable to this method is separated implant and is described in PCT international application no.PCT/US/03307 (open No.WO95/24929 is entitled as " PolymericGene Delivery System ").Biocompatible, preferred biodegradable polymer matrix that PCT/US/0307 has described, said matrix is used to comprise the foreign gene that is under the suitable promoter regulation.Polymer matrix can be used to reach the lasting release of therapeutical agent in the experimenter.
The polymer matrix optimization is the form of particulate, for example microballoon (its amplifying nucleic acid and/or other therapeutical agent are scattered in solid polymer matrix everywhere) or microcapsule (its amplifying nucleic acid and/or other therapeutical agent are stored in the core of polymer shell).The polymer matrix that is used to comprise other form of therapeutical agent comprises film, dressing, gel, implants and support.Select the size and the composition of polymer matrix equipment, make the good release dynamics of generation in the tissue that said matrix is introduced into.This is according to the size of delivering method selection polymer matrix to be used, and said delivering method typically is to be injected into tissue or through aerosol suspension-s to be used into nose and/or lung zone.Preferably, when using the aerosol approach, polymer matrix and nucleic acid and/or other therapeutical agent are included in the tensio-active agent media.Can select the polymer substrate compsn, make it both have good degradation rate, the material by bioadhesion forms again, thereby when matrix is used to nose that continues damage and/or lung surface, further improves the validity that shifts.Also can select not degrade but substrate compsn through discharging in the time period that is diffused in prolongation.In some preferred embodiments, through implant nucleic acid is used to the experimenter during by acute administration when other therapeutical agent.Be applicable to that the biocompatible microballoon of sending (for example mouth or mucosal delivery) is disclosed among Chickering et al. (1996) Biotech Bioeng 52:96-101 and Mathiowitz E etal. (1997) Nature 386:410-414 and the PCT patented claim WO97/03702.
Abiotic degradable and biodegradable polymer matrix all can be used for giving the experimenter with nucleic acid and/or other therapeutic agent delivery.Preferred biodegradable matrices.This type polymer can be natural or the synthetic polymer.Polymer is selected according to desired section time of releasing, usually by several hours to 1 year or order more of a specified duration.Typically, the release of scope on the time period between several hours and three to 12 months is expected most, especially for nucleic acid reagent.Polymer randomly is the form of hydrogel (its in water, can be adsorbed to many its weight approximately 99%), and is perhaps randomly crosslinked with polyvalent ion or other polymer.
The interested especially bioadhesion polymer of people comprises H.S.Sawhney, C.P.Pathak and J.A.Hubell in Macromolecules, and hydrogel is separated in the biology erosion that (1993) 26:581-587 describes, and this paper is incorporated in the instruction of this reference into.These comprise the poly mucinase; Casein; Gelatin; Glitin; Polyanhydride; ROHM; Alginate; Chitosan; Poly (methacryloxyethyl acid methyl esters); Poly (Jia Jibingxisuanyizhi); Poly (NSC 20956); Poly (Propenoic acid, 2-methyl, isobutyl ester); Poly (N-Hexyl methacrylate); Poly (isodecyl methacrylate); Poly (lauryl methacrylate); Poly (phenyl methacrylate); Poly (methyl acrylate); Poly (isopropyl acrylate); Poly (NSC 20949) and poly (vinylformic acid stearyl).
If therapeutical agent is a nucleic acid, then also compression agent (compaction agent) is used in expectation.The compression agent also can be used separately or use with bio-carrier or chemical/physical carrier combinations.This paper use " compression agent " thus in being meant with nucleic acid on negative charge allow a kind of reagent of nucleic acid boil down to fine granular, for example histone.The compression of nucleic acid is convenient to nucleic acid and is taken in by target cell.The compression agent can be used separately, i.e. form nucleic acid delivery more effectively to be absorbed by cell, or more preferably itself and one or more above-mentioned carrier combinations use.
Other exemplary composition that can be used for promoting nucleic acid to absorb comprises other chemical media, microinjection compsn, electroporation and the homologous recombination compsn (for example being used for nucleic acid is integrated in the previously selected site of target cell genome) that transports in calcium phosphate and the born of the same parents.
Compound can be used (for example in salt solution or damping fluid) separately or use any delivery medium known in the art to use.Delivery medium for example is described: spirochete (Gould-Fogerite et al., 1994,1996); Emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Mowat et al., 1993, Carlsson et al., 1991, Hu et., 1998, Morein et al., 1999); Liposome (Childers et al., 1999, Michalek et al., 1989,1992, de Haan 1995a, 1995b); Bacteria carrier (for example Salmonella, Escherichia coli, Bacillus Calmette-Gu é rin, Shigella, Lactobacillus) (Hone et al., 1996, Pouwels et al. live; 1998, Chatfield et al., 1993; Stover et al.; 1991, Nugent et al., 1998); Live vector (for example cowpox, adenovirus, herpes simplex) (Gallichan et al., 1993,1995, Moss et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999); Microballoon (Gupta et al., 1998, Jones et al., 1996, Maloy et al., 1994, Mooreet al., 1995, O ' Hagan et al., 1994, Eldridge et al., 1989); Nucleic acid vaccine (Fynan et al., 1993, Kuklin et al., 1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); Polymer (for example CMC 99.5, chitosan) (Hamajima et al., 1998, Jabbal-Gill et al., 1998); Polymer ring (Wyatt et al., 1998); Proteoplast (Vancott etal., 1998, Lowell et al., 1988,1996,1997); Sodium Fluoride (Hashi et al., 1998); Transgenic plant (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); Virosomes (Gluck et al., 1992, Mengiardi et al., 1995, Cryz et al., 1998) and virus-like particle (Jiang et al., 1999, Leibl et al., 1998).
By being used, said solution contains the salt, buffer reagent, sanitas of pharmaceutically acceptable concentration, suitable vector, adjuvant and other optional therapeutic component to prescription of the present invention routinely in pharmaceutically useful solution.
The pharmaceutically acceptable vector of term is represented to be applicable to and is used to people or other vertebrate solid or liquid filling agent, thinner or encapsulate materials that one or more are fit to.The term vector is represented natural or synthetic organic or inorganic composition, and activeconstituents makes up with it so that use.The composition of pharmaceutical composition also can be mixed with each other with compound of the present invention in the following manner: do not have the significantly interaction of the drug effectiveness of damage expectation.
For Orally administered, can prepare compound (being nucleic acid, antigen, antibody and other therapeutical agent) through active compound and pharmaceutically acceptable vector well known in the art being mixed to come easily.This type vector makes compound of the present invention can be configured to tablet, alkyl, lozenge, capsule, liquid, gel, syrup, paste, suspension-s etc., is used for by experimenter's orally ingestible to be treated.The pharmaceutical prepn that is used for oral use can be used as solid excipient and obtains, if mixture and the process mixture particle that obtains randomly ground in expectation after adding proper supplementary material, obtains tablet or lozenge nuclear.Suitable vehicle is weighting agent such as sugar especially, comprises lactose, sucrose, N.F,USP MANNITOL or sorbyl alcohol; Cellulose preparation such as W-Gum, wheat starch, rice fecula, yam starch, gelatin, Tragacanth (gum tragacanth), methylcellulose gum, Vltra tears, Xylo-Mucine and/or Povidone, USP/EP (PVP).If expectation can be added for example sodium-alginate of the for example crosslinked Povidone, USP/EP of disintegrating agent, agar or Lalgine or its salt.Randomly, oral prepns also can be formulated in and be used in salt solution or the damping fluid and the internal acid condition, or can not used with any vector.
Lozenge nuclear provides with suitable dressing.For this purpose can be used spissated sugar soln, its optional gum arabic, talcum, Vinylpyrrolidone polymer, CARBOPOPLS gel, polyoxyethylene glycol and/or titanium oxide, lacquer solution (lacquer solution) and appropriate organic solvent or solvent mixture of containing.Dyestuff or pigment may be added to the various combination that is used to identify or characterize active compound doses in tablet or the lozenge dressing.
The pharmaceutical prepn that taking orally is used comprises the push-fit capsule of being processed by gelatin, and the soft seal capsule of being processed by gelatin and softening agent (for example glycerine or sorbyl alcohol).The push-fit capsule can contain and weighting agent such as lactose, tackiness agent such as starch and/or lubricant such as talcum or Magnesium Stearate and optional stablizer blended activeconstituents.In soft capsule, active compound dissolves in or is suspended in the suitable liquid, for example wax, whiteruss, or in the liquid macrogol.In addition, can add stablizer.Also can use preparation to be used for the microballoon that mouth is used.This type microballoon has been that this area is confirmed.Being used for mouthful all prescriptions of using should be the dosage that is applicable to that this type used.
For containing for clothes use the tablet that compsn can be taked to prepare in a usual manner or the form of lozenge.
For using through suction, the compound that is used for purposes of the present invention can be sent with suitable propelling agent (for example Refrigerant 12, trichlorofluoromethane, dichloro tetrafluoro ethane, carbonic acid gas or other suitable gas) with the form from the sprays of supercharging packing or atomizer expediently.Under the situation of pressurised aerosol, unitary dose can be confirmed through the value that is provided for sending measured quantity.The capsule and the cartridge case (for example gelatin) that are used for sucker or insufflator can be configured to the powdered mixture that contains compound and suitable powder basis (for example lactose or starch).
When expectation systemic delivery compound, it can be configured to and be used for through the injection parenteral administration, for example through injecting (bolus injection) or continuous infusion.The prescription that is used to inject can exist with unit dosage, for example ampoule or have in the multi-dose container of sanitas of interpolation.Compsn can adopt the form of suspension-s, solution or emulsion in oiliness for example or the aqueous media, and can contain preparaton such as suspension agent, stablizer and/or dispersion agent.
The formula of medicine that is used for parenteral administration comprises the aqueous solution of the active compound of water-soluble form.In addition, the suspension-s of active compound can be prepared as suitable oily injection suspensions.Suitable lipophilic solvent or media comprise wax (like til) or synthetic fatty ester (like OE) or triglyceride level, or liposome.Water injection suspension liquid can contain the material that improves suspension viscosity, for example Xylo-Mucine, sorbyl alcohol or VISOSE.Choose wantonly, suspension-s also can contain suitable stabilizers or improve the reagent of compound dissolution degree, to allow the preparation highly concentrated solution.
Perhaps, active compound can be the powder type that is used for before use with suitable medium (for example sterile pyrogen-free water) combination.
Compsn also can be formulated in rectum or vaginal compositions for example in suppository or the enema, and it for example contains conventional suppository base, like theobroma oil or other glyceryl ester.
Except aforementioned formula, compound also can be configured to the storage preparation.The long-acting prescription of this type can be used suitable polymer or hydrophobic material (emulsion in the for example acceptable oil) or ion exchange resin preparation, or is configured to slightly soluble verivate (for example slightly soluble salt).
Pharmaceutical composition also can comprise suitable solid or gel phase vector or vehicle.The example of this type vector or vehicle includes but not limited to lime carbonate, calcium phosphate, multiple sugar, starch, derivatived cellulose, gelatin and polymer such as polyoxyethylene glycol.
Suitable liquid or solid pharmaceutical dosage forms for the water-based that for example is used for sucking or salt brine solution, by micro-capsule embedding, spiral embedding (encochleated), dressing at little gold grain, be included in liposome, by sprinkling, aerosol, be used for implanting the little group of skin or dryly will be rubbed into the sharp-pointed article of skin.Pharmaceutical composition also comprises tablet, (little) capsule, suppository, syrup, emulsion, suspension-s, frost, the drops of particle, powder, tablet, dressing or prolongs the preparation of release active compound; Use vehicle and additive and/or auxiliary material, for example disintegrating agent, tackiness agent, seed dressing agent, swelling agent, lubricant, seasonings, sweeting agent or solubilizing agent in the said preparation as stated routinely.Pharmaceutical composition is applicable to multiple drug delivery system.The summary summary that is used for the method that medicine sends is referring to Langer R (1990) Science 249:1527-1533, and it is through with reference to incorporating this paper into.
Nucleic acid can self (pure) used or used with the form of pharmacologically acceptable salt with optional other therapeutical agent and/or antigen.When being used for medicine, salt should be pharmaceutically useful, but can use non-pharmacologically acceptable salt to prepare its pharmacologically acceptable salt expediently.These salt include, but are not limited to from the salt of following acid preparation: hydrochloric acid, Hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid, toxilic acid, acetate, Whitfield's ointment, p-toluenesulphonic acids, tartrate, Hydrocerol A, methylsulfonic acid, formic acid, propanedioic acid, succsinic acid, naphthalene-2-sulfonic acid and Phenylsulfonic acid.This type salt also can be prepared as basic metal or alkaline earth salt, for example the sodium salt of hydroxy-acid group, sylvite or calcium salt.
Suitable reducing comprises: acetate and salt (1-2%w/v); Hydrocerol A and salt (1-3%w/v); Boric acid and salt (0.5-2.5%w/v); With phosphoric acid and salt (0.8-2%w/v).Suitable sanitas comprises BZK (0.003-0.03%w/v); Trichloro-butyl alcohol (0.3-0.9%w/v); P-Hydroxybenzoate (0.01-0.25%w/v) and Sodium Mercurothiolate (0.004-0.02%w/v).
Compsn can exist with unit dosage form expediently, and can be through the known any method preparation of pharmacy field.All methods all comprise the step that makes compound and vector combination, and said vector is formed one or more auxiliary agents (accessory ingredients).Unobstructed, through with compound equably and directly with solid vector or this two combination of liquid vector, fine dispersion, product is shaped prepares compsn.Liquid dosage unit is pipe or ampoule.Solid dosage unit is tablet, capsule and suppository.
Other delivery system can comprise instant-free (time-release), postpone to discharge or prolong the release delivery system.This type system can be avoided the repetitive administration of compound, promotes the facility to experimenter and doctor.The delivery system of many types is obtainable, and is that this area routine techniques personnel are known.They comprise polymer basic system such as poly (rac-Lactide-NSC 403079), copolymerized oxalate, polycaprolactone, polyesteramide, many polyorthoesterses, poly hydroxybutyric acid and poly acid anhydrides.The medicine that contains aforementioned polymer microcapsule is disclosed in for example U.S.Pat.No.5, in 075,109.Delivery system also comprises following non-polymer system: lipid comprises sterol such as SUV, cholesteryl ester and lipid acid or neutral fat such as glycerine list, two and three esters; The hydrogel delivery systme; The silica gel system; System based on peptide; The wax dressing; Use the compressed tablets of conventional tackiness agent and vehicle; The implants of meromixis etc.Special example includes, but are not limited to: (a) erosion system (erosional system), and reagent wherein of the present invention is involved with the form in the matrix, U.S.Pat.Nos.4 for example, 452; 775, in 4,675,189 and 5,736,152 disclosed those; (b) indiffusion system (diffusional system), wherein activeconstituents with controlled rates from for example U.S.Pat.Nos.3,854,480,5; 133,974 and 5,407, the polymer infiltration described in 686.In addition, can use the hardware delivery system based on pump, some of them are applicable to implantation.
Following embodiment will further set forth the present invention, and said embodiment should not be considered to be used for further restriction by any way.
Embodiment
Embodiment 1
People PMBC is to containing N-U-R 1 -R 2 The responsiveness of oligoribonucleotide
Method: Luminex technology
The Luminex color code globule that is called microballoon is divided into 100 different groups.Each globule group can be used the actual packet quilt special to concrete biological assay, allows from sample, to catch and detect special analyte.In the easy analyser of Luminex, the dye inside of each microsphere particle is identified in laser excitation, and the sub-dyestuff of any report also is hunted down between this test period.Each globule group is studied many readings, further confirm the result.With this kind mode, the Luminex technology allows the quick also mensuration of 100 uniquenesses of accurately compound as many as in single sample.
Separation of human PMBC (PBMC) from the donor of health is coated with and stimulated 16 hours with multiple test and contrast immunostimulant it.Collect supernatant after 16 hours, then through the ELISA determination and analysis.With the condition of the compound and complete titration curve of DOTAP (7 concentration) under test contain N-U-R 1-R 2Oligoribonucleotide, said curve is from beginning with 25 μ g/ml DOTAP compound, 2 μ M ORN and having an extent of dilution step of 1/3.Also comprise some negative control, comprise independent with substratum with separately (25mg/ml cultivates datum hole with DOTAP; " liposome ").The contrast immunostimulant comprise imidazole quinoline R-848 (2 μ M, 1/3 extent of dilution step and 7 concentration), the report TLR7 part, have the ORN of TLR7 motif such as AU and AUU sequence (SEQ IDNO:13-SEQ ID NO:15), ORN with TLR8 motif such as CU, GU and GUU sequence (SEQ ID NO:19-SEQ ID NO:23).The result is presented in Fig. 1 and 3.
Use separated pDC, monocyte and mDC to stimulate the similar mensuration that is used to test different ORN sequences.Use and 10 μ g/ml DOTAP, 0.5 μ M CpG ODN compound, 0.5 μ MORN, or separately with DOTAP or substratum irritation cell.Collect supernatant after 16 hours and measure IFN-α, TNF-α and IL-12p40 through ELISA.The result is presented among Fig. 2.
Fig. 1 has shown the clear difference between the TNF-α and IFN-α production when with the SEQ IDNO:21 that contains the SEQ ID NO:12 of AU sequence and contain the GU sequence PBMC being stimulated.Other sequential analysis shows that it is that another is induced TNF-α and does not produce the ORN of IFN-α that CUA repeats (SEQ ID NO:24).Contain AU and compare similar result with longer ORN (SEQ ID NO:12-SEQ ID NO:23), but efficient and ability reduce with the shorter ORN demonstration that GU repeats (SEQ ID NO:29-SEQ ID NO:34).
Fig. 2 and 6 has shown on separated monocyte, pDC and mDC the analysis to AU-ORN (SEQ ID NO:13) and GU-ORN (SEQ ID NO:21); Reflected as far as the strong IFN-α production that reduces of AU-ORN (SEQ ID NO:13) with as far as two kinds of ORN TNF-α and IL-12p40 production clearly.IFN-α when stimulating from the ORN of pDC produces TLR7 mediation seemingly, and TLR8 seemingly mediates and produce from the TNF-α of separated monocyte and mDC and IL-12p40.
Luminex result has been reflected the result suitable with the ELISA data, and has proved that difference main between GU-ORN and the AU-ORN is owing to the IFN-α production gene/cytokine (Fig. 3 and 8a) relevant with IFN-α.In addition, gene/cytokine that other Luminex data presentation is relevant with IFN-α with IFN-α is opposite, and other cytokine/chemokine does not receive from the influence of an outlier of CD123-CD14-cell (Fig. 7 and 8a-d).This IL-6 production maybe be owing to the B cell-stimulating of TLR7 mediation.
Embodiment 2
Comparison to the IFN-α and the TNF-α maximum activity of oligoribonucleotide
Use with DOATP compound ORN and stimulate the human PBMC.Collect supernatant after 16 hours and measure TNF-α and the IFN-alpha levels.Measured 3-6 blood donor and two independent experiments average/maximum activity at 0.6 μ M place.The result is presented among Fig. 4.These data are clearly different between TLR8 and TLR7/8 motif: have motif N-U-R 1-R 2The IFN-α that is presented under the 300pg/ml of ORN produce, and TLR7/8ORN when being presented at PBMC and stimulating higher IFN-α production (Fig. 4 a).TLR8 and TLR7/8 separate with red line.On the contrary, the measurement of TNF-alpha levels point out to have TLR8 ORN and ORN with TLR7/8 motif the two all stimulate TNF-α production.
Embodiment 3
Comparison to the IFN-α maximum activity and the IFN-α EC50 of oligoribonucleotide
Use with DOATP compound ORN and stimulate the human PBMC.Collect supernatant after 16 hours and measure the INF-alpha levels.Measured 3-6 blood donor and two independent experiments 0.6 μ M place and the EC50 place of titration curve (scope 2 μ M are to 0.9nM) fully on average/maximum activity.The result is presented among Fig. 5.EC50 and maximum activity show the comparable result who relates to TLR8 and TLR7/8 motif.The low high maximum activity of EC50/ is represented TLR7/8 ORN, and (Fig. 5 a) and high EC50 and low maximum activity are represented TLR8 ORN (Fig. 5 b).
His-and-hers watches 1 listed ORN sequence is carried out IFN-α and TNF-α production test when the human PBMC stimulates.Stimulated the human PBMC 16 hours with specified ORN, collect supernatant and measure cytokine production through ELISA.Table 2 has been summarized minimum/maximum activity and the EC50 of ORN to IFN-α and TNF-α production.
Table 1:
Figure S2006800440306D00721
+: cytokine production
-: acellular factor production.
Table 2
Figure S2006800440306D00731
Figure S2006800440306D00741
Figure S2006800440306D00751
Embodiment 4
When people PMBC stimulated, synthetic ORN was different between IFN-α and TNF-α release
Use with 25 μ g/ml DOTAP compound 1 μ M ORN or use separately DOTAP (Figure 10 a), or specified amount with DOTAP compound ORN or use DOTAP (Figure 10 b-10c) to hatch purified pDC of CD123+ (Figure 10 a and 10b) or separated monocyte (Figure 10 c) separately.Collecting cell is also with CD123, CD11c and HLA-DR antibody (Figure 10 a and 10b) or CD14 and CD19 (Figure 10 c) dyeing after 16 hours.The facs analysis of CD86 is shown, be rich in the ORN (SEQ ID NO:13) of AU and the ORN (SEQ ID NO:21) that is rich in GU shows difference when pDC stimulates in the expression of CD86 surface marker.ORN (SEQ ID NO:13) stimulation with being rich in AU causes considerably less CD86 to activate, and causes significant CD86 to activate with the ORN that is rich in GU (SEQ ID NO:21) stimulation.It is cascade dependent (Figure 10 b) that this activation is confirmed as.The ORN (SEQ ID NO:21) that is rich in the ORN (SEQ ID NO:13) of AU and is rich in GU shows indifference (Figure 10 c) in the CD80 surface marker is expressed when human PBMC's (data not shown) and CD14-positive cell stimulate.
Embodiment 5
The ORN (SEQ ID NO:21) that is rich in the ORN (SEQ ID NO:13) of AU and is rich in GU is with agent
The mode that amount relies on stimulates special people TLR8 signal transduction
Personnel selection TLR3 or TLR8 expression plasmid and the unresponsive HEK-293 cell of NF κ B-luciferase reporter gene construct stable transfection.With specified ORN sequence (10 μ M, compound) or control stimulation (10 μ M R-848,50 μ g/ml polyIC, 3,3 μ M ODN10103 or 50 μ g/ml DOTAP) cell was hatched 16 hours with 50 μ M/mlDOATP.Activate through measuring luciferase activity measuring N F κ B-.The result induces as the multiple that is higher than background (substratum) and provides.(Fig. 9 a) to have shown representative experiment of 6 independent multiple.
Use with the ORN of DOTAP (50 μ g/ml-＞1/3 extent of dilution) compound prescribed concentration or use DOTAP (50 μ g/ml-＞1/3 extent of dilution) separately HEK-293 cytositimulations of the stable transfection of expressing human TLR8 16 hours.Activate through measuring luciferase activity measuring N F κ B-.The result induces as the multiple that is higher than background (substratum) and provides.Representative experiments of 3 independent multiple (Fig. 9 b) have been shown.
Personnel selection TLR8 expression plasmid and the unresponsive HEK-293 cell of NF κ B-luciferase reporter gene construct stable transfection.With specified ORN sequence (15 μ M, compound) or control stimulation (15 μ M R-848 or 75 μ g/ml DOTAP) with substratum (left side), 200nM Bafilomycin (Baf., in) or 1mM chloroquine (CQ, the right side) cell was hatched 16 hours with 75 μ M/ml DOATP.Activate through measuring luciferase activity measuring N F κ B-.The result induces as the multiple that is higher than background (substratum) and provides.Representative experiments of 4 independent multiple (Fig. 9 c) have been shown.
RPMI 8226 cells and 1000U/ml Intron A were hatched 3 hours, use the substratum washed twice, use stimulating of prescribed concentration then with DOTAP (50 μ g/ml-＞1/3 extent of dilution) compound ORN.Measure the cytokine release of IP-10 through ELISA.The result provides with pg/ml.Representative experiments of 3 independent multiple (Fig. 9 d) have been shown.
These digital proofs SEQ ID NO:13 and SEQ ID NO:21 are to the specificity of TLR8.
TLR8ORN (SEQID NO:13), TLR 7/8ORN (SEQ ID NO:21) and contrast ORN (SEQ ID NO:5) (table 3) with high dosage (H.D., 10 μ g/ml) and low dosage (L.D., 2.5 μ g/ml) repeat this mensuration.Only SEQ ID NO:21 handles and has caused significant IL-12 and TNF-α to produce (being respectively Figure 11 a and 11b).All ORN stimulate the production (Figure 11 c) of IFN-γ.
SEQ?ID?NO ORN
SEQ?ID?NO：5 C*C*G*U*C*U*G*U*U*G*U*G*U*G*A*C*U*C
SEQ?ID?NO：13 U*U*A*U*U*A*U*U*A*U*U*A*U*U*A*U*U*A*U*U
SEQ?ID?NO：21 U*U*G*U*U*G*U*U*G*U*U*G*U*U*G*U*U*G*U*U
Embodiment 6
In the mouse macrophage body or externally the ORN (SEQ ID NO:13) that is rich in AU is not replied
(Figure 12 a), J774 cell (Figure 12 b) and purified CD11c+ cell (Milteny, magnetic bead mark) separate from sv129 mouse boosting cell (Figure 12 c-12e) and use with DOTAP (50 μ g/ml and dilute with the ORN) ORN of compound prescribed concentration, independent R-848 or DOTAP (50 μ g/ml) stimulates the Raw264.7 cell.16 hours (Figure 12 a and 12b) or 20 hours (Figure 12 c-12e) back is collected supernatant and is used for the ELISA of TNF-α (Figure 12 a and 12b), IL-12p40 (Figure 12 c), IFN-α (Figure 12 d) and IP-10 (Figure 12 e).Data representation from the body one by one (Figure 12 a and 12b) of at least three experiments and the average (Figure 12 c-12e) of 3 mouse.In order to measure the ability of the ORN body internal stimulus mouse cell that is rich in AU, use ORN injection sv 129 mouse (n=5/ group) and the blood sampling after 3 hours of the specified amount of preparing with DOTAP (60,20 or 6 μ g/ml).In whole blood, measure IL-12p40 (Figure 12 f), IFN-α (Figure 12 g) and IP-10 (Figure 12 h) productions with ELISA.
Embodiment 7
Purified rat spleen cells is not replied the ORN SEQ ID NO:13 that is rich in AU
To merge and with SEQID NO:21, SEQ ID NO:13 (all compound, 1/5 extent of dilution), R-848 or DOTAP independent (the 62.5 μ g/ml-＞1/5 extent of dilution) stimulation of prescribed concentration from the splenocytes of 3 Sprague-Dawley rats with 62.5 μ g/ml DOTAP.Collect supernatant after 20 hours and measure the TNF-alpha levels through ELISA.As shown in Figure 13, cause TNF-α production with the ORNSEQ ID NO:21 stimulation of being rich in GU, and cause not producing TNF-α with the ORN SEQ ID NO:13 that is rich in AU production.
Embodiment 8
Rodent cells is replied the failure of the ORN SEQ ID NO:13 that is rich in AU can be by between species
The TLR8 polymorphum causes
Stimulate people and Niu cell to cause cytokine production with the ORN that is rich in AU, stimulate mouse and rat cell then not to cause.Carry out TLR8 sequence alignment and analysis.The leucine that is rich in the protein sequence of TLR8 comparison display structure territory 1 repeats intensive difference among (LRR) 3 between different vertebratess (people, monkey, orangutan, dog, ox, pig, mouse and rat).Although people, orangutan and monkey are high conservatives, with the physiognomy ratio, rat, mouse and pig are proved to be in the position 106 (mouse), 103 (rats) or 102 (pigs) deletion 4AA, and ox is proved to be the have 2AA insertion of (105-106).What is interesting is that pig and ox demonstrate another 2AA deletion in same area (position 97).The deletion of being rich in the leucine repeat region of possible structural domain 1 can disturb the ORN that is rich in AU to combine.
Equivalent
Aforementioned printed instructions is considered to enough make those skilled in the art realize the present invention.The embodiment that scope of the present invention is not provided limits, because embodiment only is intended to set forth separately one aspect of the present invention, the embodiment of other functional equivalent is all within scope of the present invention.Except shown in this paper and described, those skilled in the art describes obviously multiple modification of the present invention according to preamble, and these are all within the scope of additional claim.Advantage of the present invention is not necessarily comprised by each embodiment of the present invention.
All reference, patent and the patent publications of quoting among the application all together integral body incorporate this paper by reference into.
Sequence table
< 110>Coley Pharmaceutical GmbH
Coley Pharmaceutical GmbH
 
< 120>immunostimulating ribonucleotide
 
<130>C1041.70053WO00
 
<150>60/739,529
<151>2005-11-25
 
<150>60/778,989
<151>2006-03-03
 
<160>91
 
<170>PatentIn?version?3.3
 
<210>1
<211>8
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>1
guaggcac 8
 
<210>2
<211>8
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>2
uuaggcac 8
 
<210>3
<211>8
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>3
cuaggcac 8
 
<210>4
<211>8
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
<400>4
auaggcac 8
 
<210>5
<211>18
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>5
ccgucuguug?ugugacuc 18
 
<210>6
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>6
uguuuuuucu?cuuguuuggu 20
 
<210>7
<211>18
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(1)..(5)
< 223>wherein n is deoxyribonucleotide arbitrarily
 
<220>
<221>misc_feature
<222>(6)..(6)
< 223>wherein n is ribonucleotide arbitrarily
 
<220>
<221>misc_feature
<222>(8)..(8)
< 223>wherein n is a uridylic
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is a uridylic
 
<220>
<221>misc_feature
<222>(11)..(12)
< 223>wherein n is ribonucleotide arbitrarily
<220>
<221>misc_feature
<222>(13)..(18)
< 223>wherein n is deoxyribonucleotide arbitrarily
 
<400>7
nnnnnnanan?nnnnnnnn 18
 
<210>8
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>8
aaacaacaaa?cacacaaacc 20
 
<210>9
<211>19
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(1)..(5)
< 223>wherein n is deoxyribonucleotide arbitrarily
 
<220>
<221>misc_feature
<222>(7)..(7)
< 223>wherein n is a uridylic
 
<220>
<221>misc_feature
<222>(9)..(9)
< 223>wherein n is a uridylic
 
<220>
<221>misc_feature
<222>(11)..(11)
< 223>wherein n is a uridylic
 
<220>
<221>misc_feature
<222>(13)..(13)
< 223>wherein n is a uridylic
 
<220>
<221>misc_feature
<222>(14)..(19)
< 223>wherein n is deoxyribonucleotide arbitrarily
 
<400>9
nnnnnanana?nannnnnnn 19
 
<210>10
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>10
gccaccgagc?cgaaggcacc 20
 
<210>11
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>11
gccaccgagc?cgaauauacc 20
 
<210>12
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>12
auauauauau?auauauauau 20
 
<210>13
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>13
uuauuauuau?uauuauuauu 20
 
<210>14
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>14
uuuauuuauu?uauuuauuua 20
<210>15
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>15
uuuuauuuua?uuuuauuuua 20
 
<210>16
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>16
aauaauaaua?auaauaauaa 20
 
<210>17
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>17
aaauaaauaa?auaaauaaau 20
 
<210>18
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>18
aaaauaaaau?aaaauaaaau 20
 
<210>19
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>19
cucucucucu?cucucucucu 20
 
<210>20
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>20
gugugugugu?gugugugugu 20
 
<210>21
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>21
uuguuguugu?uguuguuguu 20
 
<210>22
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>22
uuuguuuguu?uguuuguuug 20
 
<210>23
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>23
uuuuguuuug?uuuuguuuug 20
 
<210>24
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>24
cuacuacuac?uacuacuacu 20
 
<210>25
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>25
guaguaguag?uaguaguagu 20
 
<210>26
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>26
gucgucgucg?ucgucgucgu 20
 
<210>27
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(1)..(1)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(4)..(4)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(7)..(7)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(13)..(13)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(16)..(16)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(19)..(19)
< 223>wherein n is an inosine
 
<400>27
nuanuanuan?uanuanuanu 20
 
<210>28
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(3)..(3)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(6)..(6)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(9)..(9)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(12)..(12)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(15)..(15)
< 223>wherein n is an inosine
 
<220>
<221>misc_feature
<222>(18)..(18)
< 223>wherein n is an inosine
 
<400>28
uunuunuunu?unuunuunuu 20
 
<210>29
<211>7
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>29
uuguugu 7
<210>30
<211>7
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>30
uuauuau 7
 
<210>31
<211>7
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>31
ugugugu 7
 
<210>32
<211>7
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>32
ucucucu 7
 
<210>33
<211>7
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>33
uauauau 7
 
<210>34
<211>7
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>34
guaguag 7
 
<210>35
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>35
ccgagccgcc?gccccc 16
 
<210>36
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>36
ccgagccgca?uauccc 16
 
<210>37
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>37
ccgagccgcu?auaccc 16
 
<210>38
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>38
ccgagccaua?uauccc 16
 
<210>39
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>39
ccgagccaua?uauauc 16
 
<210>40
<211>16
<212>RNA
< 213>artificial sequence
<220>
< 223>synthetic oligonucleotide
 
<400>40
ccgagccgaa?uaaccc 16
 
<210>41
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>41
ccgagccgca?uaaccc 16
 
<210>42
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>42
ccgagccgaa?uacccc 16
 
<210>43
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>43
ccgagccgcc?uaaccc 16
 
<210>44
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>44
ccgagccgaa?uccccc 16
 
<210>45
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>45
ccgagccgca?uacccc 16
 
<210>46
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>46
ccgagccgca?uccccc 16
 
<210>47
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>47
ccgagccgcc?uacccc 16
 
<210>48
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>48
ccgagccgca?uuaccc 16
 
<210>49
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>49
ccgagccgcu?uaaccc 16
 
<210>50
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
<400>50
ccgagccgca?auuccc 16
 
<210>51
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>51
ccgagccgcu?auuccc 16
 
<210>52
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>52
ccgagccgca?auuccc 16
 
<210>53
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>53
ccgagccgcu?uacccc 16
 
<210>54
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>54
ccgagccgca?uucccc 16
 
<210>55
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>55
ccgagccgcu?aucccc 16
<210>56
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>56
ccgagccgaa?ggcacc 16
 
<210>57
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>57
ccgagccgac?uuuacc 16
 
<210>58
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>58
ccgagccgag?uuuacc 16
 
<210>59
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is a thymidine
 
<400>59
ccgagccgan?uuuacc 16
 
<210>60
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>60
ccgagccgaa?uuuacc 16
 
<210>61
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>61
ccgagccgac?uguacc 16
 
<210>62
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is a thymidine
 
<400>62
ccgagccgan?uguacc 16
 
<210>63
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>63
ccgagccgaa?uguacc 16
 
<210>64
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>64
ccgagccgau?cuuacc 16
 
<210>65
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>65
ccgagccgau?auuacc 16
 
<210>66
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>66
ccgagccgau?guuacc 16
 
<210>67
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>67
ccgagccgag?uucacc 16
 
<210>68
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is a thymidine
 
<400>68
ccgagccgan?uucacc 16
 
<210>69
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>69
ccgagccgau?cucacc 16
<210>70
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(11)..(11)
< 223>wherein n is a thymidine
 
<220>
<221>misc_feature
<222>(13)..(13)
< 223>wherein n is a thymidine
 
<400>70
ccgagccgau?nunacc 16
 
<210>71
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>71
ccgagccgau?uucacc 16
 
<210>72
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(13)..(13)
< 223>wherein n is a thymidine
 
<400>72
ccgagccgau?uunacc 16
 
<210>73
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
<400>73
ccgagccgau?uuaacc 16
 
<210>74
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>74
ccgagccgau?ugcacc 16
 
<210>75
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(13)..(13)
< 223>wherein n is a thymidine
 
<400>75
ccgagccgau?ucnacc 16
 
<210>76
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>76
ccgagccgau?ugaacc 16
 
<210>77
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>77
ccgagccgag?uucacc 16
 
<210>78
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is a thymidine
 
<400>78
ccgagccgan?uucacc 16
 
<210>79
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<220>
<221>misc_feature
<222>(10)..(10)
< 223>wherein n is a thymidine
 
<400>79
ccgagccgan?uucacc 16
 
<210>80
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>80
ccgagccgaa?uucacc 16
 
<210>81
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>81
ccgagccgag?cucacc 16
 
<210>82
<211>16
<212>RNA
< 213>artificial sequence
<220>
< 223>synthetic oligonucleotide
 
<400>82
ccgagccgaa?gguacc 16
 
<210>83
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>83
ccgagccgaa?ggugcc 16
 
<210>84
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>84
ccgagccgaa?gcuccc 16
 
<210>85
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>85
ccgagccgaa?gauacc 16
 
<210>86
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>86
ccgagccgaa?gguccc 16
 
<210>87
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
<400>87
ccgagccgaa?gcuacc 16
 
<210>88
<211>16
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>88
ccgagccgaa?gcugcc 16
 
<210>89
<211>20
<212>RNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>89
acccaucuau?uauauaacuc 20
 
<210>90
<211>22
<212>DNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>90
tcgtcgtttt?cggcggccgc?cg 22
 
<210>91
<211>21
<212>DNA
< 213>artificial sequence
 
<220>
< 223>synthetic oligonucleotide
 
<400>91
tcgtcgtttt?tcggtcgttt?t 21

Claims (17)

1.RNA oligoribonucleotide (ORN), it is:
UUAUUAUUAUUAUUAUUAUU?SEQ?ID?NO：13。
2. oligoribonucleotide UUAUUAUUAUUAUUAUUAUU SEQ ID NO:13 is used for producing the purposes at the medicine of experimenter's regulation and control immunne response.
3. the described purposes of claim 2, wherein said oligoribonucleotide is sent to the experimenter with the amount of effective inducing cell factor expression.
4. the described purposes of claim 3, wherein said cytokine are selected from the group that IL-6, IL-10, IL-12, TNF α and IFN-γ constitute.
5. the pharmaceutical composition that comprises oligoribonucleotide UUAUUAUUAUUAUUAUUAUU SEQ ID NO:13.
6. the described pharmaceutical composition of claim 5 also comprises pharmaceutically useful vector.
7. the described pharmaceutical composition of claim 6, wherein said pharmaceutically useful vector is the polycation vector.
8. each described pharmaceutical composition in the claim 5,6 or 7 also comprises antigen.
9. the described pharmaceutical composition of claim 8, wherein said antigen is randomly puted together with said oligoribonucleotide.
10. each described pharmaceutical composition in the claim 5,6 or 7, wherein said compsn is used for injection by preparation.
11. each described pharmaceutical composition in the claim 5,6 or 7, wherein said compsn is used for mucosal administration by preparation.
12. each described pharmaceutical composition is used for the purposes in the medicament of experimenter's treatment virus infection in manufacturing in the claim 5,6 or 7.
13. each described pharmaceutical composition is used for the purposes in the medicament of experimenter's regulation and control immunne response in manufacturing in the claim 5,6 or 7.
14. each described pharmaceutical composition is used for the purposes in the medicament of experimenter's inducing cell factor expression in manufacturing in the claim 5,6 or 7.
15. each described pharmaceutical composition is used for the purposes in the medicament of experimenter's treatment transmissible disease in manufacturing in the claim 5,6 or 7.
16. each described pharmaceutical composition is used for the purposes in the allergic medicament of experimenter's treatment in manufacturing in the claim 5,6 or 7.
17. the described oligoribonucleotide of claim 1, wherein said oligoribonucleotide and N-[1-(2,3-two oleoyl oxygen) propyl group]-N, N, N trimethyl ammonium methylsulfuric acid ester (DOTAP) is compound.
CN2006800440306A 2005-11-25 2006-11-22 Immunostimulatory oligoribonucleotides Active CN101331229B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73952905P 2005-11-25 2005-11-25
US60/739,529 2005-11-25
US77898906P 2006-03-03 2006-03-03
US60/778,989 2006-03-03
PCT/US2006/045183 WO2007062107A2 (en) 2005-11-25 2006-11-22 Immunostimulatory oligoribonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110430925.6A Division CN102517292B (en) 2005-11-25 2006-11-22 Immunostimulatory oligoribonucleotides

Publications (2)

Publication Number Publication Date
CN101331229A CN101331229A (en) 2008-12-24
CN101331229B true CN101331229B (en) 2012-08-29

Family

ID=40206401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800440306A Active CN101331229B (en) 2005-11-25 2006-11-22 Immunostimulatory oligoribonucleotides

Country Status (3)

Country Link
CN (1) CN101331229B (en)
CA (1) CA2790802C (en)
ZA (1) ZA200804303B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021064614A1 (en) * 2019-09-30 2021-04-08 Janssen Biopharma, Inc. Toll-like receptor 7 and/or 8 agonists and uses thereof
CN115137736A (en) * 2022-02-17 2022-10-04 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Medicine for resisting African swine fever virus and screening method thereof

Also Published As

Publication number Publication date
CA2790802A1 (en) 2007-05-31
CA2790802C (en) 2016-07-12
CN101331229A (en) 2008-12-24
ZA200804303B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
CN102517292B (en) Immunostimulatory oligoribonucleotides
CN101558157A (en) Oligoribonucleotides and uses thereof
CN101821392B (en) RNA sequence motifs in the context of defined inter-nucleotide linkages inducing specific immune modulatory profiles
CN101340931A (en) Modulation of tlr-mediated immune responses using adaptor oligonucleotides
CN101310019A (en) Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
CN101331229B (en) Immunostimulatory oligoribonucleotides
MX2008006770A (en) Immunostimulatory oligoribonucleotides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: PFIZER ANIMAL HEALTH S. A.

Free format text: FORMER OWNER: COLEY PHARMACEUTICAL GMBH

Effective date: 20130702

Free format text: FORMER OWNER: COLEY PHARMACEUTICAL GMBH

Effective date: 20130702

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: ZOTIS BELGIUM CO., LTD.

Free format text: FORMER NAME: PFIZER ANIMAL HEALTH S. A.

CP01 Change in the name or title of a patent holder

Address after: Belgian Lupin

Patentee after: COLEY PHARMACEUTICAL Group Inc.

Address before: Belgian Lupin

Patentee before: Pfizer Animal Health

TR01 Transfer of patent right

Effective date of registration: 20130702

Address after: Belgian Lupin

Patentee after: Pfizer Animal Health

Address before: Field of Germany

Patentee before: Coley Pharmaceutical GmbH

Patentee before: COLEY PHARMACEUTICAL Group Inc.